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ABSTRACT 
Background 
Severe asthma exacerbations are costly to patients and the NHS and occur frequently in patients 
with severe allergic asthma.  
Objective 
To ascertain whether the use of a temperature-controlled laminar airflow (TLA) device (Airsonett®) 
over a 12-month period can reduce the frequency of severe exacerbations and improve asthma 
control and quality of life as compared to a placebo device in adults with severe allergic asthma. 
Trial Design 
A mixed methods, multi-centre, randomised, double-blind, placebo-controlled, parallel group, trial 
design. 
Participants 
Adults (16-75 years) with severe, poorly-controlled, exacerbation-prone, asthma sensitised to a 
perennial indoor aeroallergen. 
Main Outcome Measures 
PRIMARY OUTCOME:  
Frequency of severe asthma exacerbations occurring within the 12-month follow-up period, defined 
as worsening of asthma requiring systemic corticosteroids, ≥30mg prednisolone or equivalent daily 
(or ≥50% increase in dose if maintenance 30mg prednisolone or above) for 3 or more days.  
SECONDARY OUTCOMES: 
Changes in asthma control, lung function, asthma-specific and global quality of life for participants 
and device acceptability.  
Results 
240 participants were randomised. 119 Active Treatment : 121 Placebo. 202 participants (84%) 
reported use of the device for 9-12 months. Qualitative analyses showed high levels of acceptability.  
The mean rate of severe exacerbations did not differ between groups (Active: Mean 1.39 (SD 1.57), 
Placebo: Mean 1.48 (SD 2.03) Risk Ratio 0.92, 95% CI 0.66-1.27, p=0.616). There were no significant 
differences in secondary outcomes for lung function, except for a reduction in mean daily peak 
expiratory flow (difference 14.7 L/min, SD 7.35, 95% CI 0.32-29.1 L/min, p=0.045) in the active 
device, and no differences in asthma control or airway inflammation. There was no difference in 
generic or disease-specific health-related quality of life overall, although statistically significant 
higher quality of life at month 6 was observed.  
Conclusions 
Within the limits of the data, no consistent benefits of the active device were demonstrated.   
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CHAPTER 1. INTRODUCTION 
1.1. BACKGROUND AND RATIONALE 
1.1.1. THE BURDEN OF SEVERE ASTHMA 
1.1.1.1. EPIDEMIOLOGY 
Asthma affects over 5.4 million people in the UK with nearly 500,000 experiencing severe symptoms 
and frequent exacerbations that are inadequately controlled with available treatments. (Asthma UK 
2004) (Holgate and Polosa 2006). The burden of severe asthma on the NHS is enormous, accounting 
for 80% of total asthma cost (£1 billion) (Asthma UK 2017) with frequent exacerbations and 
expensive medications generating much of this cost (Hoskins et al 2000). Reported UK asthma 
deaths are amongst the highest in Europe and rates have plateaued at between 1000 and 1200/year 
since 2000 (NRAD 2014) (DoH 2011). Those whose asthma remains poorly-controlled face the 
greatest risk (Tough et al 1998) (Turner et al 1998) (Campbell et al 1997). Patients with severe 
asthma bear the greatest burden of asthma morbidity. They experience more frequent and severe 
exacerbations (Bousquet et al 2010) which reduce their quality of life, impair their ability to work 
and place an enormous burden of anxiety on them and their families (Rodrigo et al 2004).  There is 
also an increased risk of significant depression (Nejtek et al 2001).  1 in 5 asthmatics in the UK report 
serious concerns that their next asthma attack will be fatal (Asthma UK 2004). As highlighted in the 
2010 Asthma UK report ‘Fighting for Breath’, these patients also face discrimination from employers, 
healthcare professionals and society as a whole as a result of their asthma (Asthma UK 2010).  
1.1.1.2. THE UNMET NEED IN SEVERE ASTHMA  
Current treatments including oral corticosteroids, ‘steroid-sparing’ immunosuppressants and 
monoclonal antibody therapies often have limited efficacy and potentially serious side effects 
(steroids, immunosuppressive agents) or are prohibitively expensive (monoclonal antibodies). The 
adverse effects of long-term oral steroids include adrenal suppression, decreased bone mineral 
density, diabetes and increased cardiovascular mortality (Manson et al 2009).  The anti-IgE 
treatment Omalizumab
©
 has been shown to reduce exacerbations by up to 50% (Humbert et al 
2005) and improve quality of life in severe allergic asthma but costs up to £26,640 per year (NICE 
2012). The National Institute for Health and Clinical Excellence reappraised the use of Omalizumab© 
in 2012 and, whilst recognising the grave effects of severe uncontrolled asthma on quality of life for 
patients and their families, have concluded that this is only cost-effective within the NHS when its 
use is limited to those with severe, persistent, confirmed allergic, IgE-mediated, asthma 
experiencing 4 or more severe exacerbations in the preceding 12 months (NICE 2012). A large 
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number of patients are therefore left with a significant unmet clinical need and a specific 
requirement for therapies which reduce systemic steroid exposure. 
1.1.1.3. NATIONAL/INTERNATIONAL STRATEGIES TO IMPROVE ASTHMA CARE 
The Department of Health “Outcomes Strategy for COPD and Asthma” (DoH 2011) recognises the 
huge burden that poorly controlled asthma places on people’s lives and the NHS. It also describes 
the political commitment to improve asthma control and reduce asthma related emergency 
healthcare needs and deaths. The 2014 British Thoracic Society (BTS) and Scottish Intercollegiate 
Guidelines Network (SIGN) national asthma guidelines and 2010 WHO consultation on severe 
asthma (BTS/SIGN 2014) (Bousquet et al 2010) have highlighted an urgent need for research in 
severe asthma, acknowledging the limitations of available treatments in severe asthma and the 
dearth of clinical trials upon which to base management recommendations. In its research strategy 
for 2016 – 2021, Asthma UK identifies the development of new treatments as a priority for 
improving clinical outcomes and patient well-being and reducing the cost of treating severe asthma 
within the NHS. It also identifies the need to gain a better understanding of the impact of exposure 
to substances known to trigger asthma, and the impact of strategies that regulate and control this 
exposure, as a key priority.  
1.1.2. THE SIGNIFICANCE OF ALLERGEN EXPOSURE AND ENVIRONMENTAL INTERVENTIONS 
More than 70% of people with severe asthma are sensitised to common aeroallergens and/or 
moulds (Heaney et al 2010,) the level of allergen exposure determining symptom severity; those 
exposed to high allergen levels are at increased risk of exacerbations and hospital admissions. 
(Custovic et al 1996,) (Tunnicliffe et al 1999,) (Langley et al 2003,) (Rosenstreich et al 1997).  
Domestic exposure to allergens is also known to act synergistically with viruses in sensitised patients 
to increase the risk and severity of exacerbations (Green et al 2002).  Allergen avoidance has been 
widely recognised as a logical way for treating these patients (Custovic et al 1998). In controlled 
conditions, long-term allergen avoidance in sensitised asthmatics reduces airway inflammation with 
consequent symptomatic improvement, further supported by high-altitude, clean-air studies (Van 
Velzen et al 1996,) (Peroni et al 1994,) (Grootendorst et al 2001). Unfortunately, effective methods 
of allergen reduction have proved elusive (Gotzsche and Johansen 2008) (Sublett 2011) with current 
measures unable to reduce allergen load sufficiently to yield a consistent clinical improvement, thus 
leaving a significant gap in the potential strategies for reducing asthma severity through allergen 
reduction. 
1.1.2.1. RATIONALE FOR TEMPERATURE CONTROLLED LAMINAR AIRFLOW (TLA) 
THERAPY 
At night, airborne particles are carried by a persistent convection current established by the warm 
body, transporting allergens from the bedding area to the breathing zone (Spilak et al 2016). Proof-
17 
 
of-concept studies have shown that the TLA device reduces the total number of airborne particles 
>0.5μm in the breathing zone by 3000-fold (p<0.001), cat allergen exposure by 30-fold (p=0.043) and 
significantly reduces the increase in number of particles generated when turning in bed for all 
particle sizes (Gore et al 2010).  When compared to a best in class traditional air cleaner, TLA is able 
to reduce exposure to potential allergens by a further 99% (Sigsgaard 2010). We postulated that this 
highly significant reduction in nocturnal exposure, targeted to the breathing zone, explained why 
TLA might succeed in an area where so many other measures, including traditional air cleaners, had 
failed. 
1.1.2.2. CURRENT EVIDENCE OF BENEFIT WITH TLA THERAPY 
A small randomised controlled cross-over trial in Sweden (Pedroletti et al 2009,) randomised 22 
patients (age range 12-33 years) to either an active or placebo TLA device for 10 weeks, followed by 
a 2-week wash-out phase before switching to the opposite treatment group for another 10 weeks. 
The primary outcome measure was mean change in quality of life, measured as mini‑AQLQ score. 
Bronchial inflammation (FENO) and lung function (spirometry) were also measured. Treatment with 
the active TLA device resulted in an improved quality of life score that was significant compared with 
the placebo group (difference in mean score change 0.54; p<0.05). Significantly lower values of FENO 
were also detected during the active treatment period (mean −6.95ppb; p<0.05). 
These findings were replicated in a larger pan-European multicentre 12-month randomised-
controlled trial (Boyle et al 2012) (n=282, age range 7-70 years). Treatment with an active TLA device 
when compared to placebo improved asthma-related quality of life and bronchial inflammation 
(FENO). In this trial the greatest benefit was seen in the more severe asthma patients requiring 
higher intensity treatment (GINA Step 4) and with poorly controlled asthma (Asthma Control 
Questionnaire <19). GINA Step 4 is consistent with ATS/ERS Severe Asthma Guideline definitions 
2014 (Chung et al 2014) and BTS/SIGN Guideline treatment Step 4 (inhaled corticosteroid dose 
≥1000µg/day beclomethasone (BDP) equivalent plus an additional controller medication such as a 
long acting ß2-agonist, leukotriene receptor antagonist or a sustained release theophylline). Whilst 
not powered to ascertain an effect on exacerbations, a post-hoc analysis of the study data showed a 
decreased exacerbation rate in the more severe patients treated with TLA when compared with 
placebo with a trend towards significance (mean 0.23 TLA; 0.57 placebo p=0.07). The trial was 
powered to detect a difference in asthma-related quality of life and did not specifically include 
patients at risk of exacerbations (average annual rate of exacerbations in the study population was 
only 0.2 exacerbations/year).  
In a small German trial of 32 patients (Schauer et al 2015) with poorly controlled asthma (GINA 3-4) 
prospective medical records data on exacerbations and asthma control were compared in the year 
before and after introduction of TLA treatment. This study found a reduction in the annual rate of 
exacerbations (3.57 before and 1.30 after; p=0.00013) after the introduction of the TLA device. 
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Improvements were also seen in asthma control, healthcare utilisation and bronchial hyper-
reactivity after introduction of the TLA device. 
A further, pragmatic, patient-centred, RCT of this novel non-pharmacological treatment in patients 
with severe, exacerbation-prone, allergic asthma was thus warranted in order to determine whether 
TLA treatment is effective in reducing the frequency of asthma exacerbations in this patient group. 
1.1.3.  THE LASER TRIAL 
The LASER Trial (Temperature-controlled Laminar Airflow in Severe Asthma for Exacerbation 
Reduction) was designed to assess whether home-based nocturnal TLA treatment can effectively 
reduce asthma related morbidity over a 1-year period in a real-life group of poorly-controlled, 
severe allergic asthmatic patients in the UK. 
A funding grant of £1.2m was awarded by the National Institute for Health Research Health 
Technology Assessment programme to the research team at Portsmouth Hospitals NHS Trust (NIHR 
HTA Project Number 12/33/28) to deliver the Trial. The Trial was sponsored by Portsmouth Hospitals 
NHS Trust.  
1.1.3.1  OBJECTIVES 
The LASER Trial was designed to meet the following objectives: 
PRIMARY OBJECTIVE 
To determine whether nocturnal TLA treatment reduces the frequency of severe asthma 
exacerbations (defined as an acute deterioration in asthma requiring treatment with systemic 
corticosteroids, ≥30mg prednisolone or equivalent daily or ≥50% increase in dose if maintenance 
30mg prednisolone or above, for 3 or more days). 
SECONDARY OBJECTIVES 
• To assess the impact of nocturnal TLA treatment on asthma control, including: 
1. Current clinical asthma control, which is the extent to which the clinical manifestations of 
asthma (symptoms, reliever use, and airway obstruction) have been reduced or removed by 
treatment. 
2. The risk of future adverse asthma outcomes which includes loss of control, exacerbations, 
accelerated decline in lung function, and side-effects of treatment. 
• To ascertain the effect of TLA treatment on quality of life in poorly-controlled severe 
allergic asthmatic participants. 
• To evaluate the impact of TLA treatment on education/work days lost. 
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• To qualitatively evaluate the perceptions, values and opinions of the device to identify 
potential modifications to improve participant acceptance and to inform future implementation of 
the device within the NHS setting. 
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CHAPTER 2. METHODS  
2.1 TRIAL DESIGN 
The LASER trial was designed exclusively to meet the objectives previously described (See 1.1.3.1). 
The Trial design determined to best meet these objectives was a mixed-methods, multi-centre, 
randomised, double blind, placebo comparator, parallel group trial design, with each individual 
participant trialling the active or placebo device for 12 months.  
A placebo comparator was chosen as other add-on treatments in severe asthma (e.g. Omalizumab
©
 
and Bronchial Thermoplasty) vary greatly in indication, use and delivery, are not suitable for every 
patient, and would therefore not be able to be used consistently or safely in an ‘active’ control 
group. Participants were randomised in a 1:1 ratio to receive either an active treatment device, or a 
placebo device. Throughout the trial, participants in both treatment arms received standard asthma 
care in accordance with the national BTS/SIGN guidelines for the management of asthma in adults 
(BTS/SIGN 2014).  
Figure 2.1 presents a simple overview of the trial design, highlighting the 6 Study Visits (1. Screening 
Visit, 2. Randomisation Visit, 3. – 6. Follow-up Visit at 3, 6, 9 and 12 months). The full trial flow chart 
and data collected at each of these Study Visits are summarised in Figure 2.2 and Table 2.1, 
presented in full in Appendix F, and explained throughout this Methods chapter. 
 
Figure 2.1 Trial Design 
2.1.1 TRIAL PROTOCOL 
Figure 2.2 consolidates and summarises the major content of the trial protocol into a simple 
flowchart. The major activities comprising the trial are described below. The data collected at these 
visits are listed in Table 2.1. 
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• Participant recruitment (Chapter 3) 
• Study visits 
Participants were required to attend the following 6 study visits to collect the scheduled 
data indicated in Table 2.2. 
1. Screening Visit (Section 2.6.1) 
Purpose of data collection = Screen participant against trial inclusion and exclusion criteria 
(Section 2.2.2 and Section 2.2.3) 
2. Randomisation Visit (Section 2.6.2) 
Purpose of data collection = Assign participant to active or placebo device treatment arm 
(Section 2.7.2) 
3. 3-month Follow-up Visit 
4. 6-month Follow-up Visit 
5. 9-month Follow-up Visit 
6. 12-month Follow-up Visit 
Common purpose of Study Visits 3 – 6 = Secondary outcome data collection (Section 2.4.2) 
• Unscheduled data collection 
Purpose of data collection = Primary outcome data collection (Section 2.4.1) 
• Focus Group Interviews 
Purpose of data collection = Capture individual’s perceptions, expectations and meaning to 
explore acceptance, level of personal control, motivation and usefulness of the TLA device 
(Section 2.10.3.2) 
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Figure 2.2 LASER Trial Flowchart 
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Table 2.1 Data collected at each visit 
Scheduled data 
Visit 1: Screening Lung Function (Spirometry + Bronchodilator Reversibility)(FENO) 
Allergy testing (Skin Prick Tests) (Total IgE) (Serum Specific IgE) 
Questionnaires (ACQ) 
Visit 2: Baseline / 
Randomisation 
Lung Function (Spirometry + Bronchodilator Reversibility) 
Questionnaires (ACQ) (AQLQ) (EQ-5D-5L) (SNOT-22)(WPAI) 
2 week diary submission* 
Visits 3 – 6:  
Follow-up Visits 
(Treatment period) 
Lung Function (Spirometry) (FENO) 
Questionnaires (ACQ) (AQLQ) (ED-5D-5L) (SNOT-22) (WPAI) 
2 week diary submission* 
TLA diary review of device adherence 
Visit 6 only  Lung Function (Bronchodilator Reversibility) 
Additional Questionnaire (GETE)  
Unscheduled data 
Exacerbation history collected throughout study at “Exacerbation Reviews” 
Continuous daily “TLA diary” completion including daily corticosteroid dose 
Exacerbation history also recorded at Follow-up Visits 
 
*2 week diary (issued at visits 1-5) 
Diary collection of: 
i) Twice Daily Electronic Peak Flow Recordings 
ii) Symptoms (paper diary) documenting daytime/nocturnal asthma 
symptoms and reliever medication use. 
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2.2 ELIGIBILITY AND INCLUSION/EXCLUSION CRITERIA 
2.2.1 PARTICIPANTS 
The chosen eligibility criteria closely mirror those of previous studies reporting the rates of severe 
exacerbation used in the statistical models of this trial (see Appendix G). 
2.2.2 INCLUSION CRITERIA 
Potential participants had to meet ALL of the following inclusion criteria by Randomisation Visit 2 to 
be considered eligible for the study: 
• Adults (aged 16-75 years inclusive)  
• A clinical diagnosis of asthma for ≥6 months supported by evidence of ANY ONE of the 
following: 
 Airflow variability with a mean diurnal peak expiratory flow (PEF) variability  >15% during 
the baseline 2-week period or a variability in forced expiratory volume in 1s (FEV1) of >20% 
across clinic visits within the preceding 12 months, with concomitant evidence of airflow 
obstruction (FEV1/FVC ratio <70%, where FVC is forced vital capacity); 
 Airway reversibility with an improvement in FEV1 by ≥12% or 200 ml after inhalation of 400 
μg of salbutamol via a metered dose inhaler and spacer at first study visit or within the 
preceding 12 months; 
 Airway hyper-responsiveness demonstrated by Methacholine challenge testing with a 
provocative concentration of Methacholine causing at least a 20% reduction in FEV1 (PC20) 
of ≤8mg/ml or equivalent test (see Appendix H). 
• Severe asthma  
 Requirement for high-dose inhaled corticosteroids (ICS) (≥1000μg/day beclomethasone 
(BDP) or equivalent – see Appendix I) plus a second controller (long-acting ß2-agonist or 
anti-muscarinic, theophylline, or leukotriene antagonist), and/or systemic corticosteroids; 
 If on maintenance corticosteroids, the maintenance dose must have been stable for 3-
months – this excluded any interim need for short-term steroid bursts to treat 
exacerbations. 
• Poorly controlled asthma demonstrated by BOTH: 
 ≥2 severe asthma exacerbations requiring systemic corticosteroids ≥30mg prednisolone or 
equivalent daily (or ≥50% increase in dose if maintenance 30mg prednisolone or above), for 
3 or more days, during the previous 12 months, despite the use of high-dose inhaled 
corticosteroids (ICS) and additional controller medication; 
25 
 
 Asthma Control Questionnaire (ACQ) 7-point score >1 at Screening Visit 1 and 
Randomisation Visit 2.  
• Atopic status  
 Sensitisation to ≥1 perennial indoor aeroallergen  (including House Dust Mite, domestic pet 
or fungi) to which they are likely to be exposed during the study, demonstrated by a 
positive skin prick test against Der p 1, Der f 1, Asp f 1, Alt a 1, Cla h 1, Fel d 1 or Can f 1 
(wheal diameter ≥3mm more than negative control) or specific IgE ≥0.35 IU/L determined 
by blood test. 
• Recent medical stability 
 Exacerbation free and taking stable maintenance asthma medications (not including short-
acting bronchodilator or other reliever therapies) for at least 2 weeks prior to Screening 
Visit 1 and in the period between Screening Visit 1 and Randomisation Visit 2 (the Screening 
Period). Participants suffering a severe exacerbation during the Screening Period were 
rescreened 2 weeks after returning to their maintenance asthma medications. 
• Adherence 
 Able to use the TLA device during sleep on at least five nights per week (excluding holidays). 
 Able to understand and give written informed consent prior to participation in the trial and 
able to comply with the trial requirements.  
2.2.3 EXCLUSION CRITERIA 
Potential participants who met ANY of the following exclusion criteria were excluded from 
participating in the study: 
• Current smokers or ex-smokers abstinent for <6 months. 
• Ex-smokers with ≥15 pack year smoking history. 
• Partner who is a current smoker and smokes within the bedroom where the TLA device is 
installed. 
• TLA device cannot be safely installed within the bedroom. 
• Intending to move out of study area within the follow-up period. 
• Documented poor treatment adherence.  
• Occupational asthma with continued exposure to known sensitising agents in the 
workplace. 
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• Previous bronchial thermoplasty within 12 months of randomisation. 
• Treatment with Omalizumab
©
 (anti-IgE) within 120 days of randomisation. 
• Using long-term oxygen, Continuous Positive Airway Pressure (CPAP) or Non-Invasive 
Ventilation (NIV) routinely overnight as it is known that this impairs the effect of the TLA 
device. 
• Uncontrolled symptomatic gastro-oesophageal reflux that may act as a persistent asthma 
trigger. 
• Presence of clinically significant lung disease other than asthma, including smoking-related 
chronic obstructive pulmonary disease (COPD), bronchiectasis associated with recurrent 
bacterial infection, allergic bronchopulmonary aspergillosis (mycosis), pulmonary fibrosis, 
sleep apnoea, pulmonary hypertension, or lung cancer, that, in the opinion of the Principal 
Investigator, is likely to be contributing significantly to the participant’s symptoms. 
• Clinically significant co-morbidity (including cardiovascular, endocrine, metabolic, gastro-
intestinal, hepatic, neurological, renal, haematological and malignant conditions) that 
remains uncontrolled with standard treatment. 
• Participants currently taking part in other interventional respiratory clinical trials. 
2.2.4 CENTRES AND CARE PROVIDERS 
The feasibilities of 25 secondary care providers as Recruiting Centres for the LASER trial were 
considered. The 14 sites listed in Table 2.2 were selected, all with trial teams embedded within 
Respiratory Departments. Each of these Recruiting Centres activated the trial at different dates 
during the study period and these activation dates are also shown in Table 2.2. 
Table 2.2 Recruiting Centres and trial activation dates 
Site Date of activation 
Portsmouth, Trial Lead Site 7 May 2014 
Aintree 17 Jun 2014 
Heartlands Birmingham 26 Jun 2014 
Leicester 09 Jul 2014 
Southampton 09 Jul 2014 
Bradford 09 Sep 2014 
Royal Liverpool 20 Jan 2015 
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St Georges 22 Jan 2015 
Chester 03 Feb 2015 
Oxford 26 Feb 2015 
Hull 02 Apr 2015 
Maidstone 07 Jul 2015 
Queen Elizabeth Birmingham  30 Jul 2015 
Belfast 26 Aug 2015 
 
2.3. INTERVENTIONS 
2.3.1. TREATMENT VERSUS COMPARATOR 
2.3.1.1 ACTIVE DEVICES  
The active TLA device (Airsonett®) significantly reduces nocturnal allergen exposure by filtering 
ambient air through a high efficiency particulate air filter, slightly cooling the air (0·5-0·8°C) and 
‘showering’ it over the participant during sleep. The reduced temperature allows the filtered air to 
descend in a laminar stream, displacing allergen rich air from the breathing zone and thereby 
reducing allergen exposure without creating draft or dehydration.  The device is installed next to the 
participant’s bed and is easy to use with no identified safety concerns in previous trials. The device is 
CE marked and licensed for use in the UK for allergic asthma. The device uses the same amount of 
electricity as a 60W light bulb and has an anticipated life-span of 5 years with filter changes required 
every 6 months. 
 
 
Figure 2.3 The temperature-controlled Laminar Airflow (TLA) device, Airsonett® 
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2.3.1.2  PLACEBO DEVICES 
The placebo devices are adjusted to deliver isothermal air instead of slightly cooled air, and holes in 
the filter effectively allow the air to bypass it whilst still maintaining an equivalent sound and airflow 
level to an active device. This allows the placebo device to deliver non-laminar, non-filtered, non-
descending, isothermal air which, when mixed with the warm body convection, ascends towards the 
ceiling and thus has no effect on the normal air flow pattern around the breathing zone. There is no 
difference in the air delivery rate, perceived air movements or sound level between an active or 
placebo device. The human body is not able to detect an absolute temperature difference of 0.75°C 
and as such there is no perceptible temperature difference sleeping beneath an active or a placebo 
device. Electricity usage is the same as for active devices and the ‘filter’ is changed at 6-monthly 
intervals. 
 
2.3.2 ASTHMA CARE DURING THE TRIAL 
2.3.2.1  TREATMENTS WHEN STABLE 
All participants were evaluated by clinicians with expertise in severe asthma during the study follow-
up visits (Study Visits 3, 4, 5 and 6). These experts were able to identify and exclude alternative or 
co-morbid pathologies contributing to poor asthma control and confirm treatment adherence. 
No adjustment or reduction of asthma medications (excluding antihistamines and nasal 
corticosteroids) were allowed during the trial (unless required for patient safety reasons) due to the 
significant risk of precipitating severe asthma exacerbations. Any variation in non-asthma 
medication usage was recorded at each follow-up visit (including the use of over-the-counter 
medications). 
Those participants using variable “Maintenance ± Adjustable Reliever Therapy (MART)”, which 
combines inhaled corticosteroid (ICS) and bronchodilator therapy in a single inhaler, were converted 
to a fixed dose regimen (preferably without changing inhalers) and an alternative short-acting 
bronchodilator (e.g. Salbutamol, Terbutaline) by the site team for the duration of the trial. A LASER 
“BDP equivalent” dose calculator was developed to allow Centres to easily calculate the BDP 
equivalent of their inhaled corticosteroid based on the dose and frequency of use, and on known 
pharmacokinetics of all available inhaled therapy.  
Participants using Self-Management Plans (SMPs) prior to the trial were allowed to continue and 
asked not to change this during the trial treatment period. 
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2.3.2.2  ASTHMA EXACERBATIONS 
Asthma exacerbations were managed following best clinical practice in the appropriate setting 
following the national BTS/SIGN guidelines (BTS/SIGN 2014).. 
If participants required urgent medical attention at any time during the follow-up period, they were 
instructed to call 999 and/or to attend the Emergency Department. If the participant did not require 
urgent medical attention, they were instructed to follow their normal process for seeking medical 
attention either from their GP, practice nurse or asthma specialist within working hours, and to 
contact their local primary care out-of-hours service during out of hours. 
Participants who self-managed their oral corticosteroids were instructed to contact 999 if they 
required urgent medical attention or to self-manage in the community as directed by their agreed 
self-management plan if they did not require urgent medical attention.  
Participants reported severe exacerbations to their local site trial team as soon as possible after 
exacerbation onset (Section 2.4.1.1). 
Clinicians prescribed the process for reducing and ultimately stopping corticosteroid treatment and 
returning to normal maintenance dose after each exacerbation, determined by individual patient 
need.  
2.3.3 INTERVENTION STANDARDISATION 
Prior to shipping, the manufacturer (Airsonett®) ensured all devices were quality checked to CE 
standard on air temperature regulation, airflow and breathing zone particle reduction metrics. They 
also provided all the required quality control documentation. 
2.3.4 ADHERENCE MONITORING 
To simplify adherence to the intervention, study devices were programmed at installation to 
automatically turn on for a minimum of 10 hours to cover the participants’ normal sleeping hours. 
This could be overridden by the participant should they wish to start the treatment at a different 
time or turn off the device. Participants were allowed to increase their usage of the device, e.g. for 
daytime naps. All episodes of usage of the device was documented in the daily participant-
completed TLA diary (Section 2.10.2.2). 
2.4 OUTCOMES 
The trial used validated, standardised primary and secondary outcomes for clinical asthma trials 
recommended by the American and European Thoracic Societies and endorsed by the COMET 
initiative (Reddel et al 2009).  Comparison of data at multiple time-points was used to assess the 
magnitude and rate of treatment response and variation in level of control. 
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2.4.1 PRIMARY OUTCOME 
There was one primary outcome: 
1. Severe asthma exacerbations occurring within the 12-month follow-up period. 
Severe asthma exacerbations are defined in accordance with ATS/ERS guidelines (Reddel et al 2009) 
as a worsening of asthma requiring systemic corticosteroids, ≥30mg prednisolone or equivalent daily 
(or ≥50% increase in dose if maintenance 30mg prednisolone or above) for 3 or more days. Courses 
of corticosteroids separated by ≥7 days are treated as separate severe exacerbations. 
2.4.1.1  MEASUREMENT OF PRIMARY OUTCOME 
Participants were asked to start an exacerbation diary (PED) when exceeding the ‘exacerbation-
dose’ threshold of systemic corticosteroids individually defined for each participant during 
Randomisation Visit 2. The PED included PEF measurements (using the trial electronic PEF device), 
oral corticosteroid dose, reliever medication use, and nocturnal asthma symptoms. Participants 
were asked to report severe exacerbations to their local site trial team as soon as possible after 
onset via a dedicated telephone line or a secure NHS e-mail account. Wherever possible, 
participants were asked to attend an Exacerbation Review with their local trial team within 72 hours 
to corroborate the exacerbation, at which the local trial team completed an Exacerbation Review 
Form (REV) using the PED. An exacerbation was confirmed if the participant met the trial definition 
for a severe asthma exacerbation corroborated by any one or more of the following additional 
criteria: 
1. An associated decrease in morning PEF compared to maximum morning PEF achieved at 
baseline. 
2. A 50 % increase in reliever medication on at least 2 of 3 successive days compared to 
baseline. 
3. Increased nocturnal wakening. 
If participants were not able to attend an Exacerbation Review, the PED was collected at the next 
follow-up visit. 
Information about exacerbations was also collected from the participant-completed daily diary in 
which they recorded their daily corticosteroid dose (TLA Diary), and from Follow-up Visit forms (FU) 
completed by the clinician delivering each follow-up visit. 
Details about how these various sources of exacerbation data were combined to make a useable 
primary outcome are detailed in Section 2.11.2.2. 
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2.4.2 SECONDARY OUTCOMES 
2.4.2.1  QUANTITATIVE 
The quantitative secondary outcomes of the LASER trial were: 
1. Asthma control 
To assess the impact of nocturnal TLA treatment on asthma control. 
2. Quality of life 
To ascertain the effect of TLA treatment on quality of life.  
3. Impact  
To evaluate the impact of TLA treatment on work productivity and activity impairment.  
4. Treatment Effect 
To determine participant and physician perception of treatment effect. 
1) Asthma Control 
The following indicators of current asthma control were determined and recorded at the 
Randomisation Visit (as baseline data) and each follow-up visit (3, 6, 9 and 12 months during trial as 
intervention data): 
• Lung function measures 
 Pre-bronchodilator FEV1  
 Mean morning pre-bronchodilator Peak Expiratory Flow (PEF) Rate over 2-weeks preceding 
follow-up visits  
 Fractional concentration of exhaled Nitric Oxide (FENO)  
• Asthma Control Questionnaire (ACQ) score 
• Asthma Control Diary (ACD) score over 2-weeks preceding follow-up visits 
• Sino-Nasal Outcome Test (SNOT-22) score 
The following indicators of risk of future adverse asthma outcomes were also determined and 
recorded at these visits: 
• Severe exacerbations (see Section 2.3.2.2 ‘Asthma Exacerbations’ for definition) 
• Systemic corticosteroid use over the 12 month follow-up period 
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• Post-bronchodilator FEV1 at 12-month follow-up visit 
2) Quality of life 
The following health-related participant quality of life scores were determined and recorded at the 
Randomisation Visit (as baseline data) and each follow-up visit (3, 6, 9 and 12 months, as 
intervention data): 
• AQLQ(S) score 
• EQ-5D-5L score 
3) Impact  
• Work Productivity and Activity Impairment (WPAI) score 
The WPAI score was determined and recorded at the Randomisation Visit (as baseline data) and 
each follow-up visit (3, 6, 9 and 12 months, as intervention data)  
4) Treatment Effect 
• Global Evaluation of Treatment Effect  
The Global Evaluation of Treatment Effect (GETE) score was collected at the 12 month follow up visit 
for both participants and physicians.  
2.4.2.2  QUALITATIVE 
In addition to the quantitative secondary outcomes described above, there was one qualitative 
secondary outcome: 
Acceptability 
To qualitatively evaluate the trial participant’s perceptions, values and opinions of the trial process 
and TLA device to identify potential modifications to improve participant acceptance and to inform 
future implementation of the device within the NHS setting. 
2.5 SAMPLE SIZE CALCULATION 
We performed a series of sample size simulations based on baseline annual exacerbation 
frequencies of 2, 3 and 4 per patient, with estimated reductions (effect sizes) of 25%, 33% and 50%, 
with power to detect a difference at 80% and 90%.  We then approached our Public and Patient 
Involvement group in the grant application to assess what a conservative but clinically meaningful 
reduction would mean for patients with severe asthma if this treatment was adopted in the NHS, 
and they agreed that a 25% reduction (equivalent to one less severe exacerbation every 2 years) was 
quite acceptable. This level of reduction was also consistent with that observed in previous trials of 
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severe asthma with effect sizes ranging from 21% to 63%, mean 41% (see Appendix G).  Given that 
this was a pragmatic trial where we expected our intervention to be less effective than an efficacy 
trial, we deliberately chose a more conservative effect size of 25%. 
Using the exacerbation frequency as the primary dependent variable, we considered whether the 
distribution of this count data was likely to approximate a Poisson or a negative binomial 
distribution. Previous trials have modelled analyses of exacerbation frequency by either using the 
Poisson approach (Pauwels et al 1997, Castro et al 2009, Hanania et al 2011, Humbert et al 2005, 
Bruselle et al 2012) or negative binomial (Bleecker et al 2016, Pavord et al 2012, Haldar et al 2009). 
Poisson is the traditional model favoured by the LASER trial statistical team, but this assumes the 
mean of the exacerbation frequency should approximate its variance. We considered aspects of the 
trial that would lead to the variance being greater than the mean i.e. “overdispersion”. These factors 
included the within-participant clustering due multiple exacerbations, no limit on exacerbations that 
can be experienced, the duration of follow up constrained to 12 months, the effect size and how the 
event rate may change during the Trial, and how many baseline covariates that would require 
adjustment. In calculating the sample size, we selected the Poisson distribution after consideration 
of different factors but included an allowance of 20% for over-dispersion to reduce the effect of an 
unequal mean and variance. In so using a Poisson approach for sample size estimation, it was also 
agreed that the final fit of the count data would determine which model (Poisson, negative binomial 
or a mixed approach) would be appropriate for analyses of the primary outcome.  
Settling on an estimated rate of 2 severe asthma exacerbations per participant over the 12-month 
period in the placebo group, we calculated that a minimum of 222 participants (111 per group) was 
required to provide 80% power (at 5% two-sided significance level) to detect that clinically 
meaningful 25% reduction in the average exacerbation rate in the group using the TLA device. This 
sample size was based on a Poisson regression model with the treatment group as the covariate a 
10% overall dropout rate and an adjustment of 20% Poisson over-dispersion (Royston 2004).  
2.6 PARTICIPANT SCREENING AND ENROLMENT 
2.6.1 SCREENING VISIT (-2 WEEKS) 
Informed Consent was sought for participation in the main trial as well as the qualitative focus group 
sessions at the Screening Visit. Informed Consent (Appendix C and Appendix D) preceded any study 
procedures (including tests to ascertain eligibility for trial inclusion), thus ensuring the individual had 
had an opportunity to fully discuss the Participant Information Sheet (PIS) (Appendix A and Appendix 
B) with the research team. 
If the individual passed all inclusion and exclusion criteria pertinent to the Screening Visit (namely 
the baseline spirometry including reversibility test, skin prick test, blood test and ACQ score criteria 
described in Section 2.2.3), they were trained in use of the electronic PEF meter to measure morning 
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and evening PEF (prior to taking asthma medications) and completion of the Asthma Control Diary 
(ACD) for the 2-weeks prior to Randomisation Visit 2. 
2.6.1.1  EXTENSION OF SCREENING PERIOD 
To continue to be deemed a potentially eligible trial participant, individuals needed to demonstrate 
acceptable compliance with the electronic PEF recordings and Asthma Control Diary (ACD) during 
the 2-week screening period. However, in the event of electronic PEF device malfunction or if, in the 
investigator’s opinion, there were significant extenuating circumstances, the screening period was 
extended by up to a further 2 weeks. Participants experiencing a severe exacerbation during the 
screening period were no longer eligible but could be re-screened 2 weeks after returning to their 
maintenance asthma medications. 
2.6.2 RANDOMISATION VISIT 2 (0 MONTHS) 
The following data collected during the screening period and at the Randomisation Visit (Study Visit 
2) were used to assess whether the potential participant fulfilled the following remaining eligibility 
criteria (see Section 2.2.3 for full description of eligibility criteria): 
• Demographics, asthma history and asthma review (see Section 2.10.1.1) 
• Review of Asthma Control Diary (ACD), including electronic PEF recordings (see Section 
2.10.2.1) 
• Asthma Control Questionnaire (ACQ) score (see Section 2.10.1.4) 
Those individuals who met these remaining eligibility criteria were confirmed as eligible for 
participation. The data used in the final eligibility assessment were supplemented by the following 
data in the Case Report Form (CRF) to act as baseline data (see Section 2.10.1 for descriptions of 
these measures): 
• SNOT-22, AQLQ(S), EQ-5D-5L and WPAI(A) 
• Fractional concentration of exhaled nitric oxide (FENO) 
• Baseline spirometry after withholding bronchodilator (Pre-bronchodilator FEV1) 
Finally, the participant was then provided with the materials they required to measure and record 
the primary and secondary trial outcome data (see Sections 2.4.1 and 2.4.2. for outcome definitions, 
respectively), including a TLA diary for self-reported device usage (see Section 2.10.2.2), at least 3 
Exacerbation Diaries (PED, see Section 2.10.2.3), and a 2-week Asthma Control Diary (ACD, including 
electronic PEF recordings – see Section 2.10.2.1) issued for completion in the 2 weeks prior to the 3-
month follow-up visit. 
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2.7 RANDOMISATION 
2.7.1 DEVICES 
The trial statistician generated a list of LASER specific device numbers (L-numbers) coded against an 
X or a Y (i.e. active or placebo), which they sent in a password-protected electronic file to the 
following Airsonett® personnel only: Chief of Operations, the Director of R&D and the Director of 
QA. This list was generated using STATA version 13.1 command RALLOC. A total of 400 codes were 
generated in blocks of 20 (10 active and 10 placebo) in line with Airsonett® manufacturing the 
devices in blocks of 20. 
The Airsonett® personnel with access to the list oversaw the manufacture of the active and placebo 
devices according to these L-numbers. Each device was labelled with both L-number and 
manufacturing serial number.  
2.7.2 PARTICIPANTS AND MINIMISATION CRITERIA 
Once the eligibility of an individual was confirmed at the Randomisation Visit, the trial team at the 
recruiting site contacted the Oxford Respiratory Trials Unit (ORTU) to arrange randomisation. 
Participants were randomised in a 1:1 ratio to receive either an active TLA device or a placebo 
device. Randomisation was undertaken centrally by Sealed Envelope
TM
 using a validated computer 
randomisation program including a nondeterministic minimisation algorithm to ensure balanced 
allocation of participants across the two treatment groups for each clinical site, prevalent vs. 
incident cases* and the following prognostic factors at baseline: exacerbation frequency in the 
previous 12 months (2, 3, ≥3), use of oral corticosteroids (yes/no) and pre-bronchodilator FEV1 
(>50% predicted yes/no), as these are key indicators of future exacerbation risk. This approach 
accounted for the characteristics of the participants who had been previously randomised when 
randomising each new participant. By trial end, 119 of the 240 participants were allocated an active 
device, and 121 were allocated a placebo device.  
*(Participants previously known to the recruiting Centre were termed Prevalent participants, 
whereas participants not previously known to the recruiting Centre but maybe referred from 
another Centre or through a social media channel were termed Incident participants). 
Once participant randomisation was complete, Sealed Envelope
TM
 sent a secure e-mail to the local 
trial team to confirm randomisation and to provide the information required for implementation 
described in Section 2.8. Note the device allocation was embedded into the Sealed Envelope
TM
 
system. 
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2.8 IMPLEMENTATION 
After randomisation of each new participant to the active or placebo treatment group, Sealed 
Envelope
TM
 selected which device with the appropriate treatment would be received by each 
randomised participant. It then sent secure e-mail and SMS message to the local independent device 
distributors (Bishopsgate, UK-based logistics company which specialises in medical devices) with the 
following details: Participant trial number, allocated L-number (without X or Y designation so that 
allocated treatment arm remained concealed) and an exclusive link for the engineering team to log 
in to access the participant's contact details and address.  
2.8.1 DEVICE INSTALLATION 
The Bishopsgate engineering team contacted the participant within 72hrs of their Randomisation 
Visit to arrange device delivery and installation. The engineering team were trained with certificates 
of competency based on completion of a GCP training course on trial procedures, and they followed 
a standard device delivery, filter change and removal protocol developed by the Trial team. The 
agreement with Bishopsgate was that devices should be installed within 10 working days, excluding 
weekends and bank holidays. They left written instructions on device operation with the participant 
during the installation visit. 
2.8.2 DEVICE MAINTENANCE 
All devices require a filter change on a 6-monthly basis. The date for the filter change was 
automatically calculated from the date of randomisation. The Trial Manager informed Bishopsgate 
on a monthly basis which participant’s devices required a filter change. Bishopsgate contacted the 
participant to arrange a convenient date and time for filter change. 
 
2.8.3 TROUBLESHOOTING 
Participants were asked to report problems with device function with their local site team as soon as 
possible. If required, arrangements were made for a Bishopsgate engineer to attend to replace a 
faulty device with an alternative device of the same allocation (active or placebo).  
2.9 BLINDING 
The methods described above for the manufacture of active and placebo devices, the allocation of 
participants to the two treatment arms and the implementation of device installation ensured that 
all participants, trial teams and members of the installation team were blinded to the trial 
treatments. This process ensured that everyone with the exception of the Trial statistician who 
generated the codes for the devices and the programmers at Sealed Envelope
TM
 were blinded to the 
treatment allocation. The Airsonett® team were the only party to know the difference between the 
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active and placebo devices but they did not have access to any participant information or to device 
allocation in the UK. 
2.10 STUDY ASSESSMENTS 
This section describes all the data collected at the Study Visits, including those recorded between 
Study Visits: 
Quantitative Data 
• Demographics, asthma history and asthma review 
• Lung function measures 
 Pre-bronchodilator FEV1 
 Post-bronchodilator Reversibility Testing 
 Fractional concentration of exhaled Nitric Oxide 
• Allergy testing 
 Skin Prick Test 
 Serum Specific IgE Testing 
• Participant questionnaires 
 Asthma Control Questionnaire 
 Standardised Asthma Quality of Life Questionnaire (disease-specific quality of life) 
 EuroQol-5 Dimensions 5-levels (generic quality of life) 
 22-item Sino-Nasal Outcome Test (rhinosinusitis health status) 
 Global Evaluation of Treatment Effect Questionnaire 
 Work Productivity and Activity Impairment Questionnaire 
• Pre-visit data collection 
 Asthma Control Diary (ACD) 
o Peak Expiratory Flow (PEF) Rate 
o Symptom and Reliever Medication Use 
 TLA Diary  
o Device usage 
o Daily Corticosteroid dose 
o Reliever usage 
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Qualitative Data 
• Focus Groups 
This quantitative and qualitative data were used for one or more of the following six purposes: 
P1.  To inform eligibility of an individual to participate in the trial against the inclusion and 
exclusion criteria (see Section 2.2 for criteria) 
P2.  To build the primary outcome dataset (see Section 2.4.1 for Primary outcome definition) 
P3.  To build the secondary outcome datasets (see Section 2.4.2 for Secondary outcomes 
definitions) 
P4.  To create participant factor datasets used to control the primary and secondary outcome 
data against associations unrelated to the treatment 
P5.  To contribute to the baseline outcome datasets 
P6.  To build the supplementary variable datasets  
The purpose of each type of data mentioned in this section is indicated by the above corresponding 
letters. 
2.10.1 QUANTITATIVE DATA 
2.10.1.1 DEMOGRAPHICS, ASTHMA HISTORY AND ASTHMA REVIEWS 
The following data were recorded about each participant on the CRF at the Randomisation Visit only: 
• Demographics 
 Age (P1, P4) 
 Gender (P4) 
 Socio-economic class (P4) 
 Ethnicity (P4) 
• Asthma History 
 Date of asthma diagnosis (P1, P4) 
 History of life threatening and near fatal asthma exacerbations (ITU admissions) (P6) 
 Number of severe asthma exacerbations in previous 12 months (P1, P5) 
 History of previous asthma treatment (P1) 
 History of atopy (P1) 
 Family history of asthma/atopy (P6) 
 Asthma triggers (P1) 
 Medical or surgical co-morbidities (P1) 
 Occupational history (P1) 
 Smoking history (P1) 
 Height (cm) / Weight (kg) for measuring predicted lung function (P3) 
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The following data were collected at each follow-up visit as well as at the Randomisation Visit and 
recorded by the attending clinician on the FU / CRF, respectively: 
• Asthma Review 
 Current asthma symptoms and treatment (P1, P3, P5) 
 Current medications (P1) 
 History of severe asthma exacerbations since previous trial visit and current participant-
reported clinical status (still in exacerbation or recovered) (P2) 
 Unscheduled asthma-related healthcare use (P3) 
 Work / study days lost as a result of asthma symptoms (P3) 
2.10.1.2 LUNG FUNCTION MEASURES 
The following indicators of lung function were collected at the Study Visits: 
• Pre-bronchodilator FEV1 (P1, P3, P5) 
Spirometry was conducted at the Screening Visit, Randomisation Visit and 3, 6, 9 and 12-month 
Follow-up Visits to collect the following variables: 
 FEV1 (Litres) 
 FVC (Litres) 
 FEV1/FVC ratio 
 FEF25-75 (%) 
FEV1 and FVC were documented as both absolute values and as a percentage of the predicted value.  
A spirometer conforming to ATS/ERS standards (Miller et al 2005) was used as specified by the 
manufacturer’s instructions. 
• Reversibility Testing (P1, P3, P5) 
Post-bronchodilator FEV1 (both percentage change and volume change) was measured at the 
Screening Visit and 12-month Follow-up Visit only.  
Following ATS/ERS standards (Miller et al 2005,) post-bronchodilator FEV1 was defined as FEV1 
recorded 15 minutes after administration of 400μg Salbutamol via a metered dose inhaler and 
spacer device. An improvement in FEV1 post bronchodilator of ≥12% or 200mls was considered 
significant.  
• Fractional concentration of exhaled Nitric Oxide (P3, P5) 
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FENO was measured before spirometry at the Randomisation Visit and 3, 6, 9 and 12-month Follow-
up Visits. The measurements were made using a NIOX MINO® device (Aerocrine AB®, Solna, Sweden) 
as specified by the manufacturer’s instructions and outlined in the ATS/ERS standards for the 
measurement of exhaled Nitric Oxide (ATS/ERS 2005). 
2.10.1.3 ALLERGY TESTING 
The following allergy tests were made during the Screening Visit to determine whether the allergy-
related trial inclusion criteria were met: 
• Skin Prick Testing (P1) 
A standard skin prick test procedure using common indoor aeroallergen (Der p 1, Der f 1, Asp f 1, Alt 
a 1, Cla h 1, Fel d 1 and Can f 1) extracts along with negative (saline) and positive (histamine) 
controls was performed on all subjects. This occurred during the Randomisation Visit instead of at 
the Screening Visit if antihistamine hold was required (see Appendix J). Skin prick testing was 
performed in accordance with the Practice Parameter released by the American Academy of Allergy, 
Asthma and Immunology (Bernstein et al 2008). A positive skin prick test reaction was measured as a 
wheal of at least 3mm in diameter greater than the negative control. 
• Serum Specific IgE Testing (P1) 
If skin prick testing was not available, a blood sample was taken to measure serum specific IgE to 
common indoor aeroallergens (Der p 1, Der f 1, Asp f 1, Alt a 1, Cla h 1, Fel d 1 and Can f 1). A specific 
serum IgE >0.35IU/L was considered to represent allergen sensitisation. Serum specific IgE testing 
could also have been used if there was uncertainty about a skin prick test result or there was a 
negative skin prick test result in the context of a patient on long term maintenance systemic 
corticosteroids. 
2.10.1.4 PARTICIPANT QUESTIONNAIRES 
• Asthma Control Questionnaire (ACQ) (P3) 
The well-validated 7-item Asthma Control Questionnaire (ACQ) (Juniper et al 1999) was used to 
assess asthma control over the 7 days leading up to the Screening Visit, Randomisation Visit and 3, 6, 
9 and 12-month Follow-up Visits. It was administered at the same time during each visit with the 
participant blind to the results of other tests.  
The ACQ includes 5 symptom scores, the amount of daily rescue bronchodilator usage and a 
measure of airway calibre (FEV1% predicted). Responses are given on a 6-point scale and the overall 
score is the mean of the responses (0=totally controlled, 6=severely uncontrolled). The ACQ has 
strong evaluative and discriminative properties and has been shown to be very responsive to within-
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patient changes in asthma control over time. It has a validated minimal important difference of 0.5 
to demonstrate clinical significance.  
• Standardised Asthma Quality of Life Questionnaire (AQLQ(S)) (P3) 
Asthma-specific quality of life was measured using the Standardised Asthma Quality of Life 
Questionnaire (AQLQ(S)) (Juniper et al 1993) at the Randomisation Visit and 3, 6, 9 and 12-month 
Follow-up Visits. 
The AQLQ(S) consists of 32 questions within 4 domains: 1. symptoms, 2. activity limitation, 3. 
emotional function and 4. environmental stimuli, and it has strong measurement properties and a 
validated minimal important difference of 0.5 (Juniper et al 1994). Patients are asked to think about 
how they have been during the previous two weeks and to respond to each of the 32 questions on a 
7-point scale (7 = not impaired at all, 1 = severely impaired). The overall AQLQ(S) score is the mean 
of all 32 responses and the individual domain scores are the means of the items in those domains.  
• EuroQol-5 Dimensions 5-levels (EQ-5D-5L) (P3) 
Generic Health-Related Quality of Life (HRQoL) was measured using the EuroQol-5 Dimensions 5-
levels (EQ-5D-5L) questionnaire at the Randomisation Visit and 3, 6, 9 and 12-month Follow-up Visits 
(EuroQol Group 2011).   
The EQ-5D-5L is a standardised measure of health providing a simple generic measure of health for 
clinical and economic appraisal. Patients are asked to think about their health in the day they are 
completing the questionnaire and report on any problems (none, slight, moderate, severe and 
unable/extreme) on 5 attributes (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression).  
In addition to the EQ-5D-5L score, the EQ Visual analogue scale (VAS) was also ascertained at each of 
these Visits. EQ-VAS was determined by asking the participants to indicate their health status on a 
20 cm vertical scale with end points of 0 and 100 (VAS; 0=worst health you can imagine to 100=best 
health you can imagine) at each Visit.  
EQ-5D-5L is the most widely used HRQoL measure in adults in the UK and has been shown to be a 
reliable and valid means of measuring quality of life in asthma patients (Pickard et al 2008).   
• 22-item Sino-Nasal Outcome Test (SNOT-22) (P3) 
The 22-item Sino Nasal Outcome Test (SNOT-22) score is a well validated and sensitive measure of 
rhinosinusitis health status (Hopkins et al 2009) that was recorded at the Randomisation Visit and 3, 
6, 9 and 12-month visits.  
42 
 
The SNOT-22 questionnaire consists of 22 questions related to symptoms and the social/emotional 
impact of those symptoms (rating symptoms on a scale from ‘no problem’/0 to ‘problem as bad as it 
can be’/5). Participants were asked to rate the problems according to how they had been over the 
previous 2 weeks. 
• Work Productivity and Activity Impairment: Asthma version 2.0 (WPAI(A)) (P3) 
The WPAI(A) is a validated questionnaire tool for assessing work productivity and activity 
impairment that was completed by participants at the Randomisation Visit and at the 3, 6, 9 and 12-
month visits.  
This questionnaire comprises 6 questions addressing absenteeism, presenteeism (reduced 
effectiveness whilst working,) overall work productivity loss (absenteeism + presenteeism) and 
activity impairment (Reilly et al 1993). Participants were asked to count the number of hours they 
had missed from work because of problems associated with their asthma and the number of hours 
missed for other reasons (such as vacation, holidays, etc) over the past seven days. In addition, 
participants were also asked to report from a scale (1=asthma had no effect to 7=asthma completely 
prevented me) the impact of asthma on their work and on the ability to do regular daily activities.  
WPAI(A) outcomes are measured as percentages and a higher percentage relates to greater 
impairment and reduced productivity. A modified WPAI(A) was used for student participants.   
• Global Evaluation of Treatment Effect (GETE) (P3) 
The Global Evaluation of Treatment Effect (GETE) questionnaire (Lloyd et al 2007) is a simple 
measure of perceived treatment effectiveness that was completed by participants and clinicians at 
the 12-month visit. 
This questionnaire has been used in the evaluation of other treatments in patients with severe 
allergic (IgE mediated) asthma. For the purposes of the LASER trial, it required participants and 
physicians to rate the global treatment effectiveness of the TLA device as excellent (complete 
control of asthma), good (marked improvement of asthma), moderate (discernible but limited 
improvement in asthma), poor (no appreciable change in asthma), or worsening (deterioration in 
asthma). 
2.10.2 PRE-VISIT DATA COLLECTION 
2.10.2.1 ASTHMA CONTROL DIARY (ACD) 
Participants were issued with a validated Asthma Control Diary (ACD) (Juniper et al 2000) at the 
Screening Visit, Randomisation Visit and 3, 6 and 9-month visits to record data for the 2-weeks 
leading up to their subsequent visit. Towards the end of the trial, a text reminder system was set up 
43 
 
to remind participants when to start their ACD and to remind them of the date of their follow-up 
visit. 
Participants recorded the following data on a daily basis for 2 weeks: 
• Peak Expiratory Flow (PEF) Rate 
During the trial, participants performed 3 morning PEF measurements using a hand-held device 
supplied by the trial team, and recorded these measurements in the ACD. 
During the screening period, participants also performed 3 evening PEF measurements to assess 
variability as part of eligibility assessment. This additional PEF data was stored on the PEF device and 
downloaded at the Randomisation Visit. 
• Symptom and Reliever Medication Use 
The ACD measures a morning score (2 items; 0-6 point scale), a bedtime score including 
bronchodilator requirement (4 items; 0-6 point scale) and a best morning peak expiratory flow rate 
measured as percentage of predicted best (0-6 point scale). The overall daily score is the mean of 
the responses (0=perfectly controlled, 6=severely uncontrolled). 
2.10.2.2 TLA DIARY 
Participants were issued with a TLA diary (Appendix K) at the Randomisation Visit to record the 
following data on a daily basis:  
 Use of the TLA device (hours), i.e. participant-reported treatment adherence 
 Reliever used (number of times) 
 Dose of corticosteroids (mgs) 
 
2.10.2.3 EXACERBATION DIARY (PED) AND EXACERBATION REVIEW FORMS (REV) 
Participants were asked to start an exacerbation diary (PED) (Appendix L) when exceeding the 
‘exacerbation-dose’ threshold of systemic corticosteroids individually defined for each participant 
during Randomisation Visit 2. The PED recorded the following during exacerbations for a period of 7 
days:  
 Morning PEF (L/min) (recorded using the trial-supplied electronic PEF device) 
 Steroid Dose (mgs) 
 Reliever use (number of times) 
 Nocturnal wakening (yes/no) 
 
In addition to completing the PED, participants were asked to report severe exacerbations to their 
local site trial team as soon as possible after onset via a dedicated telephone line or a secure NHS e-
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mail account. Wherever possible, participants were asked to attend an Exacerbation Review session 
with their local trial team within 72 hours to corroborate the exacerbation, at which the local trial 
team completed the Exacerbation Review Form (REV) (Appendix M). The following information were 
captured on the REV:  
 Onset of symptoms (date) 
 Steroid Dose (mgs) 
 Corroboration of exacerbation dose of corticosteroid (at least 30mg for 3 days) 
 Change in symptoms vs. baseline 
 Change in daily reliever use vs. baseline 
 
If participants were not able to attend an Exacerbation Review, a review of the exacerbation 
occurred by telephone and a REV was still completed. If a telephone review was not possible either, 
a REV was completed at the next Follow-up Visit. The nature of the review (face-to-face or 
telephone) was recorded on the REV. 
In all cases, the participant’s PED was collected at their next Follow-up Visit and used to corroborate 
other sources of primary outcome data. 
2.10.2.4 FOLLOW-UP VISIT FORMS 
A regular 3-monthly Follow-up Visit Form (FU) was completed by the Trial site team at each Follow-
up Visit (at 3, 6, 9 and 12 months), prompting discussion with the participant about key issues 
related to the past 3 months.  This included numbers of exacerbations, a review of the TLA diary, 
medication use, work and study days lost, reported device use, completion of Trial questionnaires, 
FENO and spirometry. These data were used to corroborate other sources of primary and secondary 
outcome data during statistical analysis. 
 
2.10.3 QUALITATIVE DATA  
2.10.3.1 SAMPLING AND RECRUITMENT 
All 240 LASER trial participants were invited to participate in the qualitative study and were given 
written information about the qualitative component of the trial as a separate Participant 
Information Sheet (Appendix B).  
Informed consent for participation in the qualitative study was sought at the LASER Trial Screening 
Visit (Appendix D). 
Not all participants who consented to taking part in the focus group sessions were selected: 5-10 
participants were selected for each of three focus group sessions on the basis that they best 
reflected multiple variation (including balance of gender, age and ethnicity).  
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2.10.3.2 FOCUS GROUPS 
A focus group is an interview technique where a group of individuals are encouraged to debate and 
discuss around specific topic areas. The rationale for choosing focus group discussions during the 
LASER trial was to stimulate alternative views and experiences, evaluate the process and assess the 
feasibility of the intervention. 
28 participants were invited to attend focus group sessions based on the fact that they had 
completed at least 9 months of the trial and had consented to attend local focus group sessions 
when asked at the start of the trial. 20 of these 28 participants agreed to attend a session and were 
sent invitation letters to attend one of three focus group sessions hosted by the Portsmouth site 
during January 2016. The three sessions were held on separate dates at different times of the day 
including an evening focus group in order to provide choice to those invited to attend and maximise 
attendance. The venue chosen was a non-NHS, non-trial centre, within an easily accessible location 
with on-site parking, namely, the Premier Inn Hotel in Port Solent. 
Acceptance of the invitations covered consent for the use of verbatim quotations and assurance that 
the information that a participant provided would be kept strictly in confidence and anonymised.  
The focus groups were led by a senior qualitative researcher from the University of Portsmouth (Dr 
Ann Dewey); with a Senior Medical Research Fellow (Dr Will Storrar) attending as facilitator and note 
keeper. 
Focus Group One was held on 21st January 2016 at 1800hrs. Five participants agreed to attend but 
only one participant attended.  It was agreed to conduct a one-to-one interview with this 
participant, following the focus group topic guide.   
Focus Group Two was held on 26th January 2016 at 1000hrs. Seven participants agreed to attend 
but only three participants attended on the day. 
Focus Group Three was held on 28th January 2016 at 1400hrs. Eight participants agreed to attend 
but only six attended on the day.  
In total, ten participants took part in the focus group sessions. These ten participants represented 
both satisfied and non-satisfied participants (determined from a combination of device reported 
usage and participant-reported device usage) and there were slightly more females than males 
represented (Females 7; Males 3). 
At the beginning of each focus group discussion, the facilitator checked that participants were aware 
of the purpose of the focus group discussion, likely topics to be discussed, and the right to leave, at 
any time, without giving a reason to do so.  All participants were asked to respect others views, and 
to take turns in speaking to aid the recording of the discussions.  
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The topics were based on key themes identified during qualitative telephone interviews conducted 
during the pilot phase of the LASER trial (Appendix K – LASER Focus Group Interview Schedule). Free 
discussion of experience and ideas was encouraged throughout.  
The focus groups were audio recorded and lasted between 60 and 90 minutes. Afterwards, audio 
recordings were transcribed verbatim by the ‘Way With Words’ secure online transcription service. 
Participants were offered tea or coffee, with biscuits, with water available throughout. 
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2.11 STATISTICAL METHODS 
All statistical analyses were undertaken using a validated statistical package: STATA/IC version 14.2 
(StataCorp LLC www.stata.com). The results are presented as comparative summary statistics 
(difference in response rate or means) with 95% confidence intervals, in accordance with the 
CONSORT 2010 statements (Schulz 2010). All the tests are done at a 5% two-sided significance level.  
2.11.1. DEFINING POPULATIONS FOR DATA ANALYSIS 
2.11.1.1 PRIMARY STATISTICAL ANALYSIS 
The primary statistical analysis was based on the intent-to-treat (ITT) population, which is defined 
as all participants included and analysed according to their allocated treatment group irrespective of 
the treatment received. Note that in the primary analysis, the five participants who were 
randomized and withdrew consent to allow data usage were still included, with data set to missing 
and assumed no severe exacerbations. All other participant data deemed to be ineligible post-
randomisation or associated with protocol violations was also included in these primary outcome 
data.  
• Per-protocol population 
As the ITT population but excluding: 
 participants who did not receive a device  
 participants who withdrew consent for data use 
• Minimum data population 
All participants who have at least 90 days of steroid dose information reported (in TLA Diary or 
exacerbation diary (PED)) or have reported at least one PED. This requirement counted the assumed 
doses on the TLA Diary, and PEDs where the dosage was left blank. 
2.11.1.2 SECONDARY STATISTICAL ANALYSIS 
Analysis of secondary outcomes was carried out on a variable-by-variable complete case basis i.e. 
participants were only included in each individual secondary outcome analysis if all data relevant to 
that specific analysis were available, with no requirement on their remaining (non-relevant) data. 
Secondary outcomes with insufficient data were not analysed.  
2.11.2 ANALYSIS OF PRIMARY ENDPOINT 
2.11.2.1 DEFINITIONS 
Primary end-point definition = rate of severe exacerbations in a 12-month period. 
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Severe exacerbation (defined in accordance with ATS/ERS guidelines (Reddel et al 2009)) = a 
worsening of asthma requiring systemic corticosteroids, ≥30mg prednisolone or equivalent daily (or 
≥50% increase in dose if maintenance 30mg prednisolone or above) for 3 or more days.  
Courses of corticosteroids separated by ≥7 days are treated as separate severe exacerbations. 
A post-hoc analysis included the use of a worsening of asthma requiring systemic corticosteroids, 
≥10mg prednisolone or equivalent daily for 3 or more days with exacerbations separated by ≥7 days 
treated as separate exacerbations. 
2.11.2.2 DATA COLLECTION 
In an attempt to not miss any exacerbations, the primary outcome was collected from several 
different sources, which are listed in Table 2.3, along with a description of the source of these data: 
patient or trial site.  
Some participants provided detailed information including dates and doses of corticosteroids, but 
others just provided number of severe exacerbations with no corroboration regarding the severity 
and duration of the exacerbation in relation to the definition described above.  
It was decided that the most appropriate data to use for the primary outcome was the dated 
information as this was the most accurate and would enable duplicate reporting to be removed and 
the definition to be applied. The primary outcome for this study was therefore determined from the 
dated primary outcome data only. 
Table 2.3 Sources of primary outcome 
Source Abbreviation Timing / Description Source 
    
Dated Severe 
Exacerbations 
   
TLA Diary TLA Daily Participant 
Exacerbation Diary PED As severe exacerbation happens Participant 
Exacerbation Review 
Form 
REV After reported severe 
exacerbation 
Site 
Adverse Event / Serious 
Adverse Event 
SAE Ad hoc  Site 
Hospitalisations recorded 
on Follow-up Visit form  
HOSP Every 3 months, with dates 
obtained retrospectively from 
site of hospitalisation 
Information provided by 
participant and recorded 
and validated by site 
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Primary Outcome Dated Severe 
exacerbations 
Combination of all the above, 
with duplicates removed 
 
    
Undated severe 
exacerbations 
   
Number of severe 
exacerbations recorded 
on Follow-up Visit form 
FU Every 3 months Information provided by 
patient and recorded by 
site 
 
2.11.2.3 STATISTICAL MODEL 
The primary efficacy end point, which is the rate of severe exacerbations over the 12-month period, 
was analysed using the negative binomial model. The only adjustment made to the model was the 
minimisation factors used in the random assignment. In theory, randomisation provides balance for 
the known and unknown factors, and given the large sample size in this trial, it was expected that 
overall balance would be achieved without additional adjustment for time or device usage. The 
Minimisation factors used in the models were prevalent vs. incident cases, exacerbation frequency 
in the previous 12 months (2, 3, ≥3), use of oral corticosteroids (yes/no) and pre-bronchodilator FEV1 
(>50% predicted yes/no). Recruiting Centre was included in the models. The negative binomial 
model was chosen over the originally planned Poisson model because it was more flexible and gave 
a better fit to the overall blinded data.  
In the current data, there are approximately 60 cases where the participant reported a severe 
exacerbation in the PED but there was no report or no data in the daily diary. There are also 
approximately 50 severe exacerbations reported by the research team without corresponding daily 
diary entries or PED report. Thus, there are approximately 110 severe exacerbations without 
documentation of how long the participants were being observed. Therefore, as it could not be 
ascertained which days participants were actively reporting severe exacerbations if they did not 
complete the daily diary, it was decided that for dated severe exacerbations the observation period 
would extend from randomisation to 365 days after randomisation for the primary analysis. By 
taking a full year as the denominator for all participants, we essentially assumed that all days were 
at risk as we did not have exact days at risk for the model. This method most likely leads to an 
underestimation of the rate of events, however it was deemed the best approach to handling the 
problems of large amounts of missing diary data, and so supporting the use a negative binomial 
approach. When using undated data from the FU, all data up to and including the 12-month Follow-
up Visit was used. 
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2.11.2.4 SENSITIVITY ANALYSES 
The following individual sensitivity analyses were carried out to test the robustness of the primary 
outcome to the missing data: 
1) Participant population definition 
The primary analysis was repeated with the ITT participant population replaced by the Per-protocol 
population (see Section 2.11.1 for descriptions), meaning that participants who did not receive a 
device and the five who withdrew their consent for their data to be used in the analyses were 
excluded from the primary analysis. All other protocol deviations were deemed as minor. 
2) Best and Worst Case 
The primary analysis was repeated but with the following best and worst case severe exacerbation 
substitutions for those participants who did not contribute a minimum amount of data (see Section 
2.11.1 for definition): 
Modified best and worst case 
 Worst imputed case 
Placebo arm with missing data: best possible outcome is assumed.  
Active arm with missing data: worst possible outcome is assumed. 
 
 Best imputed case 
Placebo arm with missing data: worst possible outcome is assumed. 
Active arm with missing data: best possible outcome is assumed. 
 
Usually a best and worst case scenario would use the maximum and minimum number of observed 
attacks. We instead used the 90th  and 10th  percentile to avoid using extreme values and so refer to 
our best and worst case analysis as modified best and worst case analysis. This should put a 
reasonable bound on the assumptions made about missing data and how these affect the outcome 
of the trial. It is believed most other reasonable attempts at estimating the missing data will fall 
between these two extreme bounds, and this will aid correct interpretation of the results. 
2.11.3 ANALYSIS OF SECONDARY ENDPOINTS 
Complete case analysis (or, in the case where we were looking over multiple time points, cases with 
data from at least one Follow-up Visit) was carried out for all secondary outcomes, i.e. only available 
data was analysed with no missing data imputation. Missing data is reported. 
A multilevel mixed-effects linear regression which includes the treatment term, a time point term, 
an interaction term of treatment arm and time point, the baseline measure, and the minimisation 
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factors, and that is adjusted for repeated observations on participants, was used to analyse the 
continuous secondary outcomes. The minimisation factors for the secondary outcomes were 
prevalent vs. incident cases, exacerbation frequency in the previous 12 months (2, 3, ≥3), use of oral 
corticosteroids (yes/no) and pre-bronchodilator FEV1 (>50% predicted yes/no). 
For continuous variables with only baseline and 12 months data available, only the minimisation 
factors and the baseline variable were included in the mixed-effects model. Where sufficient data 
for analysis was not available only descriptive statistics are reported. 
2.11.4 QUALITATIVE DATA ANALYSIS 
Focus Groups were digitally recorded, transcribed verbatim and entered into NVivo 8, a qualitative 
software package for systematic and transparent data management. An identification using a 
pseudonym was assigned to each participant at recruitment. After tape recordings had been 
transcribed, the pseudonym was used to refer to individuals and no “real” names were included in 
any reports to maintain participant anonymity. Care was taken to always ensure any direct quotes 
used in study reports or papers to illustrate the findings were not directly attributable to individuals.  
We used Framework Analysis, a three-stage analytic process, to analyse the qualitative data. This 
Analysis method involves identifying initial themes by indexing the content of the data and using 
these themes to guide the formation of a framework within which transcribed material is 
synthesised (Spencer et al 2013). Key categories are then identified to help describe the data.  
The two researchers who had collected the qualitative data independently coded it all. They then 
compared findings and scrutinised the framework matrix to see if there was agreement with the 
categories generated. In the case of disagreement, a solution was sought to clarify the meaning of a 
code/theme developed until mutual consent was reached. The aim of this stage was to attempt to 
enhance the validity of the development of the conceptual framework and to guard against 
researcher bias. Following analysis of all focus groups, it was observed that data saturation had been 
achieved as no new themes were emerging from the participants. 
Finally, the researchers explored patterns of association between the categories and attempted to 
explain why those patterns occurred. 
2.12 ETHICAL CONSIDERATIONS 
The LASER Trial protocol and all patient facing documents were submitted for review by the NRES 
South Central (Berkshire) Committee on 6th February 2014. The ethics committee met to consider 
the ethical implications of the trial on 18th February 2014. The Trial Chief Investigator and Trial 
Coordinator attended to answer questions from the ethics committee. 
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The primary issue of concern raised by the ethics committee was the risk to participants of being in 
the placebo arm of the trial. It was explained that unfortunately there was no suitable alternative 
comparator to the placebo device. Alternative treatment options for these patients including 
Bronchial Thermoplasty and the anti-IgE treatment Omalizumab vary significantly in indication, use 
and delivery. Omalizumab is only indicated in patients requiring maintenance oral corticosteroids for 
the treatment of asthma or who require 4 or more courses of oral corticosteroids to treat asthma 
exacerbations in a 12-month period. Bronchial Thermoplasty excludes patients with more severe 
lung function deficits who would not be able to tolerate the bronchoscopy procedure, requires 
skilled operatives and is only available in a small number of centres. A placebo comparator was 
hence chosen in the absence of a practical, directly comparable alternative.  
Following the Declaration of Helsinki and CIOMS guideline statements (World Medical Association 
2013) (CIOMS 2002) on the use of placebo controls in RCTs, it was felt that the use of a placebo was 
necessary to determine the efficacy of the treatment and that the participants receiving placebo 
would not be subjected to any increased risk of serious or irreversible harm.  
The committee questioned the length of the trial treatment period. It was explained that the trial 
treatment period of 12 months was required to ensure that the seasonal variability in asthma 
control and symptoms was taken into account for all participants. 
It was explained that the risk of being in the placebo arm of the trial for the 12-month trial period 
was being offset by the offer of 4 years of treatment with an active treatment device in the post-trial 
provision period. The device manufacturer, Airsonett®, had committed to providing to all 
participants who had completed at least 6 months of follow-up in the trial, the use of an active 
treatment device including servicing and filters changes for a 4-year period. The question was raised, 
what would happen after this 4-year period if participants had responded to the treatment. It was 
explained that by this time, there would be evidence either for or against whether there was a 
beneficial treatment effect in this patient group and that if so the treatment would be validated and 
available as a treatment within normal NHS provision. 
The ethics committee questioned whether there was any risk that removal of the filter from the 
placebo device might result in increased delivery of allergens to the participants in the placebo arm 
of the trial, increasing their allergen exposure. It was explained that the filter was bypassed in the 
placebo device and that because there was no cooling of the air or laminar flow, the air delivered to 
the participant was no different to the ambient air in the bedroom environment. Although no 
particulate counts were being measured during the trial, each device was validated and tested 
before leaving the factory in Sweden for quality control purposes. In the 4A’s trial where a similar 
placebo device was used, particulate counting was measured to ensure that there was no risk of 
increased allergen exposure in the placebo group. 
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The ethics committee asked about the cost to participants of running the treatment device. It was 
explained that the device uses an equivalent amount of electricity as a 60W light bulb and that the 
cost of electricity would be reimbursed to participants on a pro-rata basis during the trial follow-up 
period. It was agreed that this would be explained in the Participant Information Sheet. 
The ethics committee were interested to understand about the noise level of the treatment device. 
It was explained that the measured noise level of the treatment device is 38dB and that this is 
equivalent to a quiet whisper or similar to an air conditioning unit. The committee asked whether 
this might be a barrier to device use. It was explained that in previous trials of the treatment device, 
very few participants had withdrawn as a consequence of the device noise. It was agreed that the 
noise level of the treatment device would be included in the Participant Information Sheet. It was 
also explained that the qualitative interviews would explore barriers to use of the treatment device 
and that we would specifically ask about tolerability of the noise level during these interviews. 
The impact of the treatment on trial participant’s partners was raised as a concern. The ethics 
committee asked whether the device would have any impact on participant’s partners as they would 
also have to accept the installation of the device in the bedroom. It was agreed that this was an 
important consideration and that this was being addressed through invitation to participate in 
qualitative interviews conducted during the pilot phase of the trial. The purpose of these interviews 
was to determine the impact of the treatment, if any, on participant’s bed-sharing partners. 
The ethics committee asked about holiday periods and inclusion of participants who work away from 
home during the week and whether this would impact on their participation and the results. It was 
explained that this was a pragmatic trial and that we wanted the results to reflect real-world use of 
the treatment device and that this meant that we would have to accept that participants would not 
be able to use the device every night during the 12 month follow up period. It was explained that the 
trial eligibility criteria required participants to use the device on average 5 out of every 7 nights. 
Holiday periods were also acceptable. Use of the device was captured in the daily completion of the 
TLA-diary which specifically asked participants whether the treatment device had been used and for 
how many hours. 
The committee queried whether it was possible to use a fan or air-conditioning unit in the same 
room that the device was installed and whether it was possible to have a window open in the room 
and the impact that this might have on the function of the device. It was explained that the function 
of the device would only be compromised if there was a significant cross draught that might 
interrupt the laminar flow of air delivered by the treatment device. As long as this could be avoided 
by ensuring that the fan or air-conditioning unit were not directed at the treatment device then 
there was no reason why they could not be used. Similarly, there was no reason why a window could 
not be opened as long as it did not result in a cross-draught that might interrupt the laminar airflow. 
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The ethics committee were advised that we wanted the trial to reflect real-world use of the device 
and that participants would be encouraged to continue ‘life as usual’ whilst using the device. 
The ethics committee were satisfied with the responses to their questions and a favourable opinion 
for the trial was received on the 26th February 2014. 
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CHAPTER 3 RECRUITMENT 
3.1 PARTICIPANTS 
The LASER Trial opened to recruitment at Portsmouth Hospital on 7th May 2014 with the first 
participant randomised to receive an active or placebo treatment device on 25th May 2014 and the 
last participant recruited in January 2016. In total 545 participants were identified against the 
eligibility criteria for the trial during this period. 56 of these participants were later excluded with a 
total of 489 being approached for consent. 100 participants either refused consent or were excluded 
with a total of 389 being consented. Of these 389, 149 participants failed the screening phase. A 
total of 240 participants met all of the eligibility requirements and were randomised to receive 
either an active or placebo treatment device. These recruitment numbers are presented in Figure 
3.1.  
 
Figure 3.1 Participant recruitment 
3.2 RECRUITMENT TARGETS 
During the grant application process the NIHR-HTA requested an ambitious recruitment plan with an 
expectation of meeting the 222 participant target over an 18 month recruitment period (Figure 3.2). 
This recruitment plan was based on the large cohorts of asthma patients (prevalent cases) at the 4 
lead recruiting centres, Portsmouth, Southampton, Leicester and Birmingham-Heartlands. Each of 
these centres has experience of recruiting patients to clinical research trials in asthma. It was 
expected that recruitment would be front loaded with a tail off towards the end of the trial (Table 
3.1).    
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Figure 3.2 HTA Projected recruitment 
Table 3.1 Monthly recruitment targets 
Month 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
Recruitment 
Target (n) 
16 16 16 16 14 14 14 14 14 14 14 10 10 10 10 7 7 6 
 
Unfortunately in the early stages of the trial it became apparent that the projected recruitment 
targets set out by the NIHR-HTA were not being met (Figure 3.3) and that we would need to take 
action to improve recruitment to the trial to ensure that the trial recruited to time and target 
without incurring additional costs. 
 
Fig 3.3 Early trial recruitment  
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This experience is not unique to the LASER trial; A review of recruitment data of a cohort of 151 RCTs 
funded by the NIHR-HTA Programme between 2004 and 2016 found that final recruitment sample 
size was only achieved in 85/151 studies (56%). (Walters et al. 2017). 
Understandably the slower than expected early recruitment rate raised concern at the NIHR that the 
LASER trial might not reach its sample size or that there might be significant delays in reaching the 
recruitment target and subsequent publication of results.   
The NIHR-HTA set a revised recruitment trajectory (Figure 3.4).  
 
Figure 3.4 Revised recruitment trajectory  
Having been set this challenge, the trial team identified a number of factors that might have 
contributed to the slower than expected early recruitment rate (Section 3.2.1) and put in place a 
number of remedial actions in order that the trial succeed in recruiting to the previously agreed time 
and target (Section 3.2.2). 
3.2.1 FACTORS CONTRIBUTING TO EARLY RECRUITMENT FAILURE 
3.2.1.1 DELAYS IN OPENING RECRUITING CENTRES 
There were significant delays in opening the initial 4 recruiting centres owing to unexpected delays 
in Research and Development department approval processes.  
3.2.1.2 SMALLER THAN EXPECTED POOL OF ELIGIBLE PARTICIPANTS  
Thorough feasibility assessments were conducted at the 4 lead trial centres, Portsmouth, 
Southampton, Leicester and Birmingham-Heartlands during the grant application process. It was 
thought that we would be able to recruit the 222 participants from existing clinic cohorts at these 4 
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sites. When sites were opened it became apparent that the pool of eligible participants was smaller 
than had been expected. This is thought to be due to a number of contributory factors including:  
CHANGE IN NICE RECOMMENDATIONS FOR OMALIZUMAB 
After the trial began, NICE re-appraised their Technology Appraisal Guidance for Omalizumab, a drug 
manufactured by Novartis which is a costly injectable anti-IgE therapy, delivered from Centres with 
asthma specialists, and a treatment option that competes directly with the TLA device being tested 
in this Trial. In the 2007 guidance, the NICE recommendation included confirmation of IgE mediated 
allergy to a perennial allergen by clinical history and allergy skin testing, and with either two or more 
severe exacerbations of asthma requiring hospital admission within the previous year, or three or 
more severe exacerbations of asthma within the previous year, at least one of which required 
admission to hospital, and a further two which required treatment or monitoring in excess of the 
patient's usual regimen, in an accident and emergency unit. 
The revised guidance broadened the inclusion criteria to include any patient who needed continuous 
or frequent treatment with oral corticosteroids (defined as at least 4 courses in the last year).  
This expanded the population of patients who might be eligible for Omalizumab (no requirement to 
attend hospital or Emergency Departments and everyone on oral corticosteroids for asthma, 
irrespective of their prior exacerbation history). This change in NICE guidance had a negative impact 
on LASER Trial recruitment as it dramatically shrunk the anticipated ‘prevalent’ population of severe 
asthma patients previously identified by recruiting centres when performing our extensive feasibility 
assessments and recruitment projections.  
OMALIZUMAB TREATMENT PATHWAY 
The change in licensed indication for Omalizumab led to considerable variation among Centres 
regarding the treatment option offered to patients. Several of our recruiting centres elected to offer 
patients Omalizumab therapy prior to being considered for the LASER Trial, even though they 
potentially met the eligibility for both treatments; some specialists were concerned that half of 
patients may be randomised to placebo in this Trial, and therefore could still remain potentially 
uncontrolled. 
Our eligibility criteria allowed participants with severe allergic asthma to be recruited who had failed 
or only partially responded to Omalizumab therapy after a wash-out period of 120 days. Even then a 
‘trial’ of Omalizumab treatment involves 2 weekly injections for 16 weeks before a patient is 
deemed to have responded or failed treatment. Thus, any potential participant who was first offered 
Omalizumab in preference to the LASER Trial device would test Omalizumab for 16 weeks (4 
months) and then could not then be screened for another 3 months, delaying recruitment to the 
LASER trial even further.  
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COMPETITION WITH OTHER COMMERCIAL RESEARCH TRIALS 
There has been a plethora of monoclonal antibody treatments for severe asthma in the last 3 years, 
sponsored by the pharmaceutical industry, and facilitated by all local Clinical Research Networks 
(CRNs) through their commercial portfolio to encourage Centres to participate in more commercial 
trials. The 30-day metrics of the CRNs ensures that Centres are incentivised and performance 
managed to recruit patients into all portfolio trials, including those that were competing with the 
LASER Trial. Naturally, nearly all of our Centres were approached to participate in the trials with 
significant variation in Centres signing up to such Trials, and in some cases, recruiting to them in 
preference to the LASER Trial.  
NHS ENGLAND SERVICE SPECIFICATIONS FOR SEVERE ASTHMA CENTRES 
In 2013, NHS England controversially approved the service specification for a limited number of 
Centres to be designated as Specialist Asthma Centres (SACs) (Birmingham, Brompton, Leicester and 
Manchester being approved at the time of commencement of the LASER Trial). Discussions continue 
to take place to revise the designation and the numbers of SACs. One criterion for specialist status 
had been the introduction of ‘Bronchial Thermoplasty’ (BT) as a new treatment option in severe 
asthma, with a requirement that each SAC perform 10 procedures per year to maintain status, and 
those aspiring to become a SAC required to perform a similar number over a 12-month period. Given 
the political incentives, potential participants eligible for LASER trial were, in some instances, 
considered for BT in preference to the LASER trial in order to meet the politico-clinical targets set by 
the service specification. 
3.2.1.6 HIGHER THAN EXPECTED SCREEN FAILURE RATE 
The number of participants requiring active screening to the point of consenting was not known, and 
consequently recruiting centres had been unaware of the numbers of potential participants that 
needed to be screened over any given period of time to ensure sufficient numbers of patients would 
meet randomisation criteria. Based on our estimates we anticipated that 2 out of every 3 
participants screened would progress on to randomisation.  
Due to the patient population being assessed, a number of potential participants with poorly 
controlled asthma who met all of the eligibility criteria were unable to achieve the 6-week period of 
stable disease control required before randomisation without experiencing an exacerbation. (4 
weeks stability prior to screening and 2-weeks stability during the screening period).  
3.2.1.7 RESOURCE PROBLEMS 
Despite the Trial being on the CRN portfolio, there were several instances of CRNs not being able to 
support sites with clinical staff due to lack of funding which required transfer of potential 
participants to other Centres. Other Centres similarly completed feasibility but did were unable to 
open for recruitment due to staff shortages.   
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3.2.2 STRATEGIES TO IMPROVE RECRUITMENT 
3.2.2.1  INCREASED NUMBER OF RECRUITING CENTRES 
We recognised that we would need to open additional recruiting centres in order to meet our 
recruitment target. We identified an additional 21 recruiting centres with experience of recruiting 
patients to asthma trials and conducted feasibility assessments, eventually activating an additional 
10 sites during the trial recruitment period (See Table 2.2 for activation dates). 
3.2.2.2  TRIAL PROTOCOL AMENDMENTS 
3 major amendments were made to the trial protocol in an attempt to improve recruitment. It was 
important that these amendments were implemented without impacting on the validity of the trial 
results. All protocol amendments were approved by the Trial Steering Committee (TSC) and 
subsequently by the trial Research Ethics Committee (REC). 
DEFINITION OF SEVERE ASTHMA 
The LASER trial sought to include participants with severe asthma. For the purposes of the LASER 
trial this was initially defined in the protocol as a requirement for treatment with high dose ICS or 
treatment with maintenance oral corticosteroids. The protocol definition of high dose ICS was 
>1000mcg BDP or equivalent ICS. 
Setting the protocol threshold for trial participation at >1000mcg BDP equivalent meant that a large 
number of patients who were established on the commonly prescribed dose of 1000mcg BDP 
equivalent (e.g Symbicort 200 2puffs bd or Fostair 100 2 puffs bd) were excluded despite meeting all 
other protocol requirements for trial inclusion. 
We wished to be as pragmatic as possible with the trial definition of severe asthma to reduce 
ambiguity. 
The definition of ‘severe’ or ‘difficult’ asthma varies between different internationally recognised 
guidelines for managing asthma:  
 BTS/SIGN define severe asthma as persistent symptoms and/or frequent exacerbations 
despite treatment at Step 4 or Step 5. BTS Step 4 includes patients on >800-2000mcg BDP 
equivalent. 
 
 GINA recognises severe asthma as asthma that requires Step 4 or Step 5 treatment to 
maintain symptom control. GINA Step 4 includes patients on Medium dose ICS (500-
1000mcg BDP equivalent) and High dose ICS (>1000mcg BDP equivalent).   
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 NICE recognises difficult asthma as asthma with symptoms despite treatment with step 4 or 
step 5 of the BTS/SIGN guideline plus one of the following: 
o An event of acute severe asthma which is life threatening, requiring invasive 
ventilation within the last 10 years, 
o Requirement for maintenance oral steroids for at least 6 months at a dose ≥7.5mg 
Prednisolone per day or a daily dose equivalent of this calculated over 12 months, 
o 2 hospitalisations within the last 12 months in patients taking and adherent to high 
dose inhaled steroids (≥1000mcg BDP or equivalent) 
o Fixed airflow obstruction with a post-bronchodilator FEV1 of less than 70% of 
predicted. 
 
Following discussion with the TSC it was agreed that the protocol requirement for high dose ICS 
should be reduced to include participants on ≥1000mcg BDP equivalent.  This remained consistent 
with the BTS/SIGN, GINA and NICE definitions of severe or difficult asthma and remained inclusive of 
participants who would be clinically recognised as having severe asthma. 
REDUCED LENGTH OF PRE-SCREENING STABILITY 
In order to reduce the ‘screen failure’ rate in those patients who had such poorly controlled asthma 
that they were unable to meet the requirement for 4 weeks of stable asthma treatment prior to 
entering the 2-week screening period for the trial, the stability period required prior to screening 
was reduced from 4 weeks to 2 weeks (Figure 3.5). 
 
Figure 3.5 Reduced length of pre-screening stability. 
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REDUCED LOWER AGE LIMIT FOR PARTICIPATION 
After consultation with the Trial Steering Committee it was agreed that the lower age limit for 
participation in the trial could be lowered to 16 years of age having previously been set at 18 years 
of age.  
 
3.2.2.3  INCREASED ENGAGEMENT WITH TRIAL CENTRES 
INVESTIGATOR MEETINGS 
3 investigator meetings were held during the trial recruitment period. The first meeting was held in 
Portsmouth with subsequent meetings being held in a central, more accessible location, the 
Marriott Hotel, Leicester. Members of the trial teams from all 14 centres were invited to attend to 
learn about trial progress and share their experiences.  
These meetings were highly valued by site teams and allowed free and open discussion about 
recruitment challenges and strategies to improve recruitment rates. 
WEEKLY NEWSLETTER 
Each week after the Trial Management Group (TMG) meeting, a newsletter was circulated to the 
trial teams at each recruiting centre with updates and information about the trial. Each week the 
newsletter included a ‘Tip of the Week’ to keep sites interested and engaged and focussed on 
recruitment targets. 
RECRUITMENTOMETER 
A ‘Recruitmentometer’ designed as a mock-up of a peak flow meter was added to the trial website 
homepage to display progress against the trial recruitment target. This gave trial teams real time 
updates of recruitment progress. 
INCENTIVISATION 
As a means of incentivising trial teams to recruit patients to the LASER trial, an iPad was offered as a 
reward for the site with the best recruitment rate over the final 6 months of trial recruitment.     
 
3.2.2.4  TRIAL ADVERTISEMENT 
In order to offer the trial to a wider population of potential patients who might not otherwise be 
able to access the trial if they were not already under the care of a severe asthma clinic at one of our 
recruiting centres we ran a number of media advertising campaigns to raise awareness and increase 
the profile of the trial.  
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TRIAL WEBSITE 
At the start of the trial, a dedicated LASER trial website was developed (www.lasertrial.co.uk, see 
Figure 3.6). The website was approved by the ethics committee and was primarily designed to 
function as a resource for both trial participants and trial centre teams, providing information about 
TLA treatment and about the trial itself.  
 
Figure 3.6 LASER trial website landing page 
Within the website there were details about how to register interest in the trial. Visitors to the 
website could visit the ‘Am I Eligible to Take Part’ page on the website where they could submit 
details about their asthma to the trial team for consideration of their eligibility. The 7 ‘pre-screening’ 
questions closely matched the trial eligibility criteria:  
1. Age  
2. Postcode 
3. Smoking Status 
4. Allergy Status 
5. Number of exacerbations in the preceding 12 months 
6. Current asthma treatment 
7. Current asthma symptoms  
An e-mail with the answers to these 7 questions was sent to a secure nhs.net e-mail account which 
was reviewed on a daily basis. Respondents who appeared to meet the trial eligibility criteria were 
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sent a trial PIS and put in contact with their nearest trial recruiting centre for formal assessment of 
eligibility.  
This process was approved by the information governance framework of the Sponsor and that of its 
Caldicott Guardian. 
The LASER trial website was used as the primary focus for the media advertising campaigns as a 
means of participants finding out more about the trial and registering their interest. During the 
course of the trial a total of 252 patients contacted the trial team through the website with 
responses to the 7 pre-screening questions. 86 patients were automatically excluded as they did not 
meet the trial entry criteria but of the remaining patients, after further contact and questioning, 66 
were sent further details about the trial (PIS) and were put in contact with their closest recruiting 
centre.  
All media campaigns also provided alternative contact details including a dedicated mobile 
telephone number and a text contact number (‘Text LASER to 60777’) to allow for individual 
preference in contacting the trial team.   
 
TV COVERAGE 
In September 2014, Professor Anoop Chauhan (the LASER Trial Chief Investigator) appeared 
alongside one of our trial participants in a news feature on BBC South Today. Following the 
broadcast, BBC South published the video on their Facebook and Twitter accounts. The Facebook 
post included a comment displaying the trial Web URL so that potential participants could access 
more information about the trial and, if interested, register for the trial. Using the Google Analytics 
tool, it was revealed that this social media interaction led to a significant increase in website traffic 
on the day of the broadcast, with 160 individual website sessions, as shown in Figure 3.7.  
 
65 
 
 
 
Figure 3.7 BBC South Social Media content and result 
SOCIAL MEDIA ADVERTISING 
Following on from this successful social media interaction, we recognised that social media 
advertising might be a useful strategy to improve access to the trial and increase recruitment.  
The total population of the UK is 66.38 million and there are 44 million active social media users with 
the average user spending 1hr54mins/day on social media (We Are Social / Hootsuite 2018). These 
statistics continue to show a year on year increase in social media use. 
Facebook remains the number 1 social media platform globally with a reach of 2.026 billion active 
users. The UK is ranked 10th in the world for Facebook use with a reach of 41 million users. In this 
context ‘reach’ refers to the figures Facebook releases for the total number of people that 
advertising on the Facebook platform may reach.  
One advantage of Facebook and other social media advertising is that specific groups can be 
targeted by setting demographic and geographic parameters making it an ideal resource for targeted 
clinical trial recruitment campaigns. 
Based on global values, a typical Facebook user ‘Likes’ 10 pages/30days, ‘Comments’ on 4 
posts/30days and ‘Clicks’ on 8 Facebook adverts/30 days. 
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More evidence is emerging from both commercially driven and academic trials that social media is a 
useful tool in recruitment (Pederson et al 2015) (Frandsen et al 2016).  
We developed a social media strategy for the LASER trial.  
All social media postings were approved by the ethics committee and moderated by the trial team 
(Trial Co-ordinator and the Trial lead Research Nurse) who were involved in recruiting for the trial. 
Social Media was employed in a number of different ways to raise awareness of the trial: 
1. Partnering with Asthma / Allergy Charities 
Firstly, we partnered with national charities with an interest in the new treatment, Asthma UK and 
Allergy UK, who publicised the trial on their websites and posted trial information both on Twitter 
and Facebook that signposted patients to the LASER Trial website – see Figure 3.8 for example 
content from Asthma UK, which has 29,000 followers on Twitter and have had over 40,000 likes on 
Facebook. Allergy UK has 5,000 followers and have had >7,000 likes on Facebook.   
Using Google Analytics, we saw a spike in activity on the website when posts/tweets were published, 
as shown in Figure 3.9. 
 
 
Figure 3.8 Asthma UK website, Facebook and Twitter content 
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Figure 3.9 LASER website traffic with disease charity inputs 
 
2.  Facebook and Twitter Advertising 
Secondly, we partnered with Tillison Consulting (https://tillison.co.uk) to develop a LASER trial 
Facebook page, and set up business accounts which facilitated trial advertisements on Facebook and 
Twitter such as that shown in Figure 3.10. This business account permits targeted advertising, 
enabling us to set demographic parameters based on trial inclusion criteria (age between 18 to 65 
years, both men and women, location as 50km from a recruiting centre), and also to target people 
who have a search or following history which indicates an interest in asthma or asthma awareness. 
The tweets and posts directed people towards the LASER website and through to the screening 
questions. Techniques such as ‘Google remarketing’ were also used, in which people who had visited 
the website would be shown ‘branded adverts’ in the following 30-day period, although these were 
less successful than the social media campaigns. 
68 
 
 
Figure 3.10 LASER trial Facebook advertisement 
On Facebook we reached >100,000 individuals, had 1,361 clicks through to the LASER website, and 
were able to see a large number of patients engaging with the trial via ‘likes’, ‘shares’ and 
‘comments’, which would have further increased the trial’s visibility by sharing the information with 
friends or family with the condition. Similarly, on Twitter we reached over >150,000 people.  
3. Trialbee 
Finally, in March 2015 we partnered with the Swedish company Trialbee, which specialise in social 
media solutions for clinical trials. Trialbee advertised the trial on social media platforms, Facebook 
and Twitter. An advert (Figure 3.11) was displayed in the social media ‘news-feed’ of anyone who 
had previously expressed interest in asthma or had a search history including key words related to 
asthma. Demographic parameters enabled this to be restricted to the target age group and those 
within a commutable distance from one of the trial recruiting centres  
 
Figure 3.11 Trialbee Social Media Advert 
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If interested in the advert, clicking on a link diverted to the Trialbee websites dedicated LASER trial 
landing page (Figure 3.12) where there was detailed information about the trial.  
 
Figure 3.12 Trialbee LASER trial landing page 
 
On the Trialbee LASER trial page interested patients were able to answer a series of basic screening 
questions concerning their eligibility (Figure 3.13). and the details of those patients that passed this 
screening process were passed on to the LASER trial team at the respondents nearest recruiting 
centre to arrange further contact for formal eligibility screening. 
 
Figure 3.13 Trialbee pre-screening questions  
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The 5 Trialbee pre-screening questions were answered 14,059 times, with 910 respondents meeting 
the basic eligibility requirements. Of these, and following more in-depth screening by the trial team, 
57 were deemed eligible for the trial and 27 of these were subsequently consented and randomised 
to participate in the trial.  
NEWSPAPER ADVERTISING 
The LASER trial team worked with a media company with a track record in advertising for clinical 
trials, Media With Impact. A newspaper advert was designed to include the trial web URL and 
contact details for the trial team (Figure 3.14).  
Newspaper adverts appeared in the local newspaper of our 5 leading trial centres over a 2-week 
period in March 2015.  
This newspaper advert was approved by the ethics committee. 
 
 
Figure 3.14 LASER Trial Newspaper Advertisement 
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RADIO ADVERTISING 
Media With Impact also set up a 30 second radio advertisement which was broadcast on the local 
radio stations of the same 5 trial centres over the same 2 week period in March 2015. The radio 
advert’s audio text included the following: 
“Have you been told that you have allergic asthma? Have you had two or more asthma attacks in 
the last year? Well, it’s time you heard about the LASER trial…. 
…On the LASER trial you will help us assess a new, non-drug treatment for asthma, in the hope 
that we can reduce asthma attacks in the future. 
If you’re aged 18-75, check if you’re eligible on lasertrial.co.uk or text LASER to 60777. 
LASER Trial, a breath of fresh air in asthma. 
The LASER Trial is funded by the NIHR” 
The radio advert audio text was approved by the ethics committee. 
3.3 RECRUITMENT TO TIME AND TARGET 
These combined strategies resulted in an increased rate of recruitment (Figure 3.15). The revised 
recruitment trajectory was met (Figure 3.16) and the recruitment target ultimately exceeded (240 
participants recruited instead of 222) because the 2-week screening period meant that a number of 
new participants had already entered the screening period once the recruitment target had been 
met. It was felt unethical to exclude these participants on the basis of meeting a target. 
 
 
Figure 3.15 Monthly Recruitment Rate 
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Figure 3.16 Participant recruitment rates 
 
3.4 RECRUITMENT SOURCES 
Table 3.2 lists the sources that referred the 240 recruited participants to the trial. 80% of 
participants were recruited from existing cohorts of patients at the 14 recruiting centres. The 
majority of the remaining participants were recruited through social media channels, which are 
described in detail in Section 3.2.2.4 Social Media Advertising. The Trialbee social media campaign 
was notably successful with 16% of participants recruited during the period that the campaign was 
active (Mar-Dec 2015) being recruited through this channel.  
Table 3.2 Participant referral sources 
Referral Source Randomised Participants (%) 
Existing Clinic Patient 192 (80%) 
Social Media (Trialbee) 27 (11%) 
Social Media (Asthma UK / Allergy UK / Tillison) 13 (5%) 
Newspaper Advertisement 0 
Radio Advertisement 1 (<1%) 
0
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Other 7 (3%) 
 Total 240 
 
 
  
74 
 
CHAPTER 4  QUANTITATIVE RESULTS 
4.1 PARTICIPANTS 
4.1.1 RECRUITMENT 
Screening and recruitment for the LASER trial took place between 25th May 2014 and 11th January 
2016, resulting in the randomisation of 240 participants.  A total of fourteen centres randomised 
participants into the trial. The randomisation of participants by recruiting centre are listed in Table 
4.1. 
Table 4.1 Randomisations by Centre 
Recruiting Centres Placebo, n (% of 
treatment group) 
Active, n (% of 
treatment group) 
Total, n (% of all 
participants) 
ALL 121 119 240 
Belfast 1 (1%) 2 (2%) 3 (1%) 
Birmingham-Heartlands 15 (12%) 13 (11%) 28 (12%) 
Birmingham-Queen Elizabeth 3 (2%) 2 (2%) 5 (2%) 
Bradford 4 (3%) 5 (4%) 9 (4%) 
Chester 3 (2%) 3 (3%) 6 (3%) 
Hull 6 (5%) 4 (3%) 10 (4%) 
Leicester 7 (6%) 7 (6%) 14 (6%) 
Liverpool-Aintree 5 (4%) 8 (7%) 13 (5%) 
Liverpool-Royal 8 (7%) 10 (8%) 18 (8%) 
London 6 (5%) 5 (4%) 11 (5%) 
Maidstone 9 (7%) 8 (7%) 17 (7%) 
Oxford 3 (2%) 4 (3%) 7 (3%) 
Portsmouth 38 (31%) 36 (30%) 74 (31%) 
Southampton 13 (11%) 12 (10%) 25 (10%) 
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4.1.2 BASELINE CHARACTERISTICS 
The baseline characteristics of the 240 participants randomised into the two participant groups are 
summarized in Table 4.2. The 5 participants who withdrew consent to use previously collected data 
(see Section 4.1.4 for details) are indicated by “~Missing”.  
These baseline data indicate that the two participant groups are proportionately balanced.   
Table 4.2 Participant baseline characteristics 
Factor Level Placebo, n 
(% of 
treatment 
group,         N 
= 121) 
Active, n    
(% of 
treatment 
group,          
N = 119) 
Total, n      
(% of all 
participants    
N = 240) 
     
Origin of case     
New to clinic (incident) 
or existing patient 
(prevalent) 
Incident 26 (21%) 24 (20%) 50 (21%) 
Prevalent 94 (78%) 91 (76%) 185 (77%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
     
Demographics     
Gender 
Female 90 (74%) 82 (69%) 172 (72%) 
Male 30 (25%) 33 (28%) 63 (26%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
Age at Randomisation 
(yrs) 
16-17 1 (1%) 0 (0%) 1 (<1%) 
18-34 33 (27%) 26 (22%) 59 (25%) 
35-59 69 (57%) 70 (59%) 139 (58%) 
60-75 17 (14%) 19 (16%) 36 (15%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
Age at Randomisation 
(yrs), mean (SD) 
 45.3 (13.8), 
n=120 
46.8 (13.8), 
n=115 
46.1 (13.8), 
n=235 
Ethnicity 
White 103 (85%) 100 (84%) 203 (85%) 
Bangladeshi 1 (1%) 0 (0%) 1 (<1%) 
Black Caribbean 1 (1%) 2 (2%) 3 (1%) 
Black Other 1 (1%) 0 (0%) 1 (<1%) 
Indian 5 (4%) 4 (3%) 9 (4%) 
Mixed White 2 (2%) 2 (2%) 4 (2%) 
Other 1 (1%) 2 (2%) 3 (1%) 
Pakistani 5 (4%) 4 (3%) 9 (4%) 
UNK 1 (1%) 1 (1%) 2 (1%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
Category of Body Mass 
Index (kg/m
2
) 
Severely underweight (15-16) 1 (1%) 1 (1%) 2 (1%) 
Normal (18.5-25) 24 (20%) 26 (22%) 50 (21%) 
Overweight (25-30) 33 (27%) 38 (32%) 71 (30%) 
Obese Class I   (30-35) 33 (27%) 26 (22%) 59 (25%) 
Obese Class II   (35-40) 9 (7%) 17 (14%) 26 (11%) 
Obese Class III   (40 or over) 18 (15%) 6 (5%) 24 (10%) 
~Invalid data 2 (2%) 1 (1%) 3 (1%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
Body Mass Index 
(kg/m2), mean (SD) 
 31.2 (7.2) 
n=120 
29.6 (5.9) 
n=115 
30.4 (6.6) 
n=135 
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Smoking     
Smoking status 
Ex-smoker 36 (30%) 22 (18%) 58 (24%) 
Never smoked 84 (69%) 93 (78%) 177 (74%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
Does anyone smoke in 
the bedroom where the 
TLA will be installed? 
No 120 (99%) 115 (97%) 235 (98%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
Does anyone smoke in 
the house? 
No 116 (96%) 112 (94%) 228 (95%) 
Yes 4 (3%) 3 (3%) 7 (3%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
     
Exacerbation history     
Exacerbation frequency 
in preceding 12 months* 
2 38 (31%) 37 (31%) 75 (31%) 
3 30 (25%) 27 (23%) 57 (24%) 
>3 52 (43%) 51 (43%) 103 (43%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
Number of 
exacerbations in 
preceding 12 months, 
mean (SD) 
 4.3          
(3.7), n=116 
             3.5 
(1.8), n=112 
             3.9 
(2.9), n=228 
Hospital admissions in 
preceding 12 months 
00 81 (66.9%) 80 (67.2%) 161 (67.1%) 
01 21 (17.4%) 17 (14.3%) 38 (15.8%) 
02 8 (6.6%) 11 (9.2%) 19 (7.9%) 
03 6 (5.0%) 2 (1.7%) 8 (3.3%) 
04 1 (0.8%) 4 (3.4%) 5 (2.1%) 
06 1 (0.8%) 0 (0.0%) 1 (0.4%) 
07 0 (0.0%) 1 (0.8%) 1 (0.4%) 
10 1 (0.8%) 0 (0.0%) 1 (0.4%) 
12 1 (0.8%) 0 (0.0%) 1 (0.4%) 
~Missing 1 (0.8%) 4 (3.4%) 5 (2.1%) 
Previous asthma related 
ITU admission 
No 96 (79%) 87 (73%) 183 (76%) 
Yes 24 (20%) 28 (24%) 52 (22%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
     
Physiological measures     
Pre-bronchodilator FEV1 
> 50% 
No 28 (23%) 27 (23%) 55 (23%) 
Yes 92 (76%) 88 (74%) 180 (75%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
Pre-Bronchodilator FEV1 
(litres) 
 2.0 (0.8), 
n=118 
2.1 (0.9), 
n=115 
2.1 (0.8), 
n=233 
Pre-Bronchodilator FEV1 
Percent 
 68.5 (21.7), 
n=118 
69.9 (22.6), 
n=115 
69.2 (22.1), 
n=233 
Pre-Bronchodilator FVC  3.0 (1.0), 
n=118 
6.2 (33.9), 
n=115 
4.6 (23.9), 
n=233 
Pre-Bronchodilator FVC 
Percent 
 86.4 (19.4), 
n=118 
88.3 (17.5), 
n=115 
87.4 (18.5), 
n=233 
FENO (ppb)  36.3 (36.0), 
n=114 
38.7 (35.7), 
n=110 
37.5 (35.8), 
n=224 
     
Asthma treatments     
Use of maintenance 
corticosteroids? 
No 91 (75%) 86 (72%) 177 (74%) 
Yes 29 (24%) 29 (24%) 58 (24%) 
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* All participants should have experienced at least two exacerbations in the previous 12 months to 
enter the study 
 
4.1.3 PARTICIPANT FLOW 
The overall flow of the 240 participants randomised into the trial is shown in Figure 4.1. This 
diagram shows the compliance of the two participant groups to device usage (measured as days in 
possession of device during the 365 days of their trial participation), as well as their compliance to 
reporting of steroid dose (again number of days steroid dose reported during the 365 days of their 
trial participation). There was a requirement for participants to remain active in the trial for a 
minimum of 6 months before they became eligible for four years’ post-trial provision of the active 
device. 
  
~Missing 1 (1%) 4 (3%) 5 (2%) 
Category of Baseline 
dose of Maintenance 
Steroid (mgs/day, 
prednisolone equivalent) 
1- 9 10 (8%) 13 (11%) 23 (10%) 
10-19 5 (4%) 12 (10%) 17 (7%) 
20-29 5 (4%) 0 (0%) 5 (2%) 
30 1 (1%) 1 (1%) 2 (1%) 
40 2 (2%) 1 (1%) 3 (1%) 
None 97 (80%) 88 (74%) 185 (77%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
Steroid sparing 
immunosuppressant? 
No 115 (95%) 109 (92%) 224 (93%) 
Yes 5 (4%) 6 (5%) 11 (5%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
Monoclonal antibody 
therapy? 
No 105 (87%) 106 (89%) 211 (88%) 
Yes 15 (12%) 9 (8%) 24 (10%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
Bronchial Thermoplasty? 
No 119 (98%) 112 (94%) 231 (96%) 
Yes 1 (1%) 3 (3%) 4 (2%) 
~Missing 1 (1%) 4 (3%) 5 (2%) 
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Figure 4.1 LASER CONSORT: Participants Randomised (n=240) 
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4.1.4 WITHDRAWALS 
59 participants either did not have minimum data, died, or had a withdrawal form completed 
(Appendix M – Table M1). In some cases, data was provided after the withdrawal date, bringing into 
question the withdrawal status. In other cases, the withdrawals were participants lost to follow-up. 
Five participants withdrew consent for the use of previously collected data. All participants were 
included in the primary analysis and the CONSORT table provides data on when the devices were 
removed. Of the 59 participants, 31 were in the active group and 28 were in the placebo group. 
4.1.5 MISSING DATA 
Steroid dose is the key indicator of the primary outcome and unfortunately a considerable amount 
of this data was not collected from the primary outcome data sources (as shown in Section 4.2.1).  
For both active and placebo groups, we calculated the total possible study days from the date of 
randomisation to 12 month Follow-up Visit if available, or 365 days post-randomisation if no 12 
month Follow-up Visit occurred. If participants withdrew earlier than 12 months, the study days 
were calculated from randomisation to the point of withdrawal. 
Placebo group 
29,147 (66.1%) of the 44,091 possible study days of daily maintenance steroid use was collected on 
the Placebo group. 6419 (22.0%) of the 29,147 days of maintenance dose information analysed are 
based on the assumption of zero dose because these data were left blank but other fields of the 
daily diary (i.e. any of device use, reliever use or time off work) were completed.  
In addition to missing maintenance steroid dose data, there were missing exacerbation steroid dose 
data. 30 mg dose was assumed for the 24 days of Placebo group cases where exacerbation dose data 
was left blank in the PED. 
Active group 
28,753 (65.3%) of the 43,398  possible study days of maintenance steroid dose information was 
collected on the Active group. 4819 (16.8%) of the 28,753 days of maintenance dose information 
analysed are based on the assumption of zero dose because these dose data were left blank but 
other fields of the daily diary were completed. 
In addition to missing maintenance steroid dose data, there were missing exacerbation steroid dose 
data. 30 mg dose was assumed for the 25 days of Active group cases where exacerbation dose data 
was left blank in the PED. 
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Table 4.3 Missing data summary 
 Placebo Active 
Possible study days: days from Randomisation to 12 month Follow-
up Visit (or 365 days, if later), mean (SD) 
373.5 (16.2) 376.0 (22.2) 
Days where dose was reported by participant on daily diary or 
severe exacerbation report, mean (SD) 
244.2 (133.7) 245.7 (137.3) 
Days where zero dose was assumed, mean (SD) 54.1 (89.8) 41.5 (77.6) 
 
4.2. OUTCOMES 
4.2.1 PRIMARY OUTCOME SOURCES OF DATA 
Data pertaining to the primary outcome were reported in several sources, as described in Section 
2.11.2.2.  Only 18% of the dated severe exacerbations were reported in all three expected sources: 
1. TLA Diary (TLA), 2. Exacerbation Diary (PED) and 3. Exacerbation Review Form (REV). 40 (12%) of 
the severe exacerbations were only reported on the REV, with no other supporting data.  
 
The number of participants reporting none, one or more dated exacerbations between treatment 
groups during the 12 months of the trial is shown in Table 4.4. 
 
 
Table 4.4 Number of participants reporting none, one or more dated exacerbations between 
treatment groups during the 12 months of the trial 
Number Placebo Active Total 
 
N=121 N=119 N=240 
0 55 (45%) 49 (41%) 104 (43%) 
1 23 (19%) 25 (21%) 48 (20%) 
2 17 (14%) 16 (13%) 33 (14%) 
3 9 (7%) 16 (13%) 25 (10%) 
4 7 (6%) 8 (7%) 15 (6%) 
5 3 (2%) 3 (3%) 6 (3%) 
6 2 (2%) 1 (1%) 3 (1%) 
7 2 (2%) 1 (1%) 3 (1%) 
8 2 (2%) 0 (0%) 2 (1%) 
10 1 (1%) 0 (0%) 1 (<1%) 
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4.2.2 PRIMARY OUTCOME 
As shown in Table 4.5, there was no statistical difference in the rate of severe exacerbations 
between the two participant groups (p = 0.62).  
Table 4.5 Primary Outcome: Frequency of severe asthma exacerbations occurring within the 12-
month follow-up period 
 
Placebo Active 
Risk 
Ratio
* 
SD 
95% 
CI 
P 
value N / 
events 
Mean SD 
N / 
events 
Mean SD 
Total Dated 
Severe 
exacerbations 
within 1 year 
121 / 179 1.48 2.03 119 / 165 1.39 1.57 0.92 0.15 
0.66 
to 
1.27 
0.6167 
Dated Severe 
exacerbations 
within 1 year  
Per-protocol 
Population 
118 / 179 1.52 2.04 111 /164 1.48 1.59 0.951 0.15 
0.69 
to 
1.31 
0.7575 
* Adjusted for the minimisation factors 
 
4.2.2.1  SENSITIVITY ANALYSIS 
The sensitivity analyses designed to test the robustness of the results to the missing data as 
described in Section 2.11.2.4 show that the primary outcome results in Table 4.7 are very sensitive 
to these assumptions; by varying these assumptions the primary outcome treatment effects could 
go either way. This conclusion was drawn by investigating the best and worst case scenarios for 
those participants who did not meet the minimum data requirement (see Section 2.11.2.4 for 
definition). The following best and worst case scenarios describe the best and worst numbers of 
severe exacerbations that might have occurred in this population of 45 participants during the 12 
month trial period, but that were not captured in the primary outcome dataset: 
Modified best and worst case:  
 Best case = 0 
 Worst case = 4 
 
The results of the sensitivity analyses made using the best and worst case scenarios are: 
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The point estimates of the risk ratio ranged from 1.4 (worst for active) to 0.6 (best for active) in the 
modified best and worst case analysis highlighting the wide range of possible outcomes under 
different assumptions about the outcomes for those with less than the minimum amount of data 
reported.  
The amount of missing data could mask a difference between the treatments, but this could be in 
either direction. 
  
4.2.2.2. POST-HOC ANALYSIS OF PRIMARY OUTCOME DATA 
Following review of recently reported literature where exacerbations have been defined with a less 
stringent definition, the original definition of primary endpoint (see Section 2.4.1) was amended so 
that comparison with these studies could be undertaken. In the new definition, an exacerbation was 
defined as a 10 mg increase in steroid dose over any maintenance dose for 3 consecutive days. All 
other parts of the definition remained the same, i.e. separate exacerbations were identified by at 
least 7 days at or below maintenance dose.  
The primary outcome calculated for this new primary endpoint definition is presented in Table 4.6. 
This analysis also supports no rejection of the hypothesis of no difference between the treatment 
groups and therefore provides the same conclusion of the primary outcome as the analysis 
performed according to the original definition of primary endpoint. 
 
Table 4.6 Primary outcome results - alternative definition of primary endpoint post-hoc analysis 
Post-hoc analysis 
Placebo Active 
Risk 
Ratio* 
SD 95% CI P value 
N / 
events 
Mean SD 
N / 
events 
Mean SD 
New definition of 
exacerbation steroid 
dose 
121 / 
186 
1.54 2.05 
119 / 
189 
1.59 1.75 1.02 0.17 
0.7 to 
1.4 
0.910 
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4.2.3 QUANTITATIVE SECONDARY OUTCOMES  
4.2.3.1  ASTHMA CONTROL 
The Asthma Control secondary outcome results (Lung function, Asthma Control Questionnaire (ACQ) 
score, Asthma Control Diary (ACD) score and Sino-Nasal Outcome Test (SNOT-22) score) are 
presented in Table 4.7.  
The only Asthma Control secondary outcome that was found to be statistically significant was daily 
maximum Peak Flow (p = 0.045). All other aspects of the Lung Function secondary outcome (Pre-
bronchodilator FEV1, Fractional exhaled Nitric Oxide (FENO) and Post-bronchodilator FEV1) as well as 
ACQ, ACD and SNOT-22 scores were not found to be statistically significant. It should be noted that 
due to the fact that there was a large amount of missing peak flow data, and that the one significant 
result emerges against six non-significant results (the multiple testing problem), this significant 
result could have occurred by chance. 
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Table 4.7 Secondary outcomes: Lung function, ACQ Scores and SNOT-22 Scores. 
Outcome Timepoint Placebo Active     
  N Mean SD N Mean SD 
Treatment 
effect 
SD 95% CI P value 
Lung function 
           
Pre-bronchodilator FEV1 
Screening 119 2.02 0.86 113 2.01 0.84 
    
Randomisation 118 2.02 0.81 115 2.09 0.86 
3 months 100 2 .05 0.76 98 2.14 0.89 
6 months 100 2.04 0.81 94 2.16 0.86 
9 months 92 1.99 0.79 88 1.98 0.78 
12 months 91 2.01 0.79 85 2.01 0.8 
Pre-bronchodilator FEV1 Mixed 
Model Analysis        
-0.014 0.05 -0.11 to 0.08 0.7607 
            
Fractional exhaled Nitric Oxide 
(FENO) 
Screening 0 n/a n/a 0 n/a n/a 
    
Randomisation 114 36.35 35.98 110 38.74 35.74 
3 months 97 35.13 34.81 95 34.06 32.03 
6 months 95 32.67 35.07 91 32.71 30.67 
9 months 87 30.31 29.2 81 36.45 37.33 
12 months 89 33.39 33.11 82 32.56 30.19 
Fractional exhaled Nitric Oxide 
(FENO) Mixed Model Analysis        
-1.843 2.58 -6.91 to 3.22 0.4756 
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Outcome Timepoint Placebo Active     
  N Mean SD N Mean SD 
Treatment 
effect 
SD 95% CI P value 
Lung Function contd.            
Post-bronchodilator FEV1 
Screening 115 2.32 0.85 111 2.27 0.84 
    
Randomisation 0 n/a n/a 0 n/a n/a 
3 months 0 n/a n/a 0 n/a n/a 
6 months 0 n/a n/a 0 n/a n/a 
9 months 0 n/a n/a 0 n/a n/a 
12 months 81 2.17 0.77 84 2.24 0.8 
Post-bronchodilator FEV1 
Regression Analysis        
0.04 0.05 -0.07 to 0.15 0.4628 
            
Average daily maximum Peak 
Flow 
Screening 91 311.22 117.84 82 336.62 126.78 
    
Randomisation 0 0 n/a n/a 0 n/a 
3 months 93 321.52 118.68 87 341.24 130.94 
6 months 87 319.66 124.62 91 351.11 130.95 
9 months 80 307.97 112.97 80 338.3 130.52 
12 months 76 319.72 121.46 74 349.83 124.5 
Average daily maximum Peak 
Flow Mixed Model Analysis 
       14.729 7.35 0.32 to 29.14 0.0452 
        
Patient Reported Outcomes            
ACQ Score Screening 107 2.98 0.99 107 2.9 0.96     
Randomisation 110 3.05 1.08 106 2.84 1 
3 months 81 2.54 1.27 84 2.26 1.02 
6 months 89 2.55 1.27 84 2.24 1.03 
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9 months 83 2.45 1.21 78 2.38 1.18 
12 months 82 2.42 1.28 79 2.31 1.16 
ACQ Score Mixed Model 
Analysis 
       -0.054 0.11 -0.26 to 0.15 0.6061 
        
Outcome Timepoint Placebo Active     
  N Mean SD N Mean SD 
Treatment 
effect 
SD 95% CI P value 
Patient Reported Outcomes 
contd. 
           
ACD scores averaged over 
available 14 Days 
Screening 32 2.08 1 31 2.18 1.19     
Randomisation 0 n/a n/a 0 n/a n/a 
3 months 36 1.42 1.02 28 1.84 1.37 
6 months 33 1.68 1.35 37 1.96 1.19 
9 months 26 1.8 1.17 34 2.02 1.22 
12 months 36 1.59 1.08 34 1.94 1.27 
ACD scores averaged over 
available 14 Days Mixed Model 
Analysis 
       0.212 0.25 -0.28 to 0.71 0.4008 
            
Sino Nasal Outcome Test 
(SNOT-22) score 
Screening 0 n/a n/a 0 n/a n/a     
Randomisation 120 41.17 21.74 114 41.78 21.32 
3 months 106 38.53 21.28 100 34.95 20.95 
6 months 101 39.33 22.25 97 34.16 20.7 
9 months 95 37.99 22.38 89 35.24 22.12 
12 months 96 36.3 23.57 90 35.69 21.18 
Sino Nasal Outcome Test 
(SNOT-22) score Mixed Model 
Analysis 
       -3.265 1.85 -6.9 to 0.37 0.0781 
4.2.3.2   QUALITY OF LIFE 
ASTHMA RELATED QUALITY OF LIFE 
The two participant groups had similar overall AQLQ(S) scores at randomisation (p=0.213, Table 4.8). 
In both participant groups there was a statistically significant improvement in overall quality of life 
over the trial. When quality of life at 12 months was compared to that at randomisation, an 
improvement in the overall AQLQ(S) score of 0.57 (p<0.001) in the placebo group and 0.68 (p<0.001) 
in those receiving the TLA device was identified. Although, the improvement in overall quality of life 
was higher in participants in the TLA group, this improvement was not statistically significant when 
compared to participants in the placebo group (p=0.543).  
Overall AQLQ(S) scores between the two participant groups were similar at each follow-up visit, 
except at 6 months, where participants receiving the TLA device had a significantly higher quality of 
life than those receiving placebo (4.74 vs. 4.30, respectively; p=0.020). This difference at 6 months 
was also observed for the following domains: activity limitation (p=0.022) and environmental stimuli 
(p=0.009). In addition, participants in the Active TLA group also had higher quality of life scores in 
the domain for environmental stimuli at 9 months (p=0.038).  
Table 4.8 Responses to the AQLQ(S) 
 Placebo, 
mean (S.D) 
Active, 
mean (S.D) 
P Value Mean difference  
(95% CI) 
Overall score, across all 4 domains 
Randomisation 3.87 (1.22) 
n=120 
4.07 (1.20) 
n=115 
0.213 0.20 (-0.11 to 0.51) 
3 months 4.39 (1.41) 
n=107 
4.67 (1.25) 
n=100 
0.139 0.27 (-0.09 to 0.65) 
6 months 4.30 (1.42) 
n=101 
4.74 (1.22) 
n=97 
0.020 0.44 (0.07 to 0.81) 
9 months 4.36 (1.53) 
n=95 
4.65 (1.35) 
n=90 
0.166 0.29 (-0.12 to 0.72) 
12 months 4.50 (1.47) 
n=96 
4.76 (1.33) 
n=90 
0.219 0.25 (-0.15 to 0.66) 
Difference at 12m 0.57 (1.12) 
n=96 
0.68 (1.24) 
n=90 
0.543 0.11 (-0.24 to 0.45) 
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Symptoms Domain 
Randomisation 3.74 (1.28) 3.93 (1.21) 0.233 0.19 (-0.13 to 0.51)  
3 months 4.35 (1.51) 4.59 (1.34) 0.239 0.23 (-0.15 to 0.63) 
6 months 4.25 (1.53) 4.63 (1.28) 0.061 0.38 (-0.02 to 0.78) 
9 months 4.36 (1.57) 4.58 (1.46) 0.319 0.22 (-0.22 to 0.66) 
12 months 4.56 (1.54) 4.62 (1.36) 0.761 0.06 (-0.36 to 0.49)  
Difference at 12m 0.74 (1.29) 0.69 (1.32) 0.816 -0.04 (-0.42 to 0.33) 
Activity Limitation Domain 
Randomisation 4.02 (1.29) 4.29 (1.30) 0.103 0.28 (-0.06 to 0.61) 
3 months 4.47 (1.41) 4.76 (1.34) 0.141 0.28 (-0.09 to 0.66) 
6 months 4.39 (1.43) 4.84 (1.28) 0.022 0.45 (0.07 to 0.83) 
9 months 4.41 (1.54) 4.75 (1.43) 0.121 0.34 (-0.09 to 0.77) 
12 months 4.54 (1.49) 4.92 (1.35) 0.070 0.38 (-0.03 to 0.79) 
Difference at 12m 0.47 (1.09) 0.62 (1.19) 0.394 0.14 (-0.19 to 0.47) 
Emotional Function Domain 
Randomisation 3.83 (1.58) 3.95 (1.47) 0.572 0.11 (-0.28 to 0.51) 
3 months 4.36 (1.73) 4.72 (1.52) 0.111 0.36 (-0.08 to 0.81) 
6 months 4.21 (1.79) 4.67 (1.58) 0.055 0.46 (-0.01 to 0.94) 
9 months 4.33 (1.92) 4.55 (1.59) 0.399 0.22 (-0.29 to 0.73) 
12 months 4.39 (1.82) 4.68 (1.68) 0.257 0.29 (-0.22 to 0.80) 
Difference at 12m 0.51 (1.36) 0.76 (1.59) 0.259 0.25 (-0.18 to 0.67) 
Environmental Stimuli Domain 
Randomisation 3.92 (1.51) 4.02 (1.52) 0.599 0.10 (-0.29 to 0.49) 
3 months 4.38 (1.56) 4.62 (1.57) 0.277 0.24 (-0.19 to 0.67) 
6 months 4.32 (1.64) 4.90 (1.44) 0.009 0.58 (0.14 to 1.01) 
9 months 4.25 (1.63) 4.73 (1.45) 0.038 0.48 (0.03 to 0.93) 
12 months 4.36 (1.65) 4.79 (1.59) 0.070 0.43 (-0.04 to 0.90) 
Difference at 12m 0.41 (1.42) 0.69 (1.53) 0.205 0.28 (-0.15 to 0.70) 
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GENERIC HEALTH RELATED QUALITY OF LIFE 
Responses to the EQ-5D-5L questionnaire are presented in Table L1. The utilities that these 
responses were converted into are shown in Table 4.9. For participants who completed the EQ-5D at 
both randomisation and 12 months there was no statistically significant improvement in overall 
quality of life over the trial in either participant group (p=0.983 for the placebo group and p=0.105 
for the TLA device group). No significant differences in utility values were observed between the two 
groups at any of the follow-up visits either (using data complete for each follow-up visit only).  
Table 4.9 also shows that there was a statistically significant improvement in overall quality of life 
over the trial in both participant groups when assessed by EQ-VAS scores. When quality of life at 12 
months was compared to that at randomisation, an improvement in VAS scores of 7 was observed 
both for the placebo and those receiving the TLA device (p=0.002 and p=0.001, respectively). At 3 
months, participants in the TLA device group had significantly higher VAS scores than those in the 
placebo group (65 vs.59; p=0.032) 
Table 4.9 EQ-5D-5L utility and visual analogue scale (VAS) scores 
 Placebo Active P Value Mean difference  
(95% CI) 
EQ-5D-5L utility, mean (S.D). 
Randomisation 0.67 (0.25) 
n=119 
0.68 (0.26) 
n=115 
0.633 0.02 (-0.05 to 0.08) 
3 months 0.68 (0.27) 
n=104 
0.73 (0.23) 
n=98 
0.123 0.05 (-0.01 to 0.12) 
6 months 0.67 (0.28) 
n=101 
0.71 (0.24) 
n=96 
0.265 0.04 (-0.03 to 0.12) 
9 months 0.64 (0.30) 
n=95 
0.72 (0.22) 
n=90 
0.052 0.08 (-0.00 to 0.15) 
12 months 0.67 (0.30) 
n=96 
0.74 (0.24) 
n=90 
0.081 0.07 (-0.01 to 0.15) 
Difference at 12m -0.00 (0.17) 
n=96 
0.03 (0.17) 
n=90 
0.226 0.04 (-0.02 to 0.08) 
EQ-VAS score, mean (S.D). 
Randomisation 58 (20) 
n=120 
61 (19) 
n=115 
0.329 2 (-2 to 7) 
3 months 59 (23) 
n=104 
65 (18) 
n=98 
0.032 6 (1 to 12) 
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6 months 63 (21) 
n=102 
64 (20) 
n=95 
0.690 1 (-5 to 7) 
9 months 62 (21) 
n=94 
65 (19) 
n=89 
0.193 4 (-2 to 10) 
12 months 65 (20) 
n=95 
67 (18) 
n=90 
0.471 2 (-4 to 8) 
Difference at 12m 7 (19) 
n=95 
7 (20) 
n=90 
0.790 1 (-5 to 7) 
 
4.2.3.3  IMPACT 
Responses to the Work Productivity and Activity Impairment questionnaire are shown in Table 4.10. 
Half of all participants in each group were not working at randomisation. There were no significant 
differences in employment between the two participant groups at subsequent follow-ups. In terms 
of self-reported hours missed from work due to the disease, responses were non-significantly 
different between the two participant groups at randomisation and at each of the 4 follow-ups, 
except for that at 12 months. At 12 months, participants in the TLA device group reported having 
missed 2.1 (S.D. 7.7) hours during the past 7 days as opposed to 4.0 (S.D. 9.3) hours in the placebo 
group (p=0.049). Regardless of this finding, participants rated the impact of asthma on their ability 
to work and perform their daily activities similarly across all follow-ups.  
Table 4.10 Responses to the Work Productivity and Activity Impairment (WPAI(A)) questionnaire 
 Placebo Active P Value 
Currently employed, n (%) 
Randomisation n=117 59 (50) n=111 59 (53) 0.681 
3 months n=106 54 (51) n=98 56 (57) 0.375 
6 months n=97 47 (48) n=95 56 (59) 0.145 
9 months n=93 43 (46) n=89 49 (55) 0.234 
12 months n=91 48 (53) n=86 49 (57) 0.572 
Hours missed work during past seven days due to asthma, mean (S.D)  
Randomisation n=55 3.6 (8.7) n=58 2.2 (5.8) 0.306 
3 months n=54 3.7 (9.5) n=56 2.4 (9.2) 0.484 
6 months n=47 3.5 (8.9) n=55 2.1 (7.7) 0.386 
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9 months n=43 3.1 (9.2) n=48 2.1 (5.0) 0.513 
12 months n=49 4.0 (9.3) n=50 1.1 (4.1) 0.049 
Hours missed work during past seven days due to other reasons, mean (S.D) 
Randomisation n=54 3.4 (13.6) n=58 2.8 (9.2) 0.779 
3 months n=53 4.2 (9.4) n=56 4.5 (10.5) 0.867 
6 months n=46 3.3 (12.2) n=55 2.8 (7.8) 0.807 
9 months n=43 7.0 (27.0) n=47 3.4 (9.0) 0.393 
12 months n=48 1.5 (5.6) n=49 0.8 (3.5) 0.436 
Hours actually worked during past seven days, mean (S.D). 
Randomisation n=57 28.3 (16.4) n=59 31.8 (17.6) 0.270 
3 months n=54 23.9 (18.8) n=56 28.4 (17.4) 0.190 
6 months n=47 26.9 (19.3) n=56 30.4 (17.7) 0.350 
9 months n=44 24.8 (18.0) n=49 30.9 (20.8) 0.133 
12 months n=48 28.8 (18.0) n=49 31.1 (15.5) 0.506 
Impact of asthma on work productivity*, mean (S.D). 
Randomisation n=61 4.0 (2.8) n=54 3.4 (2.8) 0.285 
3 months n=51 2.8 (2.8) n=53 2.8 (2.5) 0.895 
6 months n=50 3.0 (3.0) n=55 2.7 (2.5) 0.543 
9 months n=43 2.4 (2.5) n=50 3.4 (3.0) 0.083 
12 months n=47 2.5 (2.7) n=54 2.7 (2.6) 0.658 
Impact of asthma on regular daily activities*, mean (S.D). 
Randomisation n=116 5.4 (2.4) n=109 5.0 (2.5) 0.266 
3 months n=105 4.6 (2.9) n=95 4.1 (2.5) 0.171 
6 months n=93 4.6 (2.9) n=96 3.9 (2.9) 0.141 
9 months n=89 4.2 (2.9) n=90 4.1 (2.7) 0.807 
12 months n=90 3.9 (3.0) n=87 3.9 (2.7) 0.966 
*On scale of 0 (asthma had no effect) to 10 (asthma completely prevented work/doing daily 
activities) 
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4.2.3.4  TREATMENT EFFECT 
Responses to the Global Evaluation of Treatment Effect questionnaire are shown in Table 4.11, for 
over half of all participants there was a perceived improvement in the participant’s asthma in both 
participant groups over the 12 months of the trial. However, regardless of who completed the GETE, 
either participant or trial physician, there were no statistically significant differences in GETE 
responses between the two treatment groups.  
Table 4.11 Responses to the global evaluation of treatment effect 
 Placebo 
n (%) 
Active 
n (%) 
p>|z| 
Completed by trial physician* 
Complete control  1 (3) 1 (3) 0.861 
Marked improvement 13 (33) 13 (42) 
Discernible but limited improvement 13 (33) 9 (29) 
No appreciable change 11 (28) 8 (26) 
Worsening 1 0 
Completed by participant, confirmed only† 
Complete control  4 (11) 2 (6) 0.425 
Marked improvement 15 (39) 12 (39) 
Discernible but limited improvement 7 (18) 10 (32) 
No appreciable change 12 (32) 6 (19) 
Worsening 0 1 (3) 
Completed by participant, confirmed and possible** 
Complete control  7 (8) 5 (6) 0.347 
Marked improvement 34 (38) 33 (38) 
Discernible but limited improvement 22 (24) 32 (37) 
No appreciable change 25 (28) 16 (18) 
Worsening 2 (2) 1 (1) 
*Numbers completing: placebo=39; TLA device=31 
†Numbers completing: placebo=38; TLA device=31 
**Numbers completing: placebo=90; TLA device=87 
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4.2.4 SAFETY, HARM AND UNINTENDED EFFECTS 
Three participants died during the trial and post-trial period: two during the trial and one after the 
primary time point at 12 months. The SAE report classification for these deaths is shown in Table 
4.12. 
Table 4.12 Study deaths 
Days from 
Randomisation to 
death 
SAE report classification Dated severe 
exacerbations at 
1 year 
Total Maximum 
severe 
exacerbations 
Follow up severe 
exacerbations 
reported 
22 Cardiac event/secondary sepsis  1 1 0 
345 Cause unknown 1 3 3 
417* Aortic Aneurysm 0 0 0 
* After trial primary endpoint of 365 days 
 
Table 4.13 summarises the AEs and SAEs reported in the sources of primary outcome data (see 
Section 2.11.2.2 for list) by treatment group, respectively. The protocol did not require asthma 
exacerbations to be reported separately as SAEs or AEs, so these are excluded from the table.   
Table 4.13 Summary of AEs and SAEs Reported 
 Serious adverse event Adverse event 
Event description Active Placebo Total Active Placebo Total 
Acute coronary syndrome . 1 1 . . 0 
Acute pulmonary embolism . 1 1 . . 0 
Aortic aneurysm . 1 1 . . 0 
Bronchospasm (following 
lung function tests) 
 1 1 1 . 1 
Cellulitis 1 1 2 . 3 3 
Dental disease . . 0 . 1 1 
Depression . . 0 1 . 1 
Dry eyes . . 0 . 1 1 
Dry mouth . . 0 . 1 1 
Ear infection . . 0 . 1 1 
Exacerbation of eczema . . 0 . 1 1 
Exacerbation of multiple 
sclerosis 
. . 0 2 . 2 
Fall . . 0 . 1 1 
Fracture (ankle / leg) 1 . 1 . 1 1 
Gastroenteritis 1 . 1 . . 0 
Gynaecological symptoms 1 . 1 . 1 1 
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Headache/migraine . 1 1 . 4 4 
Hip fracture 1 . 1 . . 0 
Hypertension . . 0 . 1 1 
Hypokalaemia . 1 1 . . 0 
Ischaemic heart disease 1 . 1 . . 0 
Kidney infection 1 . 1 . . 0 
Lower respiratory tract 
infection 
2 2 4 . 1 1 
Musculoskeletal pain . . 0 . 2 2 
Pneumonia 1 . 1 . . 0 
Post-surgical injury 1 . 1 . . 0 
Sore eye . . 0 . 2 2 
Sore throat . . 0 . 3 3 
Stroke 1 . 1 . . 0 
Superficial skin injury . . 0 . 1 1 
Trauma to toe . . 0 . 1 1 
Upper GI bleed 1  1 . . 0 
Upper respiratory symptoms . . 0 . 1 1 
Upper respiratory tract 
infection 
. . 0 2 . 2 
Viral meningitis 1 . 1 . . 0 
Total 14 9 23 6 27 33 
 
Adverse events were similar in both treatment groups and none of the SAEs were device-related 
following causality assessments.  There were five adverse events reported (in four patients) 
considered to be probably related to the device, all in the placebo group. These included: (i) sore eye 
thought to be from a piece of the machine’s Airshower falling into the eye at night, (ii) grazed back 
of hand against the machine’s Airshower, (iii) sneezing when using the device, (iv) headaches and 
sore throat, which resolved on stopping device usage.  
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CHAPTER 5 QUALITATIVE RESULTS 
As with any qualitative research it is unlikely that the comments received can be generalised to 
include all participants in the LASER Trial and users of the TLA treatment device. Nevertheless, the 
responses received represent a range of participants and describe their experience of using the TLA 
treatment device. 
5.1 SUMMARY OF FOCUS GROUP FINDINGS 
5.1.1 DEVICE DELIVERY AND INSTALLATION 
During the LASER Trial, delivery and installation of the TLA device to participant’s homes was 
contracted to a logistics company, Bishopsgate, who specialise in the delivery of medical devices. 
It was felt important to evaluate participants’ experience and the impact of device delivery and 
installation recognising that the device was installed in the participant’s home, in their bedroom, 
and might require modification of the bedroom environment to accommodate the device.  
Participant’s experience of the device delivery and installation process was generally positive with 
most participants reporting that the process was easily arranged and straightforward. The device 
was set up in the participant’s bedroom by the delivery team with the participant and they were 
then left with clear written instructions. 
This was not the case for one participant who was one of the first trial participants; She described 
the process of device installation being very unprofessional with the delivery team clearly not 
understanding how the device should be set up. The participant felt that they were a ‘guinea pig’ for 
the trial. This incident was highlighted to the trial team at the time and arrangements were made for 
further training of the delivery team.     
Difficulties with device installation will have reflected badly on the trial and may have affected the 
participant’s confidence in the trial and in the treatment being delivered.   
Another point that was raised was that delivery was only available during normal working hours 
meaning that some participants had to take time off work to allow for delivery and installation of the 
device. These participants highlighted that they already felt under pressure for having to take time 
off work for hospital appointments and study visits so this requirement to take additional time off 
was not always welcome.  
Most of the focus group participants had had to make minor or major modifications to their 
bedroom in order to accommodate the treatment device. In most cases this was just removal of a 
bedside table to allow the device to be installed by the bed. In some cases, more significant moving 
of furniture and bedroom reconfiguration was required.  
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The focus group interviews will not have taken into account the views of participants who were 
unable to accommodate the treatment device in the bedroom as they were excluded from 
participating in the trial. This must be recognised as a limitation of the treatment. 
5.1.2 USER EXPERIENCE 
The most important reason for conducting the qualitative, focus group, interviews was to ascertain 
participant’s perceptions of TLA treatment including tolerability of the device and barriers to device 
use as well as the impact of TLA treatment on the participant. 
Participants were asked to comment on both positive and negative feelings towards the treatment 
device.  
With all treatments, both pharmaceutical and non-pharmaceutical, there is an important balance 
between treatment benefit and the risks of treatment including unwanted side effects. Although TLA 
treatment delivered by the Airsonett® device has no recognized side effects, unwanted device 
effects could be considered to be side effects of the treatment.  
In our qualitative interviews we identified the main unwanted device effect as noise and most 
participants commented on the noise of the device. The device is quoted as having a sound level of 
38dB, roughly equivalent to a quiet whisper.  
Very few participants withdrew from the trial as a result of the device noise but those interviewed in 
the focus group acknowledged that it took some getting used to. Some participants even went as far 
as saying that they felt that they liked the noise and missed it when they were not sleeping under 
the device. 
One participant did report that they had come close to withdrawing from the trial as a result of the 
device noise but had persevered with the treatment. It is important that patients are made aware of 
the noise generated by the device before having the device installed. 
Means of reducing the noise generated by the working mechanism of the device might help improve 
device acceptability and improve compliance and so this has been fed back to the device 
manufacturer for consideration.  
Qualitative, one to one, telephone interviews conducted during the pilot phase of the trial had 
raised some concern about smell and heat generated by the device but this did not seem to be a 
barrier to device use within the group of participants interviewed in the focus groups. 
A number of the focus group participants felt that there had been an improvement in their asthma 
symptoms in the year that they had received the trial treatment, acknowledging that they did not 
know if they were on an active or placebo device.  
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One participant reported that whether or not their asthma had improved, their sleep quality had 
improved during the trial treatment period. 
A number of participants highlighted that they had been injured whilst using the TLA device. The 
Airshower of the TLA device is covered in an abrasive material. Due to it being positioned directly 
above the participant’s head whilst in bed, they reported that there had been occasions when they 
had sustained minor abrasions when knocking their head or hand on the device whilst getting up or 
turning over in bed at night. None of those participants that took part in the focus group interviews 
felt that this was a barrier to the use of the treatment device but this will be reported back to the 
device manufacturer. 
5.1.3 DESIGN FEATURES 
In order to inform product development, participants were asked about design features that they 
felt could be modified or introduced to improve user experience. 
The most frequent observation was that the Perspex table which is integral to the treatment device 
is too small. Most participants had been required to remove a bedside table in order to 
accommodate the treatment device. They reported that the device was too small to hold what 
would usually be stored on a bedside table such as a lamp, medications or a drink. Participants were 
concerned that the device might malfunction if they were to inadvertently spill liquid on to, or in to, 
the device.   
Most participants had a lamp on their bedside table which had also been removed along with the 
bedside table to accommodate the device. It was suggested that a useful design feature would be an 
integral light for reading as a substitute for the bedside lamp. 
Some participants had problems with the device’s power cord. The power cord is inserted under the 
device. Participants reported that this was difficult to locate and due to the angle of insertion, the 
cord had a tendency to become dislodged or fall out. 
Participants also agreed that a helpful design modification would be to the neck of the device, 
making it swivel so that the device user could move it out of the way when getting into and out of 
bed and when making the bed. Currently the neck position is fixed. 
Participants also commented on the weight of the device complaining that it was too heavy to move. 
This was particularly in the context of cleaning the bedroom where they felt that they were unable 
to clean effectively around the device without being able to move it. 
Participants also felt that a lighter, more portable machine might be beneficial so that it could be 
used in other rooms of the house, for instance whilst watching television.  
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5.2  DETAILED RESULTS INCLUDING VERBATIM QUOTATIONS 
5.2.1 DELIVERY AND INSTALLATION 
Participants were asked about their experience of the installation of the TLA device in their home.  
Delivery and installation of the TLA devices was contracted to Bishopsgate, a company specialising in 
medical device logistics.  
Most participants felt that the delivery and installation had been straightforward. 
They seemed to be very knowledgeable. I didn’t know whether they were just delivery or whether 
they were...how much knowledge they had but they seemed to be quite knowledgeable. (P2) 
They did actually, I’ve just remembered, they did have a tape measure and take photographs of 
where my pillow came and they took away a photograph and we were told we couldn’t move it 
from its position. (P6) 
[AD And did they set the machine all up for you, did they?] 
[General yes]. 
[AD And did they give you instructions to set them up?] 
Yes. (P4) 
Yes. (P1) 
Clear, clear as mud. (UF) 
Yes, yes, very good. (P2) 
I thought they worked rather well together, because I work well with my colleagues at work and 
we know the task to be done and there’s no verbal conversation about who’s going to do what, 
someone just gets on and does one task while someone gets on and does the other task…there’s 
no verbal communication; you just do it as a team. And this is what I observed with them, so I was 
quite enthusiastic. (P10) 
[AD So you thought they were competent.] 
Yeah, oh yeah, of course. (P10) 
I think it's just one young chap on his own at first who installed it, it was just quite 
straightforward…he was very pleasant. And then when the filter needed to be changed after six 
months... one chap came…he knew what he was doing. (P7) 
 
Early in the trial, there were some problems with devices being installed incorrectly. This was 
identified and rectified with further training for the team members who were responsible for the 
installations.  
One of the participants in Focus Group 2 was one of the participants where there was some concern. 
She reported that the staff did not seem 100% competent. The device was eventually installed 
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correctly but this did not give a good impression of the trial and may have affected the participant’s 
confidence in the trial and the treatment. 
I mean, they were lovely. It was a... they were the delivery chaps and it was a dad and son and 
they were so bumbly, sort of Stan and Errol, and they put it round the wrong way and so I had a 
picture of the... we had all the pamphlets and everything, and I said that doesn't look... should it 
be the other way, and he said oh, give us that picture. And he said, oh yes, I think you're right. And 
he said he'd been on the course the week before. Now, these are delivery chaps, so they're not 
[unclear] and they're trying to put it together and so and then they got the tape measure out and 
the son wasn’t doing it right, so dad took over. And it was funny, but it was a bit bumbling... 
because I was not confident about the two lovely chaps. I read the whole thing in a hurry, read the 
book of words and how it should be and we all measured it again and...  
[AD So in fact it had a positive effect, you took more interest in it, sense of ownership.] 
Yeah, in what it was, but I hope that the people that were having it delivered the rest of the time 
they'd got their act together. (P9) 
Yeah, I felt the pilot, the guinea pig. [overtalking] he'd never seen it…at least I'd seen what it was 
supposed to look like. (P9) 
Reassuringly, in that same Focus Group the other participants who entered the trial at a later date 
reported that they had not had a similar experience. 
I don't know if it was the same two chaps that came to me, but they were quite efficient by the 
time they got to our house…They obviously knew what they were doing by that point. (P8) 
I think it's just one young chap on his own at first who installed it, it was just quite 
straightforward…[unclear] and then put it to the appropriate height…he was very pleasant. (P7) 
 
One participant complained that he had to take time off work for the device to be delivered. He was 
given a time slot and the device was delivered on time. Many of the participants would have had 
time off work through illness or to attend hospital appointments and these additional days for 
delivery of the device and for the filter changes will add up. 
I had to have a day off work to wait for the little man to come, two little men…it had to be 
installed and then we had to be trained up on using it…Which is fine, but I’ve had a bad year and 
used up all my holiday…and this was just another one of those things; so that’s a downside for 
me…it’s a shame it couldn’t just be here are some instructions, assemble it yourself. (P10) 
[AD What about an evening, did they offer you an evening?] 
I don’t recall being offered an evening, it was a nine to five thing, which is time off work. 
[AD And no weekends.] 
I wasn’t offered weekends. 
[AD Okay, would that have helped?] 
It would’ve, yeah (P10) 
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Other participants worked from home so did not find this to be a major inconvenience. 
Well, I work from home, so it didn’t matter (P8) 
No, I mean, I can work from home, so I know the day they gave me... it wasn’t tortuous. (P9) 
 
5.2.2 BEDROOM MODIFICATION 
Participants were asked about their experience of having the TLA treatment device in their 
bedroom. A number of participants reported that they had to make minor modifications to their 
bedrooms in order to accommodate the TLA device such as removing a bedside table. 
I just picked up the bedside table that I had and moved it to a room next door while this thing was 
put in place; that was the only thing, I had to clear a bit of space for. (P10) 
We haven’t got a big bedroom and it was just getting things right but we did and it’s all worth the 
effort at the end of the day, very much so. (P2) 
Yes I had to shift things around because I’ve really got a small room because I live back at home 
with my mum, and me and my boyfriend sleep in there but it’s like a box room quite... That’s the 
only thing. (P1) 
[AD Right, so you had to do a bit of shifting around to get the machine in there.] 
Yes. (P1) 
I’ve just finished with my bedside lamp and my bedside cabinet (P6) 
 
Other participants had to make more significant changes. 
We had to swap sides of the bed, which was a bit odd after 20 years…Because it doesn't fit the 
other side, so because the way the bedroom's laid out with the furniture… you couldn't swap it 
round because the position of the window and so yeah, that was a bit odd. (P8) 
We have a small bedroom and we have individual single beds that were pushed together but now 
they’re apart to get the [device in]... If I was a bit more sensitive and perhaps we’d been married 
less long I would have said it’s come between us…But it’s all worthwhile, definitely worthwhile but 
we did have to do some major upheaval to get everything right in the bedroom. (P2) 
One participant was not able to close his bedroom door when the device was in situ. He commented 
that this was because the device footprint was in a different orientation to his bedside table. 
…bedside tables are quite narrow and deep, whereas this machine’s the opposite way round and 
it’s so wide that I can’t shut the bedroom door…because of where the bed is and the shape of the 
room I think, I can’t shut the bedroom door, which I don’t really care about. But when we’ve got 
visitors staying my snoring helps keep them awake as well and if we could shut the door it would 
be slightly better for them. (P10) 
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5.2.3 USER EXPERIENCE 
One of the most important reasons for conducting the Focus Group interviews was to understand 
participant’s perceptions of TLA treatment. 
This is important to allow us to identify barriers to treatment adherence and to inform the device 
manufacturer’s product development in order to make the device as user friendly as possible. 
5.2.3.1  USER EXPERIENCE - NEGATIVE 
Device Noise 
A number of participants commented on the noise of the device. The device is quoted as having a 
noise level of 38dB – equivalent to a quiet whisper or a suburban street. Participants are made 
aware of this in the PIS. 
Some found the noise difficult to get used to at first. 
…Very difficult to get used to the first few nights. Not much sleep at all. Because it's just constant 
noise. I was expecting it to be a lot quieter having heard it at the hotel. We just thought there was 
going to be no noise at all. It's great. But there is noise and it's a lot more than I expected. But you 
do get used to it. And then, actually, you go somewhere else and you haven't got it and you can't 
sleep. So it's almost like mood music. You get used to it then you can't live without it. (P1) 
I agree. My husband, he's been totally on board with it, no complaints. But we both did struggle to 
get used to the noise. (P5) 
Others had no problem with the noise at all 
No problems with the noise whatsoever. (P6) 
It was very handy in the morning as I know when to get up. [when the device switched itself off 
and the noise stopped] (P3) 
I had no problems with the noise. (P4) 
 
One participant reported that they had come close to turning the device off due to the noise. 
I have come close through not being able to sleep with the noise to turning it off, but haven't, but 
have come close. (P5) 
 
In total 3 participants withdrew from the trial as a result of not being able to tolerate the noise of 
the device. 
Two of the focus group participants reported that the noise had been a problem for their partners. 
This is an important consideration as this may also be a reason why some patients might not be able 
to use the device in future. 
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My wife…is a bit of a light sleeper, so she’s getting a bit grumpified [sic] about the bloody 
machine… it keeps her awake…the noise when it starts up and the noise when it goes off, it shakes 
and vibrates a little bit, and the air coming out of the machine. 
[AD So that’s while it’s on all the time, she can hear that continually.] 
Yeah. She’s got quite delicate hearing. I don’t know how with my snoring, but it keeps her awake. 
And the nearer we’re getting to the end of the thing the grumpier she’s getting. So I won’t be 
taking up your offer of keeping it. 
[AD That’s interesting because... not because you...] 
No, not because... I’d like to, but it’s just too noisy. And it’s better to have a patient wife than 
anything else.  
[AD Okay. She didn’t make you stop using it at all?] 
No. 
[AD Well, you can be honest.] 
No, because I was saying I’ve signed up for the study, we’ve got it for a year, I asked her in 
advance and you said yes, so it’s here for a year; live with it. (P10) 
 
The noise. My boyfriend complains about the noise. It sounds like an aeroplane, he says. But I 
don't find it that bad but I think other people… I think we're used to it, but they're… yes. (P1) 
 
Smell and Heat 
The early trial telephone interviews identified that some participants had noticed that there was a 
distinctive smell whenever the device was switched on and one participant complained about the 
heat generated by the device. 
Each of the Focus Groups was asked specifically about heat and smell. 
One participant in Focus Group 2 reported that she had notice a smell of dust and one participant in 
the same Focus Group noticed that there was some heat generated by the mechanism of the device. 
 
It does smell, that's why I wonder whether mine's not an actual device because sometimes it 
smells of dust when it first turns on, so I get the slight odour of dust. (P8) 
Mine is hot. (P4) 
 
None of the participants in Focus Group 3 noticed any smell or heat. 
 [AD Any smell to it?] 
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[All say no]. 
[AD Is there any heat from the machine that worries anyone?] 
[All say no]. 
 
Airshower Injury 
A number of participants reported that they had hit their head or hand on the Airshower of the TLA 
device. The Airshower has a rough surface which is engineered to ensure that the descending 
laminar airflow is kept separate from the ambient room air. 
Due to its position above the patient’s pillow, there were occasions when participants hit their head 
or hand whilst getting in or out of bed. No major injuries were sustained but participants questioned 
why this was such an abrasive surface. 
Hitting your head, even after six months, I'd... you always knew it was there, but just now and 
again just sitting yourself... sit up or sit down and you know you've got to sort of... round it or cup 
of tea in bed, I've got my little iPad thing, and just ugh, bang. (P9) 
A couple of... a few times. Not too often. 
[AD Not enough to say not using this thing again.]  
No. (P8) 
 
You learn to not sit up too quick. (P4) 
Oh, yes! (P2) 
You only do it once or twice don’t you? (P5) 
Yes. (P4) 
[AD How many of you have hit your head?] 
[General yes]. 
Several times. (P4) 
[AD Everybody?] 
Everybody. (UF) 
[Seven of the seven have hit their head. Often?] 
No. (P6) 
No. (P3) 
I don’t do it very often. (P1) 
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It’s not noticeable anyway. If you do, it’s only plastic. (P3) 
I scraped my hand on it a few times. (P1) 
Yes I’ve done that lots of times. (P2) 
And it hurt (P6) 
It’s like pumice stone, scrapes your knuckle. It’s a small price to pay. (P5) 
Yes, yes, it is. (P4) 
If I sit up, my head doesn't touch it. When I knock my head on it is when we're trying to make the 
bed…But again, a small price to pay. But if I sit up I don't touch it. 
It's more if you're leaping out, springing out. So it's not a big issue. (P6) 
 
Weight 
A number of participants commented on the weight of the device. This was in the context of when 
trying to move the device to clean the room.  
The device weighs 23kg. Ideally participants are asked not to move the device during the trial. 
Participants commented that they would like the device to be lighter so that it could be moved more 
easily and potentially then made portable so that it could be taken away from home when on 
holiday or spending extended periods away from the home. 
It's incredibly heavy…it's got a quite heavy base. I mean, I've put the Hoover edges to it, I do 
Hoover , I just... but I have trouble...it's not like a chair you can drag and [overtalking]... the base is 
very heavy. (P9) 
I would like a bit more movement underneath so small casters or something. I’m always afraid of 
moving it too much out of position but it would help if it was a bit easier especially when I’m 
breathless. (P2) 
…you need either lockable wheels because asthma’s all about dust and if you can’t move it...We 
were told not to move it at all by the people. We’ve also got a drawer under the bed which we 
can’t use now but considering asthma’s all about dust it needs to be made more easily mobile so 
you can move it once a week to vacuum under it. I can’t move it at all. (P6) 
 
2 participants reported that they didn’t try to move the device because they would be concerned 
that they had not returned it to the correct position, 
I think I would be afraid of would I definitely put it back in the right place? (P5) 
I haven't actually tried to move mine, so I don't know. (P8) 
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Use of Fan/Air Conditioning 
Participants are asked to avoid using fans or air conditioning units in the room where the device is 
installed as this would affect the laminar flow of cooled, filtered air. Participants are also asked not 
to have windows open if possible and if the window is open to ensure that the door is shut to 
prevent a cross draught from disturbing the laminar airflow. 
One participant complained that she had been unable to sleep with a fan on during the trial.  
…we can't now have fans on. You can't have any air flow through the bedroom. For me, the 
biggest problem is I wasn't sleeping… I was so hot, I was absolutely dripping, so I could… I 
normally have a fan on me all night, and this thing isn't blowing any cold air onto me. And I was 
just so tired because I was absolutely sweltering. No window open. You're not allowed to have any 
air flow through. And then no window open and no fan. (P2) 
This participant came close to withdrawing from the trial. 
I would say nearly switched it off during the summer to have the fan on because I was so hot. (P2) 
 
5.2.3.2  USER EXPERIENCE - POSITIVE 
Noise 
Although as described above, some participants and their partners found the noise difficult to get 
used to, a number of participants commented on how they got used to the noise and even missed it 
when they were away from home. 
It's a bit weird the thing on your face initially, but it didn’t take long to get used to and I quite like 
the hum (P8) 
You kind of miss it after a while.  
[AD Really?] 
Yeah, if I had... I rarely but Saturday night, couple of sherries, and it's sparked out. And I wake up 
about 1:00 and I think what's wrong? Yeah, and it's... apart from him snoring away, I go oh, I 
haven't turned the stupid thing on…(P9) 
 
One participant reported that her partner quite liked the noise. 
I'm ex-Navy and my husband's Navy and it makes us feel like we're on a ship, it's like a [inaudible: 
laughter] you've got that hum in the background. (P8) 
[AD But not the sway.]  
Not the sway, if you'd add the sway he'd feel quite at home. (P8) 
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Improved Sleep 
Two participants reported that they felt that their sleep quality had improved. 
I'm finding that I'm sleeping much better (P7) 
…Once we got over the noise we slept really well and even my husband said we'll keep this 
machine because we sleep better under it. (P1) 
  
Improved Asthma Symptoms 
A number of participants commented on positive treatment effects with a reduction in asthma 
symptoms and reduced frequency of exacerbations. 
I've gone from having four or five exacerbations a year to none. (P6) 
I've done my year and I'm into my second year. The first year, it was noticeable, I only had one 
exacerbation in that year. Just coming down from one at the moment. So it doesn't do away with 
it all together but mine is infection based as well. That one year, I nearly got away with that one 
winter of having an infection and getting problems, it was noticeable… it's been a lot… I think it's 
been marvellous. (P6) 
…my cough wasn’t nearly so bad after I'd been using it for a while. (P7) 
I'm certainly a lot better than I was before the trial started. Whether it's to do with the machine or 
not, I don't know. But I'm delighted. I have had other problems but certainly my breathing has 
markedly improved. (P4) 
I haven’t had to have antibiotics and steroids or anything like that, so that’s another plus point. 
(P10) 
And some days I’ve given got up and gone off to work without having my puffers [reliever inhaler] 
[AD Really.] 
Yeah. Because I used to have to reach for them when I got up, after being in the bathroom, but I 
had to have them before I could get dressed and before I could walk the dog and before I could 
ride my motorbike to work, I’d have to have my puffer. But for the last year or so I haven’t needed 
it. (P10) 
This wasn’t the case with all participants. 
I'm not too sure. I've had a few exacerbations; I've been in hospital, I think, beginning of 
November and I'm on steroids at the moment now. So I am not too good at the moment. I can 
breathe a bit better but I've been off work this week. 
[AD So for you you're not sure if it is the machine.] 
I'm happy to take part though, I think it'll be useful, hopefully. (P1) 
One participant who has now completed the trial and is using an active treatment device in the post-
trial provision period felt that she might have been on a placebo device as her symptoms had 
improved since finishing the trial. 
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Knowing that I'm on the real one and have been for six months, I feel that... I do feel the 
benefits…I was very ill during my time, my year with it…so I think I had the placebo, because now 
having had six months of the real thing, I can tell the difference. (P9) 
 
Partner Benefits 
Interestingly one participant felt that perhaps the TLA treatment might be having a beneficial effect 
in reducing her husband’s snoring. 
I have to say, I think he got a bit quieter, I wondered if he was benefiting from it. I don’t... you 
know (P9) 
  
5.2.4 DESIGN FEATURES 
Participants were asked to comment on any issues they found with using the device and any design 
modifications that they might recommend for future product development in order to make the 
device more user friendly. 
A number of participants commented on the Perspex shelf/table that is provided with the device. As 
described above, the device often replaces a bedside table and so participants felt that this should 
be able to accommodate what would usually be stored on a bedside table. 
…a better table attachment, because it replaced the bedside table and there's not a lot of space, I 
read a lot of books, there's a lot of books. It would be helpful to have something you felt confident 
putting your glass of water on, which I don't put my glass of water on it…If it falls into the device, 
then what, it's not going to be ideal.  
[AD And would you normally have your bedside light on that table, so you had to compromise, 
did you?] 
Yeah. (P8) 
 
It's quite sturdy, isn't it, it seems to be... because it's Perspex, it looks a bit... so I was hesitant to 
put a coffee or a water on it, but it's stronger... I think it's stronger than it looks. (P9) 
[AD Right, but not big enough perhaps for what you really wanted.] 
Yeah, it's a small area, it's more my concern about trashing it, I suppose. (P8)  
 
[AD And then the table, you're not keen on the table, the little table?] 
Not much. (P3) 
Well, it's useful. (P2) 
Better than nothing. I had to lose the bedside cabinet, but it was better than nothing. (P5) 
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I had to lose my bedside cabinet and there's nowhere to put my coffee. (UF) 
[AD Are you worried about where you put your coffee?] 
I wouldn't put coffee on anything…(UF) 
It's not quite flat. It's always slightly…(P3) 
What I do at night is take a bottle of water up with a lid on it. I don't have a glass of water. (P2) 
I have a sports bottle. (P5) 
Yes, me too, so there's no chance of spilling. (P2) 
[AD But can you get a bedside table, a lamp on it?] 
No. (UF) 
No. (UF) 
[AD It's just your clock, is it?] 
Not only that, it's the wrong size, it doesn't cast a light. (P4) 
I have my contact lenses and my inhaler and that's it. (P3) 
 
One participant commented on the socket for the mains electrical lead to the device. This is 
positioned in an awkward location under the device and in a position that would be difficult to 
access when the device is in situ. He had noticed that his device had stopped working and eventually 
found it to be due to the plug having become disconnected for the device. 
Other participants agreed that this was a problem. 
 
I thought it was broken for a while, it seemed dead, but because the power cord goes up into the 
bottom, I'd actually left the power cord in and it fell out. You switch it on at the wall. But I must 
have moved it somehow and the power cord just fell out the bottom because it goes in upwards. 
(P3) 
Yes, it is really difficult to find (UF) [overtalking]. 
I hadn't even noticed it but once I saw that, it was about six or seven days, and once I plugged it 
back in I felt silly as well. (P3) 
Yes. Actually, I found that plug very difficult to cope with because you've got to go down on your 
hands and knees. (P2) 
[Others agree it is difficult]. 
 
Two participants talked about the positioning of the device in relation to the bed. 
One participant thought that the device would be better positioned at the head of the bed. 
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I wouldn’t have thought it wouldn’t be that difficult to get it to go behind the bed instead of at the 
side of the bed, probably redesign the machine to some extent. We can pull the bed out that way 
but this side is not functional. (P4) 
The other participant questioned whether the main body of the device could be positioned under 
the bed, out of the way. 
For me, design-wise, I mean I know everyone's bed is different, you have divans or whatever, but 
the bit at the back, if they could somehow encompass it so you can have a different model that's 
got a lot of workings that go under the bed. So you push it like a forklift truck under the 
bed…Because the back bit is the bulky bit. And that's why you have to get rid of your bedside 
cabinets. (P3) 
 
A common and popular suggestion was that perhaps the neck of the device and the Airshower could 
be adjustable for ease of positioning and on a swivel so that it could be moved out of the way of the 
bed when getting in and out of bed and when making the bed. 
An arm that swivels round so you could get up and sit back (P9) 
So if this was on a swivel and you wanted to sit in bed, you could just swivel it out the way and sit in 
bed…But as it is it’s fixed. 
[AD Right, so you have to get in and get under it.] 
If you was an old person I doubt whether you could just pick it up and move it. (P10) 
 
One participant commented on how he was required to re-programme his device following a power-
cut. He thought that there should a memory capacity so that this was not required each time the 
mains power was switched off. This would seem like a good idea. 
…when we had a power cut we... someone had to programme in the times again, because it 
seemed to erase its memory for some reason. 
[AD Right, easy to do?] 
I thought it would’ve had a little bios battery in there that stored everything. 
[AD So it all went blank and you had to...] 
Yeah, I had to put the date and the time in. (P10) 
 
As a result of having to replace her bedside table with the treatment device, one participant no 
longer had a bedside light. She suggested that a future design might incorporate a light into the 
device. 
I've got no light by my bedside table now. So if I wake up during the night and I need my tablets, I 
am having to feel for them and end up dropping them on the floor. They couldn't encompass just 
some sort of light in the bit that goes up like that, or somewhere where you could somehow click. 
110 
 
Or just say a moulded bit that you could then clip the light onto somehow. I don't read at night but 
if you read at night it would be very awkward. (P2) 
 
One participant felt that it was important that future models were smaller and more portable so 
that the treatment could be used when away from the home. 
Is there any chance that they will invent something which is more portable? 
[AD …Something more portable so you can have it when you're away.] 
Yes, for people who are working it probably would be nice for them to have a session in their lunch 
break. 
[AD So a mini version of it.] 
Yes. (P6)  
 
Finally, one participant thought the device should come equipped with a minibar! 
Minibar [overtalking]. A table for the minibar. (P9) 
 
Table 5.1: Key to Verbatim Quotation Contributors 
P1-10:  Participants 1-10 
UF:  Unidentified Female – voice not recognised in digital transcription 
AD:  Dr Ann Dewey – Senior Qualitative Researcher and Facilitator 
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CHAPTER 6 DISCUSSION AND CONCLUSION 
6.1 DISCUSSION 
The LASER Trial has found that, in the population of patients with severe, exacerbation prone, 
allergic asthma randomised to treatment, the addition of a TLA device to standard medical care 
resulted in no statistically or clinically significant benefit in reducing the frequency of severe 
exacerbations.  
Although there were no significant differences in the secondary outcomes for spirometric lung 
function (pre- or post-bronchodilator FEV1), asthma control or eosinophilic airway inflammation 
(FENO), there was a significant improvement in mean daily PEF in favour of the TLA device. In the 
light of a lack of improvement in other parameters of lung function, this improvement needs 
cautious interpretation, although the levels of improved PEF are in the order of expected reductions 
in peak flow during exacerbations in this patient group.  
Use of the TLA device yielded higher levels of generic and disease-specific health-related quality of 
life with results showing statistically significant higher quality of life at some intermediary follow-up 
visits.  
There were no significant safety concerns between groups and adverse events were similar between 
the participant groups.  
The different outcomes in this Trial compared to previous TLA studies and other anti-allergy 
interventions in this patient group requires interpretation and this is discussed here in more detail. 
6.1.1 ASSESSMENT OF EXACERBATIONS  
Frequency of severe exacerbations was chosen as the primary outcome in the LASER Trial for a 
number of reasons. A significant proportion of the cost of managing asthma derives from the use of 
acute and unscheduled care for the management of severe exacerbations. As determined by our PPI 
representatives, asthma exacerbations are also important to patients as they have such an impact 
on patients’ quality of life and their ability to work/study.  
Our definition of a severe asthma exacerbation was accurately described and consistent with 
international trial endpoint criteria. For the purposes of the LASER Trial we chose a threshold of 
≥30mgs of Prednisolone or equivalent corticosteroid as it is consistent with the BTS/SIGN guidance 
for the treatment of severe acute asthma. A post-hoc analysis using a less stringent definition for an 
exacerbation, an increase in Prednisolone dose of ≥10mgs over baseline dose, showed the same 
results with no significant reduction in exacerbation frequency.  
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We had sought to ensure we collected severe exacerbation data from multiple sources to avoid 
under-reporting and attempted to provide some clinical if not data corroboration that a severe 
exacerbation had occurred. By attempting to capture more information we unfortunately also 
increased the potential risk of missing data.  
We examined several sources of exacerbation data including the daily TLA diary (TLA) filled out 
continuously during the trial with a daily corticosteroid dose, the Patient Exacerbation Diary (PED) 
filled out only during severe exacerbations and Exacerbation Review Forms (REV) completed by the 
clinical team when the patient reported a severe exacerbation. We had specified in the Trial 
protocol that asthma exacerbations requiring hospitalisation did not need to be reported as Serious 
Adverse Events (SAEs) to prevent duplication because this exacerbation data was being collected 
elsewhere but some of our trial centres still reported them as SAEs. Furthermore, to ensure severe 
asthma exacerbations were reported even if they had not been recorded in the TLA, PED, REV or 
SAE, participants were asked to recall the number hospital admissions for asthma exacerbations 
(HOSP) and total number of severe exacerbations (FU) that they had experienced in the preceding 3 
months at each of their follow-up visits (at 3, 6, 9 and 12 months), these were recorded as follow-up 
exacerbation data.  
As we would expect in a real-world RCT, data completion across all formats was not consistent. 
Many participants completed their daily TLA diaries, others did not, with occasional advice from 
clinical teams that if they were unable to do so that they at least fill out their PED and/or come for 
an exacerbation review visit for completion of a REV form when exacerbating. We thus cleaned and 
matched all the different sources of exacerbation data by date to avoid double counting e.g. courses 
of oral corticosteroids that coincided with a hospitalisation. We also combined the TLA Diary and 
PED by date and dose as there were some where the data was incomplete e.g. the date of 
commencement was offset by a few days, in order to create a combined T/P source of exacerbation.  
The consequence of all this is that the number of trial-end point severe exacerbations may not be 
the same as the sum of the number of severe exacerbations reported by the participants at the 
follow-up visits, as mild or moderate exacerbations that did not meet the strict trial definition may 
also have been recalled and reported at these follow-up visits. 
We sought to examine all possible measures of severe exacerbations but decided to use only the 
344 dated exacerbations in the primary analysis. By using dated exacerbations there was certainty of 
the data and clinical evidence of oral corticosteroid use to meet our protocol definition. Using this 
method, we had to assume that where there was missing TLA or PED corticosteroid dose data that 
patients were not taking oral corticosteroids and therefore did not have a severe exacerbation. This 
may potentially have led to severe exacerbations being missed.  
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Using either the reported FU exacerbations or a combination of the dated exacerbations and 
reported FU exacerbations would allow inclusion of more exacerbations but these two methods 
would both be subject to recall bias as we could not be certain that participants did not include non-
protocol, mild or moderate, exacerbations in their reported FU exacerbations. Examining the 
reported FU exacerbation responses, it was evident that some participants either under-reported or 
over-reported exacerbations over and above their dated severe 0exacerbations. Surprisingly, there 
was evidence of over-reporting of severe exacerbations even by some participants who filled out 
their TLA diary fully. Another disadvantage of using the reported FU exacerbations is that it would 
not allow for those who under-reported on FU exacerbations if we had evidence of more 
exacerbations from dated severe exacerbation sources. Another problem with the use of reported 
FU exacerbations is that we would not be able to ascertain whether participants contravened the 7-
day rule for separating exacerbations which could potentially allow for over-reporting of 
exacerbations by participants reporting one exacerbation as two or even more separate 
exacerbations.  
We have also considered the impact of missing TLA diary data on the primary outcome of the rate of 
severe asthma exacerbation events. The missing data on the TLA diary relates to the failure to 
record any value (diary entry left blank), and the majority are due to a failure to record a value of 
zero where likely no exacerbation occurred. Where participants were taking oral corticosteroids at 
levels of the protocol definition of an exacerbation (≥30 mgs), the proportion where a value had to 
be assumed as zero in the TLA diary was small, and where the doses of oral corticosteroids were 
much lower than the protocol definition (<30 mgs) then the proportion of values having to be 
assumed to be zero was much larger. This indicated that participants were less likely to record lower 
doses of oral corticosteroids, when for example on maintenance oral corticosteroids or when 
tapering off from prolonged courses, or recording as zero when they were not taking any and so not 
in exacerbation (the commonest occurrence). While we had not sought to determine the severity 
and duration of exacerbations other than their frequency for our primary analysis, this approach 
may have led to underestimating the rate of events, as we did not have the number of days 
participants were “at-risk” for the denominator in the model, and we had to assume all days (where 
there was no value recorded in the TLA) to be considered at risk. The amount of potential missing 
data according to the TLA diary was potentially significant and could have caused a type 2 error for 
the primary outcome, i.e., a treatment benefit is not shown even if such an effect existed.  
Ultimately, despite merging all available records to provide an integrated record of the number of 
exacerbations per participant, we were not able to demonstrate a difference in frequency of 
exacerbations between groups.  
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6.1.2 APPROPRIATENESS OF PATIENT POPULATION AND MINIMISATION 
There was a remarkable reduction (approximately 50%) in exacerbation frequency in both groups 
from baseline to completion of the Trial, but no difference between groups. Across the two groups, 
43% of participants reported no exacerbations during the 12-month trial having had at least two 
exacerbations in the preceding year. This phenomenon of improvement in outcomes under study 
conditions has been reported in other diseases as well as previously in asthma, and is not explicable 
simply by a regression to the mean effect; we would have expected that not to have occurred in a 
year-long study.  
The placebo effect in asthma is well recognised but poorly understood (Dutile et al 2014) and needs 
to be taken into consideration when designing clinical trials. Inclusion of a ‘no treatment’ arm in the 
trial is one possibility but there is also evidence of improvement in these groups as well under study 
conditions (Hróbjartsson et al 2010).  
It must be considered that there may be an additional unknown factor or treatment effect related to 
the treatment device that contributed to the significant improvement in both the active and placebo 
arms of the trial. One possibility is that this may have resulted from improved sleep quality. Several 
observational studies have shown a relationship between atopic diseases, including asthma, and 
sleep disturbance. This relationship is interesting and there is a suggestion that they are interrelated, 
with either condition being a risk factor for the other (Jernelöv et al 2013). The qualitative focus 
groups identified that a number of respondents felt that their sleep quality had improved as a result 
of the device use although it is unclear whether these participants were in the active or placebo arm 
of the trial. Improvement in sleep quality may or may not have been related to the treatment 
delivered as it could equally be related to the noise of the device or another unknown factor. 
Improved sleep quality may have had a positive outcome on asthma control and may help explain 
the improvement in exacerbation frequency in both treatment arms in the trial.   
Other possible explanations for the improvement seen in both treatment groups during the LASER 
Trial include the improved adherence with treatment under study conditions and the support gained 
from regular visits and access to healthcare professionals from the site trial teams. We recruited a 
number of participants into the trial who may not have previously been known to the recruiting site 
(incident cases) and so the opportunity to correct for factors that might have been driving poor 
asthma control may have been missed prior to enrolment and become evident during the trial. The 
risk of this impacting on trial outcome was reduced by including the origin of the case (prevalent or 
incident case) as a minimisation factor. 
It is remarkable that 4 participants in the placebo group recorded a prior exacerbation frequency of 
14, 18, 20 and 25 exacerbations in the year prior to participation in the trial. The impact of this was 
however reduced by including the exacerbation frequency in the previous 12 months (2, 3, ≥3)  as a 
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minimisation factor, and further analysis of the dated exacerbations during the trial shows that 
there were no participants with skewed exacerbation frequency between the groups.  
Although not presented here, we measured the number of hours that the device was used by each 
participant. The majority of participants possessed a device for more than 6 months of the trial, 
making them eligible to benefit from the four years’ post-trial provision of an active TLA device free 
of charge. This incentive may have helped with participant retention but this is not a perfect 
indicator of adherence as even measured hours is not representative of the time spent under the 
device as the device is pre-programmed to automatically switch on and turn off. Nevertheless, the 
TLA diaries which asked participants to record their use of the device suggested that, where it was 
recorded, most participants used the device for sufficient hours to include overnight sleep (8 or 
more hours). There were instances when participants were on holiday or abroad and in this 
pragmatic trial we allowed them to continue participation in the trial as long as this meant they 
spent no longer than a week without the device.  
6.1.3 TRIAL CONDUCT 
All trial centres had a face-to-face site initiation by the Trial Coordinator to ensure all trial 
procedures were followed. Despite this, 12 incidents of admission to hospital due to exacerbation 
were identified from SAE reporting (with or without other acute comorbidities); these were re-
framed as data contributing to the primary outcome rather than reportable adverse events.  
Some site trial teams recognised the onerous nature of the TLA diaries and this may explain why 
some participants were less likely to record values of zero when well, and why often only PED were 
completed with accompanying REV. Earlier data quality checks at sites may potentially have 
identified this problem earlier and reduced the amount of missing data. 
6.1.4 MULTIPLE COMPARISONS 
We had considered carefully in the statistical analysis plan that multiple comparisons of the 
secondary outcome variables would be made, even though these were important to assess 
and were agreed a priori. We anticipated the possibilities of a Type I error (finding of ‘false 
significance’) and had designed the Trial specifically to reduce the chances of such findings.  
We have conducted a prospective study with adequate power to test our hypothesis, 
exacerbations were confirmed from multiple sources wherever possible by the research 
team, we estimated secondary outcome measures objectively by questionnaires and lung 
function, and we ensured adherence to TLA treatment or placebo as much as was possible 
We also anticipated the potential of Type II errors which are no less important than Type I.  
We believe that even if appropriate, while adjustments for the p-value could reduce Type I 
errors (which we have done already by other steps outlined above), such a step would 
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potentially increase the chances of making Type II errors and increase the possibility that 
important relationships between TLA treatment and asthma symptoms and lung function 
would not be discovered (Perneger 1998).  We had considered the potential adjustment of 
the p-value at the outset but recognised that such a calculation would have been arbitrary 
and variable.  For example, there would be uncertainty about the number of variables to 
adjust for.  If we had lowered the alpha level and maintained the beta level in the design 
phase of our study, this would have also greatly increased the sample size required 
(Rothman 1990), and we consider that such a financial burden would have meant this type 
of study would have been unlikely to have ever been conducted.   
Finally, as we found no consistent and significant effects of TLA treatment in the secondary 
outcomes, we did not pursue any corrections for multiple comparisons but had considered 
their potential impact at the outset of the Trial design. 
6.1.5 COMPARISON WITH OTHER EVIDENCE OF THE TLA DEVICE 
A larger placebo-controlled trial of the TLA device (Boyle et al 2012) had previously shown an 
improvement in asthma-related quality of life and reduction in exhaled nitric oxide, with a greater 
benefit shown in patients with severe asthma (GINA Step 4) and with poor control. That trial was 
however in a heterogeneous group of asthmatics (age range 7-70 years) randomised 2:1 active to 
placebo and about half or just less had GINA Step 4 severity of asthma, meaning that the event rate 
of exacerbations was low. Consequently, despite adequate numbers of participants, the trial was 
unable to show a reduction in exacerbation frequency. In our trial with a higher proportion of people 
with severe asthma, we were able to demonstrate improvements in both generic and asthma-
related quality of life.  
In another, smaller open-labelled study of the TLA device (Schauer et al 2015), in which the 
participant population was more severely exacerbation-prone than that of our trial (33% were on 
maintenance oral corticosteroids and 43% were on Omalizumab treatment at baseline, i.e., 
significant number of BTS Step 5 participants), TLA treatment was found to reduce exacerbation rate 
from 3.6/year to 1.3/year – a 64% reduction. That study differed from ours in that participants were 
their “own control” rather than a placebo group, and it included 50% children with an even gender 
distribution. We report a similar reduction in exacerbation frequency before and after the trial in 
both groups, but with a female and obese predominant allergic asthma population reflective of ‘real-
world’ severe asthma patients.  
We have confirmed benefits of improved quality of life in keeping with other evidence, but not in 
reducing eosinophilic inflammation or exacerbations. We have not tested on systemic effects of 
allergy, though there were improvements in the sino-nasal scores in favour of the active device 
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(comparable to the minimally important difference of the SNOT-22 questionnaire) but this was not 
statistically significant in this population (p=0.07).  
6.1.6 ALLERGIC ASTHMA AND ITS LINK WITH SYMPTOMS 
It is plausible that a proportion of severe asthma cases attributable to allergy may be overestimated 
and that aetiological mechanisms other than allergy may be important in the pathogenesis of severe 
asthma. For instance, numerous studies have reported a strong association between asthma 
exacerbations and respiratory viral infections suggesting a viral‐induced mechanism (Holt et al 
2012). Rather than being mutually exclusive, viruses and allergens may interact in increasing the risk 
of severe asthma and exacerbation frequency (Green et al Lancet 2002). It is not possible from the 
data obtained in the LASER trial to determine the aetiological mechanisms of each individual 
exacerbation and whether other factors were playing a role in the reported exacerbations. A better 
understanding of the aetiology of specific exacerbations may have demonstrated a different 
outcome in the trial. 
Consistent with European standards (Heinzerling et al 2013), allergic sensitisation was defined in the 
LASER trial as either an allergen specific serum IgE detected >0.35 KU/l, or a positive skin prick test 
(SPT) to a defined allergen with a mean wheal diameter of ≥3 mm. These allergy tests have high 
sensitivity, but in themselves do not necessarily signify disease. A considerable proportion of non-
asthmatic individuals are sensitised to one or more aeroallergens and a positive test in an asthmatic 
patient does not always result in clinical response upon exposure to that allergen. There is a 
difference between allergic asthma with asthma symptoms induced by exposure to a defined 
allergen, and asthma in a subject characterized as being sensitised but with no relation between 
allergen exposure and clinical reaction. In the LASER trial we attempted to overcome this issue by 
recording both allergen sensitisation by either skin prick testing or measurement of serum specific 
IgE levels as well as documenting evidence of presence of symptoms on exposure to allergens to 
which the subject was sensitised. This is imprecise as it relies on subjective reporting of symptoms 
on exposure to allergens and may have led to the inclusion of participants who did not have purely 
allergic asthma.  
Exacerbations and symptoms often coexist but are not always interlinked. Some patients have 
significant daily symptoms and require high intensity treatment to maintain quality of life and 
prevent deterioration in lung function but do not experience frequent exacerbations. It is also 
recognised that there is an asthmatic phenotype characterised by development of sudden severe 
asthma symptoms and exacerbations in otherwise mild or asymptomatic subjects, often triggered by 
exposure to an allergen, a drug, an air pollutant or volatile organic compound, a viral infection or 
another unknown trigger.  
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The huge heterogeneity in asthma highlights the importance of characterising specific asthma 
phenotypes aiming to provide precision therapeutics targeted towards each individual’s disease.  
Sub-group analysis of trial populations might help to identify specific phenotypes or sub-groups of 
allergic asthmatic patients who might benefit from specific treatments such as Temperature-
controlled Laminar Airflow.   
6.1.7 DISSOCIATION BETWEEN ASTHMA SYMPTOMS AND EXACERBATIONS 
There is good evidence from previous landmark asthma studies showing that there is a dissociation 
between asthma symptoms and exacerbations. 
Early studies investigating the safety and efficacy of mepolizumab (Nucala®, GlaxoSmithKline, 
London, UK) showed no clinical safety concerns but equally were unable to demonstrate efficacy in 
the measured primary outcomes. In a double blind placebo controlled study of 24 mild allergic 
asthmatic patients (Leckie et al 2000), researchers were unable to demonstrate any significant 
improvement in airway hyper-reactivity, peak expiratory flow or FEV1 in the group treated with 
mepolizumab compared to placebo despite seeing a significant reduction in airway and blood 
eosinophil counts in the mepolizumab treated group. A further double blind placebo controlled 
study (Flood-Page et al 2003) randomised 24 participants to mepolizumab or placebo. Again, 
researchers were unable to demonstrate any improvement in their clinical endpoints of FEV1, PEF or 
airway hyper-reactivity despite again showing a significant reduction in blood and airway eosinophils 
in the active treatment group. Flood-Page et al went on to perform a large multicentre randomised 
controlled trial in 362 asthma patients with persistent symptoms (Flood-Page et al 2007). Again they 
were unable to demonstrate significant clinical improvements in symptoms, lung function measures 
or quality of life in the active treatment group.  
Phase II and III studies of mepolizumab treatment in carefully selected populations of severe 
eosinophilic asthmatic patients were later able to demonstrate a significant reduction in the 
annualised asthma exacerbation rate despite not showing consistent improvements in asthma 
symptoms or quality of life measures. The DREAM (Dose Ranging Efficacy And safety with 
mepolizumab) trial (Pavord et al 2012) treated 621 patients with IV Mepolizumab for 52 weeks. 
There was a significant reduction in exacerbation rate in the mepolizumab treated participants 
compared with placebo. It was noted that the significant reduction in exacerbation risk was only 
associated with small and not clinically significant improvement in measures of asthma symptoms, 
asthma control, lung function or quality of life.  
The SIROCCO study group (Bleeker et al 2016) investigating the anti-IL5 antibody, benralizumab 
(Fasenra™, AstraZeneca, London, UK), were able to show a similar treatment benefit in reducing the 
annualised exacerbation rate and were able to show an improvement in FEV1 in the active 
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treatment group but again could not demonstrate a consistent improvement in asthma symptoms in 
the active treatment group.   
These studies suggest dissociation between symptoms and risk of exacerbation in patients with 
severe asthma. This evidence is further supported by studies performed to reduce eosinophilic 
airways inflammation (Green et al BMJ 2002). Green et al were able to show that treatment 
strategies aimed at normalising sputum eosinophil counts were able to reduce asthma 
exacerbations and hospital admissions. Despite the significant reduction in exacerbation rate in the 
sputum management group, the group were unable to demonstrate any improvement in symptom 
scores, quality of life or lung function measures. 
Previous trials of Temperature-controlled Laminar Airflow treatment in asthma have demonstrated 
improvements in asthma quality of life and, recognising the dissociation between symptoms, quality 
of life and exacerbations in severe asthma, it may be that further studies to demonstrate efficacy of 
TLA treatment should focus on symptom control and quality of life given the lack of demonstrable 
improvement in exacerbation reduction seen in the LASER trial. 
6.1.8 DEVICE COMPLIANCE 
It is important to recognise the difficulty of managing device compliance and adherence. During the 
LASER trial, participants were asked to commit to using the device on at least 5 of 7 nights of the 
week, excluding holidays, recognising that this was a pragmatic trial and that the device was not 
sufficiently portable to allow participants to take on holiday or away from home. Participants were 
encouraged to use the device every day if possible and to ensure that the device was switched on 
when sleeping under the device at night. 
In order to try and capture a measure of device compliance, participants were asked to record their 
use of the device on the daily TLA diary including whether the device was used, yes or no, and the 
number of hours the device was used. In addition to this, participants were asked to report the 
‘device-reported use’. The device automatically recorded the number of hours ‘in-use’ when the 
device was switched on. 
The device was pre-programmed at the time of installation by the engineer to turn on and switch off 
at times defined by the individual participant to cover the ‘earliest possible time to bed’ and ‘latest 
possible time to rise’. Participants were able to over-ride this function and could turn on the device 
earlier than programmed and switch off the device earlier than programmed. This also gave 
participants flexibility to use the device during daytime naps if they wished. 
Unfortunately, it is not possible to determine from the device reported use whether the participant 
was sleeping under the device during the time that the device was switched on. 
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Difficulties in measuring device compliance mean that it is not possible to absolutely confirm that 
each participant used the device for a satisfactory length of time to receive a treatment benefit.  
Indeed it is not known what length of time a participant would be required to sleep under the device 
to obtain a positive treatment effect. It would be important in future studies of TLA treatment to 
have a more robust measure of treatment compliance to allow further analysis of treatment 
outcome determined by compliance.  
6.1.9 DEVICE ACCEPTABILITY 
Through qualitative analysis we found that TLA treatment delivered by the Airsonett® device is 
acceptable to patients with severe allergic asthma. There were few barriers to treatment use, none 
of which were insurmountable in our interviewed population. 
A number of suggested device modifications have been identified and passed on to the device 
manufacturer. The device manufacturer was grateful to receive this information to help with their 
product development and have agreed to keep us informed of future design modifications that stem 
from this research. 
6.1.10 NOVEL METHODS OF RECRUITMENT INCLUDING SOCIAL MEDIA 
We have been able to explore the benefits of using different social media platforms to recruit and 
randomise participants. Of 240 randomised, approximately 20% of participants were from sources 
other than clinic registers at participating centres.  Furthermore, fewer than 1% were from 
newspaper and radio advertisement, which are more traditional methods of recruitment, but no less 
costly. We demonstrated that use of dedicated trial websites, Google re-marketing, targeted 
Facebook advertisements and national charity Facebook and Twitter use can enhance recruitment. 
The most successful was however the use of Trialbee, a dedicated website used for directing 
participants after a short screening questionnaire to the relevant and local trial sites.  
This strategy for recruiting trial participants was considered to be especially appropriate for the trial 
population, who tend to be younger patients and therefore likely to be working and with less time to 
engage with the traditional advertising and recruitment pathways, but who are likely to explore the 
availability of new treatments and technologies for their condition via the internet and social media 
platforms. Another benefit of social media engagement is that it empowers people to approach the 
research team of their own volition, thus possibly selecting more motivated, engaged research 
participants.  
Further exploration of the use of digital and social media for recruitment to large multi-centre trials 
is needed.  
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6.1.11 FUTURE WORK 
Previous studies have shown a beneficial effect of TLA treatment in a more heterogeneous and less 
severe population of allergic asthmatics. There may be a more significant benefit in these less severe 
patients particularly in terms of improvement in quality of life. The type of patients who may benefit 
from the TLA treatment requires further exploration. 
Exploratory sub-group analysis of the LASER trial data would be helpful to determine whether there 
is a sub-group of severe allergic asthmatic patients who might benefit from TLA treatment although 
any sub-group analysis would be under-powered. Suggested analysis of interest would include sub-
groups based on gender, BMI, asthma severity, asthma control (ACQ) level and allergen sensitivity.   
Of particular interest would be sub-group analysis for specific allergen sensitivity. There may be a 
more significant response in patients who are sensitised to a specific allergen or those who are 
sensitised to more than one allergen. Sub-group analysis of patients who use additional allergen 
interventions such as dust mite prevention pillow and duvet covers would also be of interest. 
The reason for the large reduction in exacerbation frequency in both the active and placebo groups 
in the LASER trial and other severe asthma trials requires further exploration. 
Future trials in severe asthma measuring exacerbations as the primary endpoint should include a 
more robust means of collecting data and it would be recommended that electronic diary collection 
of daily corticosteroid use and asthma symptoms is used. This is more common in pharmaceutical 
company sponsored trials where funding is available. 
Further qualitative studies should be conducted outside of the trial setting where users of the device 
can also discuss the clinical benefits of using the device, weighing against the impact of having the 
treatment device installed at home. This was not possible in this study due to participants being 
blinded to treatment allocation. 
Qualitative analysis of device use in a wider asthma population including patients with less severe 
disease would be helpful to determine if the device is acceptable in a less severe asthmatic 
population. 
A qualitative analysis of the impact of the treatment device on patient’s partners who share the 
same bedroom environment as the patient using the treatment device would be useful to establish 
whether this might prove to be a barrier to device use. 
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6.1.12 REFLECTIONS ON COORDINATING A MULTICENTRE TRIAL 
Reflecting on my role as trial coordinator for the LASER trial I found delivery of a national, multi-
centre, trial to be both extremely challenging as well as highly rewarding. Through being directly 
involved in all aspects of trial delivery from concept and trial design to recruitment and data analysis 
and interpretation I have learnt a huge amount about successful delivery of both quantitative and 
qualitative research which I will use to good effect in delivery of my future clinical research. 
There are a number of areas that I found particularly rewarding, most notably working with such a 
highly motivated group of researchers and patients.  
I developed excellent working relationships with the other members of the trial management group 
who were equally motivated to deliver a successful trial. We held regular, weekly meetings to ensure 
that the trial continued to drive forwards and to make sure that problems and challenges were 
addressed in a timely manner. 
I enjoyed collaborating with patients to better understand their needs and to ensure that the trial 
was answering a clinically meaningful question.  We designed a pragmatic trial to ensure that results 
would be applicable to a ‘real-world’ population of severe asthmatic patients.  Our PPI members 
contributed at a number of key stages of the trial. Their input was invaluable at the stage of protocol 
development ensuring that the trial processes would not put undue burden on participants. PPI 
representatives also reviewed all patient facing documents to ensure that they were easily 
understood and met the needs of the trial participants.   
I arranged a number of meetings with our recruiting centre trial teams during the course of the trial, 
both before and during the recruitment phase, to share experiences and troubleshoot problems that 
were occurring. As trial coordinator this offered me the opportunity to build relationships with the 
research teams to ensure that they felt supported and able to contact me for advice about any 
aspect of trial delivery. This was particularly important with trial recruitment and close engagement 
with site teams allowed us to share good practices. Travelling to trial centres as well as bringing trial 
teams together at investigator meetings undoubtedly led to the successful recruitment to time and 
target. 
Maintaining good lines of communication with all members of the trial team is crucial to the 
successful delivery of a national, multicentre trial. 
I developed the trial website (www.lasertrial.co.uk) in collaboration with a web developer. This 
provided a valuable means of communicating the aims and objectives of the trial and provided a 
source of information for both trial participants and research teams looking to find out more 
information about TLA treatment and the trial. The trial website also provided a focus for 
recruitment with trial advertising directing potential participants to a webpage where they were 
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able to register their interest in the trial. This proved to be a valuable means of recruiting 
participants who might not have otherwise been able to access the trial.  
Alongside the website, I also set-up social media accounts for the trial to engage with patients and 
make the trial more accessible. These social media accounts linked to the trial website and to 
national charities applicable to our patient population. Patients and potential participants were able 
to engage with the trial team through social media and it was clear that through social media 
interactions, the trial was made available to a wider population than would have been able to access 
the trial had it only been advertised through trial centres and conventional means. 
With the challenges faced by trials to deliver to time and target it is key that efforts are made to 
engage with patients. In our experience the trial website and utilisation of social media helped to 
ensure that we were able to meet our targets and we would encourage others to consider using 
these tools to enhance trial engagement and recruitment. 
There were significant logistical difficulties to overcome in the LASER trial most notably with delivery 
of the trial treatment devices into participant’s homes after randomisation. I had long and detailed 
discussions with the device manufacturer and the logistics company contracted to arrange delivery 
of the devices and arrange filter changes. We put together a standard operating procedure including 
a detailed checklist to ensure that the same process was followed in each case. I put together a basic 
GCP training presentation for the Engineers from the logistics company to make sure that they 
understood the importance of maintaining blinding when installing the devices and not discussing 
possible treatment allocation with participants. Even despite these efforts there were situations 
where the device was installed incorrectly or the participant was unable to arrange a convenient 
time for the device to be delivered. These situations required prompt action to prevent impact on 
trial integrity and results. 
Early on in the trial we had problems with a number of the trial electronic peak flow devices failing. 
We made a decision to withdraw all of the allocated devices. I sourced an alternative electronic peak 
flow device from a different manufacturer. I arranged collection of the old devices and distribution 
of the new devices to our trial teams. This had to be arranged within a short time period to ensure 
that we were able to continue recruiting participants and collecting data. As a specific electronic 
peak flow device had been mentioned in the trial protocol this required an urgent ethics 
amendment to allow the use of an alternative device. 
When we discovered that we were not meeting our recruitment targets I realised that we needed to 
make changes to ensure that the trial did not fail. Working with the trial management group we 
proposed a number of protocol amendments that would enhance recruitment without damaging 
the trial’s integrity. We proposed these changes to the trial steering committee who approved and 
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supported the proposal. I approached the trial ethics committee and 3 major amendments were 
made to the protocol. 
It is important to be flexible and responsive to challenges in order to keep a trial moving in a 
positive direction.  
Missing data was a significant problem in the trial. Attempts were made to review data 
completeness during the 4-month internal pilot study so that measures could be taken if problems 
were arising. Unfortunately, data completeness was not raised as a concern by the data 
management team and when it came to the end of the trial we were faced with a number of missing 
data points most notably in the daily diary collection of symptoms and daily corticosteroid dose. This 
had an impact on data interpretation. We reflected that we could have used an electronic diary to 
collect this data which may have improved data collection or certainly flagged up missing data 
sooner. The use of electronic diaries would not have been financially viable within the constraints of 
the trial budget. Budgeting for electronic diary use should be considered by trial teams designing 
future trials where daily data collection is required. 
Every effort should be made to minimise missing data. Robust means of identifying missing data 
should be put in place so that action can be taken early to avoid problems associated with 
incomplete data. If necessary, additional training could be delivered to trial teams to highlight 
data points that are commonly missed.     
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6.2 CONCLUSION 
Despite evidence of the efficacy of the TLA device in allergic asthma, in this pragmatic, placebo-
controlled RCT we were unable to demonstrate any effect on exacerbation frequency and only some 
of the secondary outcomes. Despite the multiple sources of exacerbation data, it is possible that the 
numbers of exacerbations may have been under-reported although the source of missing data was 
not the primary source for capturing exacerbations. Any further trial would need to have a singular, 
robust measure of exacerbations and more detailed assessment of device adherence in this 
population. Although it was not the primary aim of this Trial, we found that the use of modern 
techniques of social media can enhance trial recruitment, and they are superior to more traditional 
methods in this population of severe allergic asthma patients. 
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APPENDIX A: LASER PARTICIPANT INFORMATION SHEET (PIS) 
QUANTITATIVE 
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APPENDIX B: LASER PARTICIPANT INFORMATION SHEET (PIS) 
QUALITATIVE 
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APPENDIX C: LASER CONSENT FORM QUANTITATIVE 
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APPENDIX D: LASER CONSENT FORM QUALITATIVE 
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APPENDIX E: FAVOURABLE ETHICS OPINION LETTER 
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APPENDIX F: LASER TRIAL VISIT SCHEDULE 
Table F1: LASER visit schedule up to 12 months, including time points for CRFs, FUs, Questionnaires and Diaries 
 
Data Collection Time Point 
Screening Randomisation 1 Month 3, 6, 9, 12 Months Exacerbation ADE SADE Withdrawal 
CRFs / FUs                 
 Screening Visit X               
 Randomisation Visit   X             
 Randomisation Form   X             
 1 Month Telephone Follow-up     X           
 3 Month Visit       X         
 Exacerbation Review         X       
 ADE Form           X     
 SADE Form             X   
 Withdrawal Form               X 
Questionnaires (Participant)                 
 ACQ X X   X         
 AQLQ(S)   X   X         
 EQ-5D-5L   X   X         
 SNOT-22   X   X         
 WPAI (A)   X   X         
 Indoor Air Quality   X             
Questionnaires (Carer)                 
 AC-QoL   X             
 WPAI (CG)   X             
Diaries                 
 Asthma Control - Screening   X             
 Asthma Control - Follow-up       X         
 TLA - Laser Diary       X         
 Healthcare Resource Use diary       X         
 Exacerbation Diary         X       
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APPENDIX G: COMPARATIVE TRIALS SHOWING EFFICACY FOR SAMPLE SIZE AND MAGNITUDE OF EFFECT 
Table G1: Summary table of comparative trials showing efficacy for sample size and magnitude of effect 
Author Treatment n Baseline 
Exac.Rate 
Placebo 
Group Exac. 
Rate 
Exac. 
Reduction 
% ICS Dose Exacerbation definition 
Pavord 
2012 
Mepolizumab 
621 
(4 
groups) 
3.73 (±0.8) 
2.4 (±0.11) 
over 52 
weeks 
1·24 vs 2·40 
1.46 vs 2.40 
1.15 vs 2.40 
48% 
39% 
52% 
880 μg fluticasone propionate 
equivalent/day, with or without 
maintenance OCS 
 
Requiring OCS or ED visit + 
objective evidence that 
asthma had worsened 
Haldar
 
2009 
Mepolizumab 32 5 
3.4 over 12 
months 
2.0 vs 3.4 
 
41% 1000-4000 BDP eqv mean 2000 
μg 
Requiring OCS 
Green 
2002 
Sputum Eosin 
guided 
treatment 
74 
2.0(3.0) in 
placebo 
group 
2.95 over 12 
months 
0.95 vs 2.95 68% 
 
High dose >1600 μg BDP Requiring OCS or PEF 
≤70% 
Humbert  
2005 
Omalizumab 419 
2.41(1.09) 
in 14mnths 
0.91 [0.73, 
1.14] over 
28 wks 
0.68 vs 0.91 
[Severe 0.24 
vs 0.48] 
50% > 1000 μg/day BDP GINA 2002 
Step 4 
Requiring OCS  
Hanannia 
 2011 
Omalizumab 850 
1.9(1.5) in 
12mnths 
0.88 over 48 
wks 
0.66 vs 0.88 
 
25% >1000 μg/day FDP Requiring OCS (or ↑dose 
if on maintenance) 
Castro 
2009 
Bronchial 
Thermoplasty 
288 
Not 
recorded 
 
0.70(0.122) 
over 12 
months 
0.48 vs 0.70 32% >1000 μg/day BDP Requiring OCS or doubling 
dose of ICS 
Busse
 
2008 Daclizumab 
115 
(3:1) 
Not 
recorded 
Not 
recorded 
25% vs 47.6% 
at 252 days 
47% Mod to severe % of participants in each 
group suffering an 
exacerbation requiring 
systemic corticosteroids 
Pauwels 1997 Symbicort 852 
Not 
recorded 
0.91 
0.34 vs 0.91 
 
63% Low to Moderate Requiring OCS 
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APPENDIX H: EQUIVALENCE TABLE FOR BRONCHIAL CHALLENGE TESTING 
Table H1: Equivalence table for bronchial challenge testing 
Challenge Test Positive Result 
Direct 
Methacholine PC20 <8mg/ml 
Histamine PC20 <8mg/ml 
Indirect 
Mannitol PD15 <635mg
i 
Exercise Fall in FEV1 of ≥10% from baseline
ii 
 
 
i Positive Result is > 15% FEV1 drop from baseline OR > 10% FEV1 drop in consecutive doses 
ii Measured during recovery (up to 30mins) after achieving at least 4 minutes exercise at 80-90% of 
predicted maximum heart rate (predicted maximum heart rate = 220-age) 
Performance of bronchial challenge testing conformed to international quality guidance (Crapo et al 
2000) (Anderson et al 1997) 
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APPENDIX I:  DEFINITION OF HIGH DOSE INHALED CORTICOSTEROIDS 
Table I1: Definition of High Daily Dose of Inhaled Corticosteroids 
(Table modified from the International ERS/ATS Guidelines on Definition, Evaluation and 
Treatment of Severe Asthma 2013) 
Inhaled Corticosteroid Threshold daily dose in μg considered as high in 
adults 
Beclomethasone dipropionate >1000 (DPI or CFC MDI) 
>500 (HFA MDI) 
Budesonide >800 (MDI or DPI) 
Ciclesonide  >320 (HFA MDI) 
Fluticasone propionate  >500 (HFA MDI or DPI) 
Mometasone furoate  >800 (DPI) 
Triamcinolone acetonide  >2000 
CFC: Chlorofluorocarbon; DPI: Dry Powder Inhaler; HFA: Hydrofluoroalkanes; MDI: Metered  
Dose Inhaler. 
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APPENDIX J:  INTERFERENCE OF MEDICATIONS WITH SPT REACTIONS 
Table J1: Potential interference of medications with skin prick test reactions. Adapted from Castro 
et al (2009) 
Drug Abstinence Required Before Testing 
Antihistamines 
1
st
 Generation H1-anti-histamines 
Hydroxyzine 
 
>2 days 
2
nd
 Generation H1-anti-histamines 
Cetirizine 
Loratidine 
Fexofenadine 
 
7 Days 
3 Days 
2 Days 
H2-blockers 0 
Glucocorticosteroids 
Topical >1 week (in area being tested) 
Nasal 0 
Inhaled 0 
Systemic* 0 
Other Medication 
Tricyclic Antidepressants 
Doxepin 
Desipramine 
 
7 days 
3 Days 
SSRIs Citalopram/Fluoxetine/Sertraline 0 
Beta-agonists 0 
Anti-cholinergics 0 
Leukotriene Receptor Antagonist 0 
Theophylline 0 
* Participants who were taking maintenance oral 
corticosteroids and who had a negative skin-prick test 
and supportive history of atopy proceeded to specific 
IgE testing. 
 
If there was any doubt as to the result of the skin prick 
tests when assessing eligibility criteria, allergic status 
was then confirmed with specific IgE testing (see 
Section 2.10.1.3.) 
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APPENDIX K: TLA DIARY 
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APPENDIX L: PARTICIPANT EXACERBATION DIARY (PED) 
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APPENDIX M: EXACERBATION REVIEW FORM (REV) 
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APPENDIX N: LASER FOCUS GROUP INTERVIEW SCHEDULE 
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APPENDIX O: QUALITY OF LIFE EQ-5D-5L RESPONSES 
Table L1: Quality of Life EQ-5D-5L Responses 
 Randomisation 3 months 6 months 9 months 12 months 
Placebo, n (%) 
Mobility       
   No problems in walking about 38 (32) 46 (44) 44 (44) 33 (35) 37 (39) 
   Slight problems in walking about 28 (23) 14 (13) 17 (17) 17 (18) 22 (23) 
   Moderate problems in walking about 33 (28) 29 (28) 26 (26) 35 (37) 24 (25) 
   Severe problems in walking about 21 (18) 16 (15) 13 (13) 10 (11) 13 (14) 
   Unable to walk about 0 0 1 (1) 0 0 
Self-care      
   No problems washing or dressing 87 (73) 83 (79) 72 (72) 65 (68) 61 (64) 
   Slight problems washing or dressing 13 (11) 11 (10) 17 (17) 13 (14) 22 (23) 
   Moderate problems washing or dressing 17 (14) 9 (9) 8 (8) 10 (11) 9 (9) 
   Severe problems washing or dressing 2 (2) 2 (2) 3 (3) 5 (5) 4 (4) 
   Unable to wash or dress 0 0 1 (1) 2 (2) 0 
Usual activities      
   No problems doing usual activities 24 (20) 32 (31) 34 (34) 30 (32) 31 (32) 
   Slight problems doing usual activities 38 (32) 23 (22) 20 (20) 20 (21) 28 (29) 
   Moderate problems doing usual activities 40 (34) 33 (32) 34 (34) 28 (29) 25 (26) 
   Severe problems doing usual activities 17 (14) 13 (13) 10 (10) 15 (16) 10 (10) 
   Unable to do usual activities 0 3 (3) 3 (3) 2 (2) 2 (2) 
Pain / discomfort      
   No pain or discomfort 45 (38) 40 (38) 37 (37) 35 (37) 37 (39) 
   Slight pain or discomfort 33 (28) 29 (28) 29 (29) 20 (21) 25 (26) 
   Moderate pain or discomfort 28 (23) 24 (23) 24 (24) 26 (27) 19 (20) 
   Severe pain or discomfort 12 (10) 9 (9) 9 (9) 12 (13) 12 (13) 
   Extreme pain or discomfort 2 (2) 3 (3) 2 (2) 2 (2) 3 (13) 
Anxiety / depression      
   Not anxious or depressed 61 (51) 57 (54) 54 (53) 45 (47) 54 (56) 
   Slightly anxious or depressed 29 (24) 26 (25) 24 (24) 24 (25) 15 (16) 
   Moderately anxious or depressed 21 (18) 12 (11) 8 (8) 14 (15) 15 (16) 
   Severely anxious or depressed 6 (5) 7 (7) 14 (14) 9 (9) 10 (10) 
   Extremely anxious or depressed 3 (3) 3 (3) 1 (1) 3 (3) 2 (2) 
TLA device, n (%) 
Mobility      
   No problems in walking about 49 (43) 49 (49) 43 (44) 43 (48) 45 (50) 
   Slight problems in walking about 24 (21) 21 (21) 23 (24) 16 (18) 20 (22) 
   Moderate problems in walking about 31 (27) 22 (22) 20 (21) 23 (26) 16 (18) 
   Severe problems in walking about 11 (10) 7 (7) 10 (10) 8 (9) 9 (10) 
   Unable to walk about 0 0 0 0 0 
Self-care      
   No problems washing or dressing 86 (75) 78 (80) 74 (77) 73 (81) 71 (79) 
   Slight problems washing or dressing 14 (12) 11 (11) 13 (14) 8 (9) 11 (12) 
   Moderate problems washing or dressing 13 (11) 6 (6) 9 (9) 7 (8) 5 (6) 
   Severe problems washing or dressing 2 (2) 3 (3) 0 2 (2) 3 (3) 
   Unable to wash or dress 0 0 0 0 0 
Usual activities      
   No problems doing usual activities 34 (30) 37 (37) 38 (40) 38 (42) 46 (51) 
   Slight problems doing usual activities 39 (34) 31 (31) 27 (28) 24 (27) 18 (20) 
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   Moderate problems doing usual activities 29 (25) 21 (21) 20 (21) 17 (19) 19 (21) 
   Severe problems doing usual activities 11 (10) 10 (10) 9 (9) 10 (11) 7 (8) 
   Unable to do usual activities 2 (2) 0 2 (2) 1 (1) 0 
Pain / discomfort      
   No pain or discomfort 42 (37) 37 (38) 36 (37) 34 (38) 35 (39) 
   Slight pain or discomfort 33 (29) 31 (32) 31 (32) 30 (33) 26 (29) 
   Moderate pain or discomfort 22 (19) 24 (24) 22 (23) 15 (16) 23 (26) 
   Severe pain or discomfort 15 (13) 5 (5) 4 (4) 10 (11) 4 (4) 
   Extreme pain or discomfort 3 (3) 1 (1) 3 (3) 1 (1) 2 (2) 
Anxiety / depression      
   Not anxious or depressed 64 (56) 59 (60) 55 (57) 52 (58) 57 (63) 
   Slightly anxious or depressed 26 (23) 22 (22) 26 (27) 25 (28) 16 (18) 
   Moderately anxious or depressed 17 (15) 12 (12) 10 (10) 11 (12) 12 (13) 
   Severely anxious or depressed 7 (6) 3 (3) 4 (4) 2 (2) 4 (4) 
   Extremely anxious or depressed 1 (1) 2 (2) 1 (1) 0 1 (1) 
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APPENDIX P: PARTICIPANTS WITHDRAWAL DATA 
Table M1: Full details of participants with withdrawal reports, deaths and those not meeting minimum data requirements 
Description of withdrawal Withdrawal 
Reason 
Reason for Withdrawal Reason 
specified 
Withdrew consent 
to use prior data 
Had 
minimum 
data 
Death  Follow-up Visits 
received 
Participant 
group 
Did not meet minimum data 
requirement 
   No   3  6  9 12  Placebo 
Did not meet minimum data 
requirement 
   No   3  6  9 12  Active 
Did not meet minimum data 
requirement 
   No   3  6  9 12  Placebo 
Did not meet minimum data 
requirement 
   No   3  6  9 12  Placebo 
Did not meet minimum data 
requirement 
   No  ~X~ 6  9 12  Placebo 
Did not meet minimum data 
requirement 
   No  ~X~ 6  9 12  Placebo 
Did not meet minimum data 
requirement 
   No   3  6  9 12  Active 
Death    Yes Yes   3  6  9 ~X~ Placebo 
Data Withdrawal   Yes No  ~X~~X~~X~~X~ Active 
Data Withdrawal   Yes No  ~X~~X~~X~~X~ Placebo 
Data Withdrawal   Yes No  ~X~~X~~X~~X~ Active 
Data Withdrawal   Yes No  ~X~~X~~X~~X~ Active 
Data Withdrawal   Yes No  ~X~~X~~X~~X~ Active 
Withdrawal Form completed Ineligibility   Yes   3  6 ~X~~X~ Placebo 
Withdrawal Form completed Ineligibility   Yes   3  6 ~X~~X~ Active 
Withdrawal Form completed, Other "Death, patient"  No Yes  ~X~~X~~X~~X~ Active 
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Death 
Withdrawal Form completed Other Constant sneezing when using TLA 
device 
 No  ~X~~X~~X~~X~ Placebo 
Withdrawal Form completed Other Getting headaches and sore 
throats from the device. 
 Yes   3 ~X~~X~~X~ Placebo 
Withdrawal Form completed Other Increased asthma severe 
exacerbations 
 No   3 ~X~~X~~X~ Placebo 
Withdrawal Form completed Other Machine didn't fit in room  No  ~X~~X~~X~~X~ Active 
Withdrawal Form completed Other Mental health problems  Yes   3  6 ~X~~X~ Active 
Withdrawal Form completed Other Moving house again  Yes   3  6 ~X~~X~ Placebo 
Withdrawal Form completed Other Non compliance of device. Did not 
attend study visits.  
 Yes  ~X~~X~~X~~X~ Active 
Withdrawal Form completed Other Not wanting to participate any 
more.  
 Yes   3 ~X~~X~~X~ Placebo 
Withdrawal Form completed Other Participant DNA'd multiple visits 
and is not responding to 
telephone calls 
 No  ~X~~X~~X~~X~ Placebo 
Withdrawal Form completed Other Participant has left the family 
home and is unable to use the 
machine or have it re-installed 
elsewhere and wishes to 
withdraw from the study 
 No  ~X~ 6 ~X~~X~ Active 
Withdrawal Form completed Other Participant moved out of area and 
did not with to continue FU at 
another hospital 
 Yes   3 ~X~~X~~X~ Active 
Withdrawal Form completed Other Participant became unwell 
following a PG and pressures of 
new pregnancy - contributed to 
decision to withdraw 
 No  ~X~~X~~X~~X~ Placebo 
Withdrawal Form completed Other Participant did not attend 
appointments or respond to 
phone contact 
 No   3 ~X~~X~~X~ Placebo 
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Withdrawal Form completed Other Participant unable to commit to 
last appointment  
 No   3  6  9 ~X~ Placebo 
Withdrawal Form completed Other Unable to arrange installation of 
the TLA device.  
 No  ~X~~X~~X~~X~ Placebo 
Withdrawal Form completed Other Unable to comply with protocol  No   3 ~X~~X~~X~ Active 
Withdrawal Form completed Other Unable to contact participant  No  ~X~~X~~X~~X~ Active 
Withdrawal Form completed Other Unable to contact participant  No   3 ~X~~X~~X~ Active 
Withdrawal Form completed Other Unable to contact participant  No   3 ~X~~X~~X~ Placebo 
Withdrawal Form completed Other Unable to make contact with 
participant  
 Yes   3  6 ~X~~X~ Active 
Withdrawal Form completed Other Participant has moved abroad  No   3 ~X~~X~~X~ Placebo 
Withdrawal Form completed Participant 
withdrew consent 
  No  ~X~~X~~X~~X~ Active 
Withdrawal Form completed Participant 
withdrew consent 
  No  ~X~~X~~X~~X~ Active 
Withdrawal Form completed Participant 
withdrew consent 
  No   3 ~X~~X~~X~ Placebo 
Withdrawal Form completed Participant 
withdrew consent 
  No  ~X~~X~~X~~X~ Placebo 
Withdrawal Form completed Participant 
withdrew consent 
  No  ~X~~X~~X~~X~ Active 
Withdrawal Form completed Participant 
withdrew consent 
  No  ~X~~X~~X~~X~ Active 
Withdrawal Form completed Participant 
withdrew consent 
  No   3 ~X~~X~~X~ Placebo 
Withdrawal Form completed Participant 
withdrew consent 
  No  ~X~~X~~X~~X~ Placebo 
Withdrawal Form completed Participant 
withdrew consent 
  No  ~X~~X~~X~~X~ Active 
Withdrawal Form completed Participant 
withdrew consent 
  No   3 ~X~~X~~X~ Active 
Withdrawal Form completed Participant   No   3  6 ~X~~X~ Active 
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withdrew consent 
Withdrawal Form completed Participant 
withdrew consent 
  No  ~X~~X~~X~~X~ Active 
Withdrawal Form completed Participant 
withdrew consent 
  No  ~X~~X~~X~~X~ Active 
Withdrawal Form completed Participant 
withdrew consent 
  No  ~X~~X~~X~~X~ Placebo 
Withdrawal Form completed Participant 
withdrew consent 
  No  ~X~~X~~X~~X~ Active 
Withdrawal Form completed Participant 
withdrew consent 
  No  ~X~~X~~X~~X~ Placebo 
Withdrawal Form completed Participant 
withdrew consent 
  No   3  6 ~X~~X~ Placebo 
Withdrawal Form completed Participant 
withdrew consent 
  No  ~X~~X~~X~~X~ Placebo 
Withdrawal Form completed Participant 
withdrew consent 
  Yes   3  6  9 ~X~ Active 
Withdrawal Form completed Participant 
withdrew consent 
  Yes   3  6 ~X~~X~ Active 
Withdrawal Form completed Participant 
withdrew consent 
  Yes   3  6 ~X~~X~ Active 
Withdrawal Form completed Participant 
withdrew consent 
  Yes   3  6 ~X~~X~ Active 
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APPENDIX Q: FORM UPR16 RESEARCH ETHICS REVIEW CHECKLIST 
 
  
 
